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Abstract 
This dissertation describes the development of bioanalytical strategies for a 
group of experimental and known therapeutic agents and chemically related essential 
substances. The array of analytes include the antifolate methotrexate, its various 
(in)active metabolites and related bio-conjugates, plus several forms of folic acid family, 
a  group of essential substances not synthesized by mammalian species, but 
endogenously required in numerous biochemical processes.  These analytes all share a 
common structural feature, the heterocyclic pteridine ring system. Analyte identity 
results from variations of the ptereridine-ring system redox state, a result of minor 
structural variations of the heterocyclic ring and changes in conjugation status (i.e. 
polyglutamated or nanoparticle conjugated).  
Specific and sensitive detection of the individual species was of high interest, as 
the various chemical forms of these substances may constitute biomarkers for 
individualizing low dose MTX therapy in autoimmune diseases such as JIA, but is also 
required for the (pre)clinical studies of novel nano-device MTX drug delivery systems. 
The dissertation presents state-of-the-art bioanalytical methodology suitable for the 
specific determination of any specific analyte in the presence of all other analytes. The 
strategy for each particular analyte possesses its own unique strength and weakness, 
with the final strategy collectively being based on the specific structure and associated 
physical-chemical property of a given analyte, the biological environment, and the 
clinical question to be answered.   
   
iv 
 
Acknowledgements 
At the end of August in the summer of 2005, I arrived in Kansas for the first time 
to fulfill the internship requirement of my Free University masters program in the 
laboratories of Dr. Stobaugh at the University of Kansas (KU). At the time I opted for the 
internship in the United States I felt was ready for an adventure, a 9 month adventure 
abroad. Now 5 years later, I’m writing the acknowledgements section of my doctoral 
dissertation, and realize that these small innocent choices ended up as major turning 
points in my life. Upon my first arrival at the airport in Kansas City (KC), I did not know 
anyone, and to make matters worse, the two suitcases containing my only possessions 
at that point, did not make it to KC. Since that time I have met numerous friends, that 
have made my stay in the U.S. the pleasant experience that it has been. I it will be 
impossible to acknowledge each one of you, but I’m sure you know who you are.  
First I would like to thank my advisor Dr. J. Stobaugh. As illustrated by this 
dissertation, the projects we have been working on in your laboratory have been 
challenging, but very rewarding due to their intimate relationship to “real” clinical 
problems. Your mentorship throughout my graduate career together with the experience 
obtained in your laboratory, will undoubtedly benefit me in my future career. I will 
certainly miss working in your laboratory. It is impossible to think about KU pharmchem 
and my graduate school opportunities without Dr. H. Lingeman. You have raised my 
initial interest in bioanalysis during my time at the Free University, and were responsible 
for giving me the opportunity to study abroad. I would also like to thank Dr. T. Williams, 
it was a pleasure working in your laboratory and with someone with as much mass 
spectrometry know-how as you have. Furthermore it was your willingness to think 
v 
 
outside of the box, that made this project work in the end. That being said, I apologize 
for my +128 legacy that will linger around your laboratory for the next 5 years. I would 
like to thank Dr. Lunte for being a reader of this dissertation, and Dr. Schöneich, and Dr. 
Prisinzano for serving as committee members.  
I would like to thank Dr. Becker from Children’s Mercy Hospital. You were the big 
engine behind the JIA part of the dissertation. It was, and is a pleasure working with 
somebody as highly motivated as you, and hopefully we can continue our research 
efforts in my future at CMH. The same accounts for Dr. Leeder, who generated an 
excellent post-doc position at CMH for me. I would like to thank Anton Heemskerk, who 
worked closely with me on a number of projects during his 8 month internship. Much of 
the data in chapter 6 would not have been generated without Anton. 
Furthermore I would like to thank my good friends Justin Pennington and Ryan 
Funk, without them graduate school would have not been the same. Finally I would like 
to thank my family, including my parents, brother and grandparents. Living overseas, 
1000s of miles away from home is not always easy and you are/were all missed. I would 
like to thank my parents in particular for all your support throughout my entire education, 
it would not have been possible without it, and I love you. I would like to thank my 
brother for visiting me twice during my stay here in the USA. We have made two 
memorable road trips through California and Colorado/Utah. I hope we can add some 
more trips to the list in the future. 
 
 
 
 
vi 
 
Bioanalysis of Pteroyl Derivatives in Various Aspects of Human 
Health 
 
Table of Contents 
 
Chapter 1: Introduction to Pteroyl Derivatives in General Human Health and as 
Pharmaceutically Relevant Antimetabolites  ................................................................... 1 
 
Chapter 2: Bioanalytical Method Development for a Generation 5 Polyamidoamine 
Folic Acid Methotrexate Conjugated Nanoparticle  ....................................................... 28 
 
Chapter 3: Detection of G5-MTX-FA in Urine ............................................................... 72 
 
Chapter 4: A Novel HPLC Mass Spectrometry Method for Improved Selective and 
Sensitive Measurement of  Methotrexate Polyglutamation Status in Human Red Blood 
Cells. ........................................................................................................................... 102 
 
Chapter 5: LC/MS/MS analysis of (7OH-)Methotrexate Polyglutamates in a Clinical 
Environment ................................................................................................................ 136 
 
Chapter 6: Expedient Methodology for Total Methotrexate Polyglutamation Pool 
Determination in Human Erythrocytes ......................................................................... 171 
 
Chapter 7: The Analysis of Folate (polyglutamates) in Various Blood Components by 
LC/MS/MS ................................................................................................................... 195 
 
Chapter 8: General Summary and Conclusions ......................................................... 281 
 
 
 
vii 
 
Appendices 
 
Appendix 1: Analysis of Intracellular Methotrexate Polyglutamates in Patients With 
Juvenile Idiopathic Arthrits .......................................................................................... 293 
 
Appendix 2: The Effect of Genotype on Methotrexate Polyglutamate Variability in 
Juvenile Idiopathic Arthritis and Association with Drug Response .............................. 296 
 
Appendix 3: Phenylisothiocyanate as a Multiple Chemical Dimension Reagent for the 
Relative Quantitation of Protein Nitrotyrosine .............................................................. 299 
 
Appendix 4: LC-MS/MS Method for the Determination of Carbamathione in Human 
Plasma ........................................................................................................................ 301 
 
 
 
viii 
 
List of Acronyms 
 
5,10-METHF  5,10-Methylenetetrahydrofolate 
5,10-MTHF  5,10-Methenyltetrahydrofolate 
5-FTHF  5-Formyltetrahydrofolate 
5-MTHF  5-Methyltetrahydrofolate 
7OH-MTX  7-hydroxymethotrexate 
10-FTHF  10-Formyltetrahydrofolate 
ACN  Acetonitrle 
AMP  Aminopterin 
ATIC  5-Aminoimidazole carboxamide ribotide transformylase 
CE  Capillary electrophoresis 
DAMP  2,4-diamnio-6-methylpteridine 
DAMPA  4-amino-4-deoxy-N10-methylpteroicacid 
DHFR  Dihydrofolate reductase 
DHF  7,8-Dihydrofolate 
DMF  N,N-dimethylformamide 
DMPA  N,N,-dimethylpentylamine 
DMHA  N,N,-dimethylhexylamine 
DMHPA  N,N,-dimethylheptylamine 
ESI  Electrospray ionization 
FA  Folic acid 
FD  Fluorescence detection 
FPGS  Folylpolyglutamyl synthase 
FR  Folate receptor 
FWHH  Full width at half height 
G5  Generation 5 
GART  Glycinamde ribonucleotide formyltransferase 
GGH  Gamma glutamyl hydrolase 
HLB  Hydrophilic lipophilic balance 
HPLC  High performance liquid chromatography 
IP  Ion-pair 
ix 
 
I.S.  Internal standard 
IV  Intra veneous  
JIA  Juvenile idiopathic arthritis 
kDa  Kilo dalton 
LC  Liquid chromatography 
LC-MS/MS  Liquid chromatography followed by tandem mass spectrometry detection 
LC-PC(hv)-FD  Liquid chromatography followed by post column photochemical 
degradation and fluorescence detection 
LD  Low dose 
LLOQ  Lower limit of quantitiation 
LOD  Limit of detection 
M/z  Mass over charge 
MeOH  Methanol 
MRM  Multireaction monitoring 
MS  Mass spectrometer 
MTHFR  methylene tetrahydrofolate reductase 
MTX  Methotrexate 
MTXPGs  Methotrexate polyglutamates 
NMR  Nuclear magnetic resonance 
PAMAM  Polyamido amine 
PCA  Perchloric acid protein precipitation 
PGs  Polyglutamates 
PCFT  Proton coupled folate receptor 
PK  Pharmacokinetic 
RA  Rheumatoid Arthritis 
RBC  Red blood cell 
RFC  Reduced folate carrier 
SAX  Strong anion exchange 
SC  Subcutaneous 
SEC  Size exclusion chromatography 
SPE  Solid phase extraction 
x 
 
SLC19A1  see RFC 
THF  5, 6, 7, 8-Tetrahydrofolate 
TOF  Time of flight (mass spectrometry) 
TYMS  Thymidylate synthase 
UV  Ultraviolet 
WCX  Weak cation exchange 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction to Pteroyl Derivatives in General Human 
Health and as Pharmaceutically Relevant Antimetabolites 
 
 
2 
 
Chapter 1: Introduction to pteroyl Derivatives in General Human 
Health and as Pharmaceutically Relevant Antimetabolites 
 
Table of Contents 
 
1.1 Establishment of Nomenclature ........................................................................ 4 
1.2 The discovery of folate ....................................................................................... 5 
1.3 The various folate forms .................................................................................... 6 
1.4 Folate uptake ....................................................................................................... 8 
1.5 Biological function of folates ............................................................................. 8 
1.6 Antifolates ......................................................................................................... 11 
1.7 MTX mechanism of action in cancer therapy ................................................. 12 
1.8 Polyglutamation ................................................................................................ 13 
1.9 The development of novel antifolate drugs .................................................... 14 
1.10 Use of MTX in drug delivery systems for cancer treatment .......................... 16 
1.11 Use of low dose MTX for the treatment of JIA ................................................ 18 
1.12 The measurement of folates ............................................................................ 20 
1.13 Overall goal of the dissertation ....................................................................... 21 
1.14 References ........................................................................................................ 23 
 
 
3 
 
Table of Figures 
 
Figure 1. Generic skeleton of biologically active pteroylglutamic acid derivatives.. ........ 4 
Figure 2. Molecular structures of various folate species. ................................................ 7 
Figure 3. Schematic overview of folate uptake and transport from the intestine. ............ 9 
Figure 4. Intracellular folate cycle.. ............................................................................... 10 
Figure 5. Structures of two key antifolates. ................................................................... 11 
Figure 6. Cellular folate pathway with both folic acid and MTX represented. ................ 15 
Figure 7. Chemical structure of G5-MTX-FA. ................................................................ 17 
 
 
 
4 
 
1.1 Establishment of Nomenclature 
This doctoral dissertation is centered around the development of bio-analytical 
methods for the detection of various biological and pharmaceutically relevant 
pteroylglutamic acid derivatives in biological matrices (figure 1). In a general sense, 
these molecules are composed of three different moieties (1) a pteridine ring system that 
is redox active, and changes oxidation state from the oxidized form to a 7,8-dihydro and 
a 5,6,7,8-tetrahydrofolate form (2) a para-aminobenzoic acid spacer (3) and a (γ-
poly)glutamated terminal chain (figure 1).  
 
 
 
Figure 1. Generic skeleton of biologically active pteroylglutamic acid derivatives. 
Common structural variations occur at the sites indicated by R, X, Y and Z. 
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 These entities play an important role in general human health as they are the 
chemical basis of the water-soluble B9 vitamins generally referred to as folate. For 
humans, folate is an essential vitamin necessary for normal cell growth and 
development and is aquired through the diet. The commonly accepted nomenclature for 
this vitamin is confusing because folic acid and folate are both commonly used to 
describe this vitamin, but in fact have different meanings. Based on established 
chemical nomenclature, one would believe the difference between folate and folic acid is 
just a proton. However, the term folic acid refers to pteroylglutamic acid which is the 
synthetic and most stable form of this vitamin with a fully oxidized pteridine ring system. 
In general the term folate is used for the naturally occurring, biologically active 
(polyglutamated) species, which posseses a reduced ring system with a variety of 
possible substitutions. A detailed description of these various folate structures can be 
found in section 1.3 of this dissertation. Throughout this dissertation the terms folate and 
folic acid (FA) will be used to refer to the natural and synthetic form respectively. 
 
1.2 The discovery of folate 
The discovery of folate has been closely related to the understanding of 
hematologic disorders and malignancies. In 1931, Lucy Wills reported the observation 
that macrocytic anemia during pregnancy was most predominant among women with 
vegetable, fruit and protein deficient diet[1]. She went on to discover that this anemia 
could be reversed through the addition of liver and yeast extracts to the diet, indicating 
the presence of an essential dietary component in these sources[2]. As is now well 
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known, such foods and extracts are a rich source of folate[3]. A decade after its first 
description, this component was isolated from 4 tons of spinach leaves in 1941 by 
Mitchell et al, and named “folic acid”[4]. This name was derived from the latin word for 
leaf, ‘folium’. It took another 2 years to elucidate the structure of folic acid and 
synthesize a pure crystalline form[5]. Once the synthetic for was available, folic acid 
proved to be effective in reversing several types of anemia[6-7]. 
 
1.3 The various folate forms 
On the molecular level, folic acid is composed of an oxidized pteridine ring, 
coupled to para-aminobenzoic acid and glutamic acid, leading to the name 
‘pteroylglutamic acid’ (figure 2)[8]. Soon after its synthesis it became apparent that the 
naturally occurring folates were usually structurally altered analogs of FA acid in three 
respects: (1) Reduction within the pteridine ring to 7,8-dihydrofolate (DHF) and further 
reduction to 5,6,7,8-tetrahydrofolate (THF). (2) The fully reduced form, THF, is subject to 
variations in carbon status at the N(5) and N(10) position, e.g. 5-methyl (5-MTHF), 5-
formyl-THF (5-FTHF), 10-formyl-THF (10-FTHF), 5,10-methylene-THF (5,10-METHF) 
and 5,10-methenyl-THF (5,10-MTHF) (figure 2), (3) Natural folates in foods and 
biological systems are almost exclusively in the (γ-linked) polyglutamated state (i.e. an 
increased number of glutamates). 
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Figure 2. Molecular structures of various folate species, the synthetic form folic acid 
(FA) and the naturally occurring forms of 7,8-dihydrofolate and 5,6,7,8-tetrahyrofolate 
(derivatives).   
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1.4 Folate uptake 
Folates are absorbed by the human body in the monoglutamyl form. Since dietary 
sources of the essential vitamin contain folates in the polyglutamated form, hydrolysis 
must occur in order to allow for efficient absorption. Folate hydrolysis occurs in the gut 
by the enzyme folyl-γ-glutamate carboxypeptidase (FGCP), a protein that is immobilized 
on the intestinal apical brush border. Deglutamated folate species are subsequently 
absorbed in the duodenum and upper part of the jejunum by the high-affinity proton-
coupled folate receptor (PCFT). After absorption, the bioavailable form present in the 
systemic circulation is 5-MTHF. Circulating 5-MTHF is then transported into the cell by 
the reduced folate carrier (RFC) or the folate receptors (FR) present on the cell 
membrane. Following folate internalization, the polyglutamation chain is reconstructed 
intracellularly by the enzyme folylpolyglutamate synthase (FPGS). A schematic overview 
of this process is shown in figure 3. 
1.5 Biological function of folates 
Biological active folate species consist of the various substituted forms of intra 
cellular tetrahydrofolate. These molecules function as substrates and coenzymes in the 
acquisition, transport and enzymatic processing of one-carbon units for amino acid and 
nucleic acid metabolism and metabolic regulation. Nucleic acid synthesis is facilitated by 
the role of carbon donating folates in the synthesis of purines and thymidylate and 
through deoxycytosine methylation. Furthermore, 5-MTHF is required in the 
regeneration of methionine from homocysteine, which is employed for various cellular 
methylation reactions and protein synthesis.  
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Figure 3. Schematic overview of folate uptake and transport from the intestine. 
Deglutamated folates are absorbed into the systemic circulation by the PCFT. 
Circulation 5-MTHF is internalized intracellularly trough either the reduced folate carrier 
or the family of folate receptors, after which polyglutamation by FPGS occurs. Figure 
adapted from Blom et al.[9] 
 
Due to the its multitude of functions, folate plays a pivotal role in the synthesis 
and maintenance of DNA, RNA and proteins. A general schematic representation of the 
intracellular folate cycle is given in figure 4.  
 
 
10 
 
 Folate deficiency and/or changes in folate isoform distribution have more recently 
been related to elevated blood homocysteine concentrations, which in turn is closely 
associated with various forms of vascular diseases, such as coronary heart disease and 
venous thrombosis[10]. Inadequate folate status during pregnancy increases the risk of 
neural tube defects and other birth defects[11]. Since folate species play a crucial role in 
the transmethylation reactions required for the biosynthesis of neurotransmitters, folate 
deficiency may also lead to depression[12-15]. Folate status also seems to play a role in 
the development of neurodegenerative disease such as in Alzheimers disease[16]. It has 
also been reported that an individual’s folate status is related to colon, cervical and 
breast cancers[17-18].  
 
Figure 4. Intracellular folate cycle. (figure is adapted and reproduced with permission 
from PharmGKB and Stanford University). 
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1.6 Antifolates 
 
Figure 5. Structures of two key antifolates, aminopterin (AMP) and the still widely used 
methotrexate (MTX). 
 
The first antifolates were developed as potential treatments for leukaemia. In the 
early 1940s the observation was made that leukemic lymphoblasts seen in the bone 
marrow of patients with acute lymphocytic leukaemia resembled the megaloblasts seen 
in pernicious anemia and was correlated with the observation of a low plasma folate 
status. Therefore it was postulated that acute leukaemias were the result of folate 
deficiency[19]. In an attempt to control the disease, patients were treated with FA, a 
strategy that led to the inverse of the desired effect, increasing in the number of 
leukemic cells within these patients. With FA identified as a proliferative factor, Heinle 
and Welch tried an opposite approach and demonstrated a decrease in leukemic cells in 
folate deficiency[20]. This observation triggered the development of folate anti-
metabolites/antagonists.  The first antifolate was developed in 1947 and is currently 
known as aminopterin[21] (AMP) (figure 5). A year later this compound was shown to 
cause temporarily remission in children with acute lymphocytic leukemia[22]. In the same 
year the less toxic analog of AMP, methotrexate (MTX) (figure 5), was introduced[23]. In 
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1956, it was demonstrated that MTX possessed a therapeutic index superior to that of 
AMP, and based on these results, MTX has supplanted AMP in the clinic.   
MTX therapy is now widely used for the treatment of a wide spectrum of cancers and 
tumors, including: leukemia[24], lymphoma[25], choriocarcinoma[26], head and neck 
cancer[27] and osteogenic sarcoma[28-30]. More recently the therapeutic scope of MTX 
has expanded to the treatment of various autoimmune diseases, such as, rheumatoid 
arthritis[31-32], juvenile idiopathic arthritis[33-36], and psoriasis[37-38] and for the prevention of 
graft-versus-host disease[39-40] after transplantation.  
 
1.7 MTX mechanism of action in cancer therapy 
The mechanism of action of MTX in high doses for anticancer therapy is well 
understood. As described in section 1.5 of the introduction, cells rely on a supply of fully 
reduced folates that drive a cascade of one-carbon reactions that are required for DNA 
synthesis and cell proliferation. MTX has a tight, but reversible, binding to the enzyme 
dihydrofolate reductase (DHFR), an enzyme that is responsible for the reduction of FA to 
DHF, and more importantly also facilitates the reduction of DHF to THF. Interfering with 
this enzymatic pathway will result in a buildup of partly oxidized folate species and a 
depletion of the biologically active fully reduced folates, therefore inhibiting the de novo 
purine synthesis pathway and other pathways that rely on reduced folate cofactors. MTX 
displays a stoichiometric binding to DHFR when the ratio of inhibitor to enzyme is low, 
however a complete blockade of DHFR requires an excess of unbound drug[41].  
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1.8 Polyglutamation 
An important aspect of folate homeostasis is the biological process of intracellular 
polyglutamation. Polyglutamation occurs by the sequential addition of glutamates to the 
gamma carboxylate of the terminal folate glutamate residue, resulting in a pool of folate 
polyglutamates (folatePGs). The intracellular, ATP dependant, process of 
polyglutamation is catalyzed by the enzyme folylpolyglutamate synthase (FPGS)[42]. 
Polyglutamation is an important biological process as it is responsible for increasing the 
size of the molecule, rendering it much more anionic, and as a result folate 
polyglutamates cannot diffuse outside the cell. The process of polyglutamation therefore 
allows for intracellular accumulation of folates against the extracellular space 
concentration gradient. Intracellular concentrations of folate are typically in the micro-
molar (µM) range, as opposed to the lower nano-molar (nM) range in plasma. The 
second important feature of polyglutamation is bioactivation, as polyglutamated folates 
have an increased cofactor affinity[43]. The intracellular enzyme gamma glutamyl 
hydrolase (GGH) is involved in the deglutamation of folatePGs. Since polyglutamation 
and deconjugation both are gamma-glutamate specific, the cell has the ability to tailor 
glutamate chain length without affecting other biomolecules such as peptides and 
proteins.  
MTX is a relatively poor substrate for FPGS but does compete with the other 
intracellular folates for polyglutamation. The polyglutamated forms of MTX are either 
equipotent or only marginally more potent DHFR inhibitors compared to native MTX. A 
decrease in MTX polyglutamation has been identified as an important source of clinical 
resistance to MTX. This indicates that MTX polyglutamation serves an important MTX 
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retention/accumulation mechanism rather increasing its DHFR blocking capabilities. The 
polyglutamated forms of MTX however are much more potent inhibitors of enzymes in 
the de novo purine synthesis pathway and pyrimidine synthesis pathway (figure 3). The 
Ki of the pentaglutamyl form of MTX was found to be 250 times higher for thymidylate 
synthase (TYMS), 2500 times higher for 5-aminoimidazole carboxamide ribotide 
transformylase (ATIC), and 30 times higher for  glycinamide ribonucleotide formyl 
transferase (GART) (figure 6)[44]. High-dose MTX in chemotherapy mechanistically 
works due to competitive blockade of DHFR. This is demonstrated by the effectiveness 
of leucovorin in reversing MTXs cytotoxic effect by repletion of the intracellular reduced 
folate pool. 
 
1.9 The development of novel antifolate drugs 
Attempts to further improve the spectrum of therapeutic activity and the 
effectiveness of MTX, as well as the observations of intrinsic and acquired resistance to 
MTX, has led to the search for novel antifolate entities and novel drug delivery strategies 
for the classic agent. The rationale behind the development of novel antifolates for the 
treatment of cancers has been extensively reviewed[45-46]. Briefly these new agents 
include the development of novel DHFR blockers with altered pharmacological features, 
targeting of different enzyme(s) in the folate pathway, modifications to improve affinity 
for FPGS to increase intracellular half-life, and finally “non-classical” lipophilic antifolates 
have been introduced that do not require transport or polyglutamation. Virtually all of 
these approaches are currently the topic of continuing investigations. 
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Figure 6. Cellular folate pathway with both folic acid and MTX represented. Red lines 
represent known inhibition of target enzymes with MTX. (figure reproduced with 
permission from PharmGKB and Stanford University). 
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1.10 Use of MTX in drug delivery systems for cancer treatment 
Site specific delivery of chemotherapy drugs is currently receiving renewed 
attention. Delivery of a drug to a specific tissue or cell type can be achieved by 
conjugating a chemotherapeutic agent to a base material that targets specific receptors. 
In principle the controlled delivery of chemotherapy agents allows for smaller doses of 
drug to be effective against cancer and minimizes collateral damage to the surrounding 
healthy cells and tissues.  MTX is an ideal candidate for such a strategy for 
aforementioned reasons.  
A promising experimental therapeutic for the improvement of the efficacy of MTX and 
the reduction of its side effects is a chemically elaborated generation 5 polyamidoamine 
nanoparticle (G5-PAMAM) (Avidimer Therapeutics, Ann Arbor, MI). Surface 
modifications of the nanoparticle include the incorporation of MTX and FA as the API 
and targeting vector respectively (G5-MTX-FA) (figure 7). As stated before, FA is an 
essential component for cell growth and is required in extreme amounts to support the 
rapid cellular division of cancer cells. Not surprisingly, an important characteristic of 
many cancer cells is the over expression of the folic acid receptor on the cell surface. 
Therefore conjugation of FA to a carrier system provides not only targeting, but also a 
potential internalization mechanism for these nanoparticle conjugated MTX over the free 
MTX. The efficacy of the G5-MTX-FA conjugate compared to free MTX has been 
demonstrated in several in-vitro [47] and in-vivo [48] studies. Mouse studies also 
demonstrated that MTX toxicity was significantly reduced when delivered as G5-MTX-FA 
as compared to the free drug, as indicated by the disappearance of typical high dose 
MTX side effects such as hair and weight loss[49].  
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Figure 7.  Chemical structure of G5-MTX-FA. The G5 PAMAM core is illustrated by the 
sphere (not scale). 
 
Although promising, these high molecular weight nanoparticles are challenging to 
characterize due to their polydispersity which is a result of the multistep synthetic 
procedure used for their preparation.  The inherent polydispersity, macromolecular size, 
and the use of structurally related pteridins (i.e. MTX and FA) of these nanoparticles 
generates a significant bioanalytical challenge for preclinical and clinical investigations. 
Chapter 2 and 3 of this dissertation review the history of these G5-MTX-FA 
nanoparticles and present bioanalytical methodology with high sensitivity and selectivity 
that is needed to support appropriate preclinical and/or clinical investigations of these 
experimental therapeutic agents. 
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1.11 Use of low dose MTX for the treatment of JIA 
JIA is one of the most common chronic diseases of childhood, affecting an 
estimated 300,000 children in the U.S. alone, and is an important cause of morbidity and 
disability in children[50]. Low dose (LD)-MTX intervention, although the most commonly 
used second-line therapeutic agent used to treat JIA worldwide, has shown considerable 
inter-individual variability in both clinical response and adverse reactions, regardless of 
age or disease.  Thus far, no predictive variables have been identified for outcomes in 
patients taking this medication, which is used alone and as an “anchor drug” for many 
rheumatic conditions. 
In contrast to the high dose use of MTX in cancer therapy, the mechanism of action 
of LD-MTX in the therapy of JIA is still not clearly understood. It is not due to DHFR 
inhibition alone since the therapeutic effects of MTX cannot be reversed with leucovorin. 
Although the mechanism is unclear, it is believed that the low dose mechanism of action 
is attributed to inhibition of several additional number of enzymes, including TYMS, 
GART and ATIC by intracellular MTX polyglutamates. MTX polyglutamates have a 
partially increased affinity for ATIC, with the pentaglutamate demonstrating a potency 
increase of 2500 times of that of free MTX. Inhibition of ATIC leads to a cascade of 
biological events resulting in release of adenosine, which is a potent endogenous anti-
inflammatory mediator. In other words, whereas the goal of high-dose MTX in cancer 
therapy is selective cell apoptosis, in LD-MTX the therapeutic aim is to perterb the 
various biochemical pathways of the cell to enhance the excretion of adenosine while 
minimizing cell damage and toxic effects.   
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The development of sensitive bioanalytical methodology for the detection of active 
MTX metabolites could provide an entry to the much needed objective of quantitative 
individualization of MTX therapy in JIA. Plasma MTX concentrations do not correlate to 
LD-MTX efficacy and/or toxicity in autoimmune diseases and therefore interest has 
shifted towards to detection of polyglutmated forms of MTX in human red blood cells 
(RBCs)[51]. In adult arthritis an individual’s RBC MTX polyglutamation status has been 
correlated to MTX effectiveness as well as toxicity[52-53]. However, more recent studies 
have failed to reproduce these results[54-55]. The measurement of RBC MTX 
polyglutamation status and its predictive value towards individualization of MTX therapy 
has not been investigated in JIA. 
In chapter 4 of this dissertation the performance of current methodology for RBC 
MTXPG determination is investigated. Based on the results obtained by this study, a 
novel bioanalytical method was developed which is suitable for the specific and sensitive 
measurement of MTXPG polyglutamation status in JIA. This method was applied to the 
analysis of a clinical cohort involving 100 JIA patients on weekly low dose MTX therapy 
in a collaborative effort with our colleagues at Children’s Mercy Hospital (KC, MO). The 
clinical relevance and its potential for guiding MTX therapy in JIA is discussed in 
appendix 1 and 2.  
Since the measurement of RBC MTXPGs appears to be a useful biomarker for  
individualization of MTX therapy in juveniles, analytical methodology suitable for clinical 
use is required. Chapter 5 and 6 of this dissertation present analytical methodology 
suitable for RBC MTXPG measurement in a clinical setting. 
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1.12 The measurement of folates 
            Since the polyglutamated forms of MTX are competitive inhibitors of various 
enzymes in the folate cycle, enzyme inhibition is a result of intracellular folate/MTX 
(polyglutamation) ratio. As folate is an essential nutrient (i.e. humans lack the ability to 
synthesize folate), an individuals folate status is the result of multiple factors including 
diet. The discrepancy currently noted in the literature about the usefulness of the 
measurement of MTXPG status in RA and JIA therapy, might be the result of the failure 
to recognize the MTX/folate antagonistic balance[55]. One must note that bioanalytical 
methodology for measured of folate isoforms and polyglutamation chain length has not 
been described in human tissues or cells[56]. The detection of both isoform and 
polyglutamation status is challenging from a specificity and sensitivity standpoint. 
Chapter 7 of this dissertation presents bioanalytical methodology for the detection of the 
folate isoform and polyglutamation chain length in the RBCs of JIA patients. The 
presented analytical methodology described was utilized for the determination of folate 
isoform and polyglutamation status of samples obtained from approximately 200 JIA 
patients, in a collaborative effort with our colleagues at Children’s Mercy Hospital (KC, 
MO).  
Approximately 100 patients were on MTX therapy and the other half of the cohort 
was comprised of JIA patients not on MTX therapy. The establishment of a MTX and 
non-MTX group in the patient cohort allows the establishment of a baseline folate status 
and reveals how MTX perturbation alters the intracellular folate cycle. Additionally the 
measurement of the intracellular folate distribution (i.e. isoform and polyglutamation) in 
combination with the measurement of MTXPGs gives us insight in the folate/antifolate 
species present within the cell that compete for similar enzymatic targets. As these 
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bioanalytical assays will lead to an increased understanding of the intracellular 
folate/MTX balance within the cell, it might be possible to describe a “folate signature” of 
MTX responders, or optimize (increase efficacy and reduce toxicity) MTX therapy based 
on quantitative values. This information is invaluable in guiding MTX therapy in JIA as 
alternative therapies are limited. 
  
1.13 Overall goal of the dissertation 
As can be concluded from the introduction, MTX is a versatile drug with a long 
history of clinical use. The more recent applications of MTX are its use for drug delivery, 
and the utilization of low dose MTX therapy for the treatment of autoimmune diseases. 
Classical plasma measurements of free MTX has been proven useful for the guidance of 
free MTX therapy for the treatment of cancers, but has limited value for these more 
recent applications. Therefore novel sensitive bioanalytical methods are needed to 
support the development of novel entities involving MTX and its metabolites, and for 
optimizing and individualizing MTX usage in low dosage regimes.  
From a bioanalytical perspective, the challenges involving the detection of novel MTX 
nanoparticle conjugates, MTX metabolites (polyglutamates) and the detection of folates 
are intimately related. This family of entities (folate or antifolate) all share a common 
pteridine moiety, where changes in compound identity are the result of a minor number 
of substitutions on the pteridine ring system. A similar argument can be made for the 
other end of the molecule, where MTX or folate glutamyl conjugation plays an important 
role (e.g. to a nanoparticle or a  ɣ-glutamyl-polypeptide). 
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This dissertation presents novel bioanalytical methods for the detection of (anti)folate 
species for these more recent MTX application areas. The relevance of the bioanalytical 
methods described in this dissertation is illustrated by direct clinical applications. The 
reader of this dissertation however, is encouraged to utilize the presented methods 
creatively as they are easy adaptable and could be applied to modern clinical 
investigations of antifolate therapy. An example of such an adaption is given in Chapter 
6, where a derivatization reaction initially developed for nanoparticle conjugated MTX 
determination in plasma was utilized for the determination of total MTXPG pool in human 
RBCs. Many techniques presented in this dissertation might also be relevant for the 
bioanalytical chemist working with clinicians in the optimization of MTX therapy in fields 
as psoriasis, adulthood arthritis, inflammatory bowel disease and cancer treatment.  
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2.1 Introduction 
 The following chapter deals with the bioanalytical method development of an 
experimental anticancer agent based on a chemically elaborated nanoparticle carrier. 
First the chemical structure and the physical chemical properties of the nanoparticle are 
described. Subsequently a (clinical relevant) metabolic pathway is proposed and 
analytical targets were selected based on this scheme. The remainder of the chapter 
presents analytical method development, validation, and application of the method to 
obtain preliminary pharmacokinetic data. 
 
2.1.1 Poly(amidoamine) dedritic nanocarriers 
Poly(amidoamine) (PAMAM) dendrimers are hyper-branched, spherical 
molecules with a well defined structure as a result of their stepwise repetitive synthetic 
route[1].  They are constructed around an ethylenediamine core unit, elaborated by 
repetitive alternating alkylation and amidation steps[2].  Each repetitive synthetic iteration 
results in the next dendrimer generation, which has increased size, molecular weight 
and (terminal) surface functional groups[3]. PAMAM dendrimers, the first commercial 
available dendrimers, are currently being touted as drug delivery platforms[4] as a result 
of their relatively monodisperse yet multivalent structure[5-6].  The internal cavities of 
PAMAM dendrimers are relatively hydrophobic and as a result have been utilized for 
encapsulation of poorly water soluble drugs[7], while the ionizable amines of the surface 
can undergo non-covalent electrostatic interactions with an acidic drug[8]. These drug-
dendrimer interactions provide an apparent enhancement of drug solubility[9], improved 
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bioavailability[10] and favorable release profiles. Taking advantage of their surface 
functional groups structural features to potentially achieve tissue specific targeting, these 
dendrimers have been conjugated with numerous molecules to created a chemically 
based drug delivery nanodevice (a number of conjugates are summarized by Cheng et 
al.)[5]. 
 
2.1.2 G5-MTX-FA 
G5-MTX-FA (Avidimer Therapeutics, Ann Arbor, MI) is a chemically elaborated 
generation 5 (G5) PAMAM dendrimer (figure 8). The present research focuses on the  
development of plasma assay methodology suitable to support preclinical evaluation of 
G5-MTX-FA as a targeted chemotherapeutic drug delivery device[11]. The nanodevice is 
a bi-functional G5-PAMAM dendrimer conjugate where the surface primary amine 
 
Figure 8. Chemical structure of G5-MTX-FA. The G5 PAMAM core is illustrated by the 
sphere (not scale). 
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groups have been largely blocked via acetylation[12] in order to reduce non-specific 
interactions and increase solubility[13]. Folic acid (FA) moieties are covalently bonded to 
the dendrimer surface in order to target the nanodevice towards over expressed folate 
receptors that are present on the cell surface of various forms of cancer cells[14]. 
Following receptor binding, the nanodevice appears to be internalized by folic acid 
receptor mediated endocytosis[15]. The therapeutically active agent methotrexate (MTX), 
also covalently attached to the dendrimer surface, is thus delivered to the cell. A detailed 
description of the synthesis procedure for this nanodevice is described elsewhere[16]. 
The efficacy of the G5-MTX-FA conjugate over free methotrexate has been 
demonstrated in several in-vitro[17] and in-vivo[18] studies.  
Based on this biological scenario, the obvious therapeutic goal is the clinical 
development of this potential site specific delivery system whereby the therapeutic agent 
MTX is effective at a lower overall dosage that maximizes effectiveness and minimizes 
side effects. Hence bioanalytical methodology of high sensitivity and selectivity is 
needed to support appropriate preclinical and/or clinical investigations. 
 
2.1.3 Proposed metabolic pathway of G5-MTX-FA 
Since MTX is conjugated through a potentially labile ester bond, G5-MTX-FA may 
release MTX in-vivo. The free MTX will then be subject to known metabolic pathways[19-
21] (figure 9). The major plasma metabolite, 7-hydroxymethotrexate (7OH-MTX), is 
known to exhibit approximately1/100 the bioactivity of MTX. Other known metabolites 
include various polyglutamates (PGs) and 4-amino-4-deoxy-N10-methylpteroic acid 
(DAMPA). Intracellular metabolism of MTX produces the various MTXPGs, which limit 
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the extrusion of MTX by active transport[22]. DAMPA, an inactive metabolite, appears to 
result mainly from oral administration of MTX where the drug substance undergoes 
extracellular metabolism by intestinal bacterial flora[23]. When one considers all of these 
aspects,  it is clear that one needs to develop plasma assay methodology for bound 
MTX (i.e., dendrimer associated), free MTX, and the major metabolite 7OH-MTX.  In 
contrast it is unnecessary to assay the MTXPG family of metabolites, since they are 
essentially trapped in an intracellular pool, nor DAMPA since G5-MTX-FA is intended 
only for vascular administration thus circumventing its formation.  
 
Figure 9. Proposed metabolic degradation scheme for G5-MTX-FA. 
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2.1.4 Reflection on analytical methodology 
As an analytical strategy for  plasma determination of G5-MTX-FA is devised, one 
must be aware that a number of structural deviations are introduced at different stages 
of its multistep synthesis procedure.  For example, in building the G5 PAMAM dendrimer 
core, various skeletal defects (i.e. missing arms, molecular loops, dimers and/or traces 
of trailing generations) result, and further, additional variability is introduced during the 
process of functionalizing the dendrimer surface[24].  
In the past, a variety of complementary analytical strategies have been utilized in 
order to characterize the degree of heterogeneity of such nanoparticles. Spectroscopic 
techniques include, but are not limited to: various types of NMR[12, 24-26], mass 
spectrometric methods (chemical ionization, fast atom bombardment, laser desorption, 
electrospray ionization and matrix assisted laser desorption/time of flight (MALDI-
TOF)[24, 27]) and low angle laser light scattering[1]. A number of separation methods 
including size exclusion chromatography (SEC)[1, 12, 24], capillary electrophoresis (CE) [24, 
28] and polyacrylamide gel electrophoresis[24] have been applied to PAMAM dendrimers. 
Reversed-phase liquid chromatography has been used to separate different generations 
of dendrimers[29] and in one report was able to partially resolve dendrimers of the same 
generation possessing surface modifications with minor variations[30].  
With regard to bioanalysis of G5-MTX-FA, such results are not particularly useful 
as one would expect broad or perhaps multiple unresolved peaks. Review of these 
various techniques immediately reveals that separation performance declines with 
increasing dendrimer size and/or (partial) surface elaboration, leading one to conclude 
that they are not suitable for bioanalysis of G5-MTX-FA in a biological matrix.   
 
 
36 
 
2.1.5 Analytical method requirements 
From an analytical perspective, due to imperfections in the synthetic preparation, 
G5-MTX-FA is a heterogeneous large molecule therapeutic; however, subsequent to 
dosing, this situation can potentially become even more complex, since there is the 
potential for step-wise release of MTX through ester cleavage.  Such a scenario would 
result in an altered nanodevice still possessing therapeutic potential but of lower MTX 
titer. Therefore any bioanalytical methodology should be capable of specific 
determination of total dendrimer associated MTX.  In the present report, the issues of 
macromolecular chromatographic inefficiency and analyte heterogeneity (G5-MTX-FA 
MTX titer) are addressed via a sample preparation step wherein the selective release of 
a highly fluorescent MTX reporter molecule (2,4-diamino-6-methylpteridine) is achieved.  
Assay of the reporter allows for selective and sensitive (low nM) determination by liquic 
chromatography with fluorescence detection (LC-FD) of G5-MTX-FA associated MTX. 
The remaining analytes of interest, free MTX and the metabolite 7OH-MTX, were 
determined by LC separation followed by online post column photochemical reaction 
with fluorescence detection. The developed methodology was used to obtain plasma 
pharmacokinetic profiles of G5-MTX-FA administered to rats by intravenous bolus and 
subcutaneous injections. 
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2.2 Experimental 
2.2.1 Materials  
HPLC grade N,N-dimethylformamide (DMF), Folic acid (FA), 30% solution of 
hydrogen peroxide (H2O2), methotrexate (MTX), potassium permanganate (KMnO4), 
sodium dithionite (Na2O4S2), sodium hydroxide (NaOH) and tris hydrochloride were 
obtained from Sigma-Aldrich. (St. Louis, MO).  Potassium phosphate monobasic 
(KH2PO4), Potassium phosphate dibasic (K2HPO4), Ammonium acetate and HPLC 
grade solvents acetonitrile (ACN) and methanol (MeOH) were obtained from Fisher 
Scientific (Fair Lawn, NJ). 7-Hydroxymethotrexate (7OH-MTX) was purchased from 
Synfine Research (Ontario, Canada). G5-MTX-FA was obtained from Avidimer 
Therapeutics. Blank heparin stabilized rat plasma (Sprague Dawley) was obtained from 
Bioreclamation, Inc (Westbury, NY).  
 
2.2.2 Instrumentation and Apparatus 
G5-MTX-FA System: This system consisted of two Shimadzu LC6A solvent 
delivery modules that were operated through a Shimadzu SCL-6B system controller. 
Sample introduction occured by a Shimadzu SIL-6B autosampler equipped with a 50 μL 
injection loop. A Phenomenex Luna C18(2), 5 µm, 100 Å, 250 x 2.0 mm analytical 
column was guarded by a Supelcosil LC-8, 5 µm, 2 x 2.1 mm guard column and 
maintained at 30°C by a Shimadzu CTO-6A column oven. Detection occurred by a 
Shimadzu RT-10Axl fluorescence detector with excitation and emission wavelengths of 
367 nm and 463 nm, respectively. The data was collected using TurboChrom V4.1. The 
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mobile phase used with this chromatograph consisted of solvent A: 15 mM tris-HCl 
adjusted to pH 6.8 by a 10% NaOH solution and solvent B: consisting of MeOH. The 
system was operated at a flow rate of 0.2 mL/min with 75% A and 25% B.  
Post column photo oxidation system: Solvent was delivered by a Shimadzu LC6A 
binary pumping system that was operated through a Shimadzu SIL-6B system controller. 
The sample was introduced by a Shimadzu SIL-6B autosampler equipped with a 100 μL 
injection loop. The separation was conducted on a Phenomenex Intertsil C18 (150 x 4.6 
mm) column with 5 µm particles with a 100 Å pore size that was protected by a 
Supelcosil LC-8, 5 µm, 2 x 4.0 mm guard column. Two meters of transparent Teflon 
tubing (0.012” id x 0.030” od), one meter in the center braided, was used as reactor coil 
and connected to the outlet of the column (total reactor coil volume 0.14 mL). An in-
house fabricated online photochemical reactor was constructed using a GE Germicidal 
9W lamp as a light source inside of the photochemical reactor (figure 10). Detection 
occurred by a Jasco FP-920 Intelligent Fluorescence Detector (excitation: 360nm and 
emission: 417nm) and data was collected by TurboChrom V4.1. The mobile phase used 
with this chromatograph consisted of solvent A: 975 mL 10 mM potassium phosphate 
buffer pH 6.2, 25 mL DMF and 1.5 mL 30% solution of H2O2 and solvent B: consisting of 
200 mL ACN, 800 mL H2O and 1.5 mL 30% solution of H2O2. The system was operated 
at a flow rate of 1.0 mL/min with 60% A and 40% B. A schematic of the instrument 
configuration is shown in figure 10. 
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Figure 10. Schematic of the post column photo-oxidation HPLC system 
 
2.2.3 Preparation of stock solutions, samples and calibration  
Stock solutions of MTX and 7OH-MTX were prepared according to an earlier 
method presented by Steinborner et al[31]. MTX was dissolved in 95% MeOH and 5% 
formic acid. 7-OHMTX was dissolved in 50% DMSO, 50% H2O. G5-MTX-FA is freely 
soluble and was dissolved in H2O. The stock solutions were diluted with water to the 
desired concentration and spiked into a 100 µL blank plasma matrix to yield calibration 
standards. The linearity and reproducibility of the G5-MTX-FA methodology was 
assessed by the analysis of calibrants (n=6) spiked with 0, 2, 4, 20 , 40, 100, 200, 300 
and 400 µg/mL. Samples spiked with similar concentrations were used to determine 
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intra-day (six replicate) and inter-day (18 replicates analysis conducted over 3 separate 
runs) precision and accuracy. The linearity and reproducibility of the free MTX and 7-
OHMTX methodology was assessed by the analysis of calibrants (n=6) spiked with 
0.075:0.010, 0.15:0.02, 0.75:0.1, 1.5:0.2, 3.7:0.5, 7.6:1.0. 11.4:1.5, 15.3:2.0 µM MTX:7-
OHMTX. Samples spiked with similar concentrations were used to determine intra-day 
(six replicates) precision and accuracy.  
 
2.2.4 Reduction reaction of G5-MTX-FA  
An aliquot of 100 µL of (spiked/sampled) plasma was diluted with a 1.0 M 
ammonium acetate solution to 800 µL in a plastic vial. Once all samples and calibrants 
were prepared they were placed in an in-house manufactured sample holder (details 
provided in supplemental section) that has the ability to lock the caps. Subsequently 200 
µL of a freshly prepared 50 mM Na2O4S2 solution was added and the vials were closed 
and secured by the holder. The entire holder was then vortexed for 10 seconds and 
placed into a water bath of boiling water. After 15 minutes the holder was removed from 
the water bath and stored in a refrigerator for 30 minutes. The cooled samples were 
removed from the holder and placed into a centrifuge for 5 minutes at 10,000 rpm to spin 
down denatured and precipitated plasma proteins. The supernatant was transferred into 
1.0 ml autosampler vials and 50 µL was injected into the G5-MTX-FA LC-FD HPLC 
system. 
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2.2.5 Sample preparation for MTX and 7OH-MTX analyses 
The first step for analysis of the free analyte fraction was protein precipitation 
achieved by adding 30 µL of 10% perchloric acid to 100 µL spiked or sampled plasma. 
The vial then was closed and vortexed for 10 seconds, and the precipitated proteins 
were spun down for 5 minutes at 1.000g. The deproteinized sample was diluted by 
addition of 900 µL of 100 mM ammonium bicarbonate solution (pH 8.0). Aliquots (950 
µL) of the diluted samples were subjected to Solid Phase Extraction (SPE), as described 
below. The recovered analytes were heated in 40 °C water and evaporated to dryness 
under a gentle stream of nitrogen. The residue was reconstituted in 200 µL of 100 mM 
ammonium bicarbonate (pH 8.0). The solution was transferred into a 1.0 mL 
autosampler vial with 350 µL insert and 100 µL was injected onto the post column photo-
oxidation HPLC system. 
 
2.2.6 Solid Phase Extraction (SPE) 
A 100 mg, 1.0 ml Varian Bond Elute Strong Anion Exchange (SAX) SPE device 
was activated with 1.0 ml of MeOH. The column was equilibrated with 1.0 ml of 100 mM 
ammonium bicarbonate solution (pH 8.0). Then 950 µL of sample was applied. 
Interferences were washed from the column with 1.0 ml of 100 mM ammonium 
bicarbonate solution. The retained analytes were eluted by 1.0 ml of a soltution 
consisting of 95% MeOH and 5% formic acid. During extraction the SPE cartridges were 
mounted in a Waters vacuum manifold and the vacuum was adjusted to maintain a 
flowrate of approximately 0.5 ml/min through the cartridge.  
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2.2.7 Rat pharmacokinetic studies 
Animal studies were performed externally by Bolder BioPATH (Bolder, CO), 
including obtaining the appropriate ethical permission. A total of twelve female Lewis 
rats (Charles river, Wilmington, MA) were subjected to treatment in the study. Six 
animals were treated with 65 mg/kg G5-MTX-FA by intravenous injection, and six 
animals were dosed in the subcutaneous tissue in the back of the neck. The drug 
concentration in the saline vehicle was 13 mg/mL. Blood samples were drawn at trough, 
1 hr and 4 hr for three animals and at 0.5 hr, 2 hr and 8 hr for the remaining three 
animals of the group. Blood was collected in heparinized tubes and subsequently spun 
down to obtain the plasma fraction, which was snap frozen and shipped on dry ice. The 
received samples were stored at -70 °C for a month, and thawed before analysis.  
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2.3 Results and Discussion 
2.3.1 Analytical strategy for G5-MTX-FA MTX titer determination 
As noted in the introduction, G5-MTX-FA is a G5 PAMAM dendrimer core that 
has been chemically elaborated to result in a nanodevice whose surface primary amine 
groups have undergone several differing covalent modifications including acetylation, 
conjugation of glycidol, and attachment of folic acid (via an amide linkage) and 
methotrexate (via an ester linkage) (figure 8, 9).  Purely on a statistical basis, one would 
expect a relative degree of heterogeneity in the preparation of such an nanodevice, 
including the loading of the purported therapeutic agent MTX.  For example, a typical 
loading of MTX could be described as an average of 5.5 equivalents per dendrimer, but 
in actuality be constituted from a range of various dendrimer loadings.  Similarly, the 
same arguments can be made for all of the G5-PAMAM core modifications.  Since MTX 
is attached via an ester linkage, a site that is potentially susceptible to biochemical 
mediated hydrolysis, there is the possibility for the in vivo creation of additional 
heterogeneity with respect to dendrimer bound MTX, all with respect to a therapeutic 
agent of whose molecular weight is approximately 40,000 Daltons.  For the therapeutic 
evaluation of G5-MTX-FA, one will be concerned with all the dendrimer associated MTX 
species, i.e. the total G5-MTX-FA MTX titer irrespective of molecular species,  as well as 
any released MTX. Also as noted earlier, the chromatographic efficiency for a 
macromolecule, in this case approximately 40,000 Daltons, as compared to a typical 
small molecule, is significantly compromised. 
 
 
44 
 
 
Figure 11. Two routes of generating fluorescent pteridines involving cleavage of the C9-
N10 bond. A) Oxidative cleavage mediated by KMnO4 B) Reductive cleavage with 
Na2O4S2. 
 
In reviewing various derivatization reactions typical for methotrexate, one notes 
that the C9-N10 bond is labile to oxidation [32-38] and reduction [39] reactions, in either case 
resulting in the formation of  2,4 diaminopterin derivatives, each of which are known to 
be highly fluorescent (figure 11).  The utilization of such reactions in a sample 
preparation step creates a small molecule "reporter" that would exhibit excellent 
chromatographic properties and be highly detectable.  Furthermore in the case of G5-
MTX-FA, if this approach was quantitative, it would result in an amplification of analyte 
concentration on a molar basis since there is expected to be approximately 5-
equivalents of MTX to each dendrimer equivalent.  One must also note the similar 
reactions are applicable to bound FA, and depending on the overall sample preparation 
operations, it could represent an unwanted interference.  While these reactions have 
been applied to MTX determinations [19], application to dendrimer bound MTX (or FA) is 
unknown.  However, if successful, this strategy would effectively transform a large 
molecule analyte to a small molecule analyte, a highly attractive possibility. 
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2.3.2 Initial Evaluation of the Reporter Approach 
As noted above, in order to achieve MTX analysis by HPLC with fluorescence 
detection, MTX is commonly degraded by the oxidative pathway (figure 11A). This 
transformation has been performed by pre-column addition of KMnO4 [32-34], but also can 
be performed post column with the use of H2O2 and photochemical initiation of the 
reaction[35-38]. Post-column degradation of dendrimer associated MTX is not a viable 
option since the degradation products of FA and MTX have similar excitation and 
emission profiles, resulting in a FA-MTX  total response rather than a specific response 
for G5-MTX-FA associated MTX. The application of pre-column oxidation to G5-MTX-FA 
by KMnO4, while being an effective derivatization method for unconjugated MTX (figure 
12A), resulted in a complex mixture of fluorescent products that could not be resolved by 
reversed phase LC (figure 12B). Far less known and applied is reduction of MTX by 
Na2O4S2 to form 2,4-diamino-6-methylpteridine (DAMP) (figure 11B). The yield of the 
reductive reaction has been reported to be 70% [39]. The application of this method to 
aqueous solutions of MTX is shown in (figure 12c), yielding a single peak.  Reduction of 
G5-MTX-FA followed by subsequent analysis by LC-FL yielded two distinct peaks (figure 
12D) that could be assigned as fluorescent methylpterines resulting from reduction of 
G5-MTX-FA associated FA and MTX, indicating successful release. Importantly, in 
contrast to the oxidative release result (figure 12B), the reductive approach (figure 12F) 
was devoid of the numerous chromatographic interferences observed by the oxidative 
method. 
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Figure 12. A) Chromatogram of free MTX degraded by the oxidative pathway B) 
Chromatogram of G5-MTX-FA subjected to the oxidative procedure C) Chromatogram of 
free MTX degraded by the reductive pathway D) Chromatogram of G5-MTX-FA 
subjected to the reductive procedure E) Chromatogram of blank rat plasma subjected to 
the reductive procedure F) Chromatogram of low concentrations of G5-MTX-FA 
subjected to the reductive procedure in rat plasma. 
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2.3.3 Rat plasma determination of G5-MTX-FA 
For plasma analysis, the original MTX reductive method reported the use of 
perchloric acid to achieve deproteinization prior to reduction. This approach was found 
to be incompatible with the G5-MTX-FA apparently due to quantitative co-precipitation 
with plasma proteins. Alternatively the Na2O4S2 mediated reduction of G5-MTX-FA in 
the plasma was evaluated. Reduction of a blank plasma sample at 100 °C led to the 
denaturation and precipitation of plasma proteins to the extent allowing for direct 
injection of the supernatant into the LC system without untoward consequences. The 
result obtained for blank rat plasma is illustrated by chromatogram of figure 12e, where it 
is may be noted that minimal biological noise was generated from the various plasma 
constituents. Subsequently, a G5-MTX-FA spiked rat plasma sample was treated in this 
fashion and, as illustrated in figure 12F, resulted in the successful release of the reporter 
DAMP from the nanodevice. In order to validate the bioanalytical assay, eight-point 
calibration runs involving six replicates were performed on three consecutive days (table 
1).  
 
Table 1. G5-MTX-FA intra- and inter-day precision and accuracy in a rat plasma matrix. 
  Intra-run (n=6) Inter-run (n=18) 
Nominal 
Concentration 
(µg/mL) 
Mean 
observed 
concentration 
(µg/mL) 
Precision       
(RSD %) 
 Mean 
Accuracy            
of target 
value 
(%) 
Mean 
observed 
concentration 
(µg/mL) 
Precision       
(RSD %) 
 Mean 
Accuracy            
of target 
value (%) 
400 391.1 4.9 97.8 403.1 9.0 100.8 
300 307.4 4.1 102.5 300.9 6.1 100.3 
200 202.6 6.5 101.3 200.4 6.8 100.2 
100 108.5 5.9 108.5 104.4 10.2 104.4 
40 39.8 5.5 99.5 38.7 6.7 96.6 
20 19.3 6.9 96.7 19.2 8.1 96.2 
4 3.9 6.9 97.6 3.8 8.5 95.3 
2 2.0 4.0 101.5 2.0 6.1 101.4 
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It was found that the procedure was linear over an G5-MTX-FA concentration range of 
2-400 µg/mL utilizing only 100 µL of plasma. Since G5-MTX-FA has an estimated 
molecular weight of 37 kDa, one could also express the results on a molar scale, 
ranging in a dynamic range from ~50 to 10,000 nM, covering the anticipated in-vivo 
concentration range of this experimental therapeutic. Inter-day and intra-day precision 
and accuracy were found to be well within the commonly accepted guidelines for a 
bioanalytical assay.   
 
2.3.4 Dog plasma determination of G5-MTX-FA 
 In-vivo toxicology studies of G5-MTX-FA were also conducted in Beagle dogs, 
along with the various rat studies. In order to support these studies, the suitability of the 
rat plasma method presented in section 2.3.3 was explored for the analysis of dog 
plasma samples. G5-MTX-FA spiked dog plasma gave similar chromatograms 
compared to G5-MTX-FA enriched rat plasma, indicating that the method could be 
directly transferred between these matrices. In order to assess the reproducibility and 
accuracy of the method in dog plasma, a similar validation experiment was performed as 
reported in section 2.3.3 (table 2). As demonstrated by table 1 and 2, the performance 
(precision and accuracy) of the reductive method for the analysis of G5-MTX-FA is 
similar in both, dog and rat plasma respectively. Inter- and intra-run accuracy and 
precision are well within the FDA guidelines of Crystal City defining that accuracy and 
precision should be within <15% in the calibration range, and <20% at the detection 
limit. Limits of detection were set 2ug/mL, however the precision of 8.7% at this value 
suggest limit of detection could be challenged further. 
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Table 2. Intra- and inter-day precision and accuracy in a Beagle plasma matrix. 
   Intra-run (n=6) Inter-run (n=18) 
Nominal 
Concentration 
(µg/mL) 
Mean 
observed 
concentration 
(µg/mL) 
Precision       
(RSD %) 
 Mean 
Accuracy            
of target 
value (%) 
Mean 
observed 
concentration 
(µg/mL) 
Precision       
(RSD %) 
 Mean 
Accuracy            
of target 
value (%) 
400 393.9 5.0 98.5 396.2 6.5 99.1 
300 309.6 4.1 103.2 302.9 5.4 101.0 
200 204.1 6.6 102.1 205.4 6.6 102.7 
100 109.3 5.0 109.3 107.1 7.8 107.1 
40 40.1 5.6 100.3 38.0 6.3 95.1 
20 19.5 6.9 97.4 19.0 7.8 94.8 
4 3.9 7.0 98.3 3.4 10.3 86.0 
2 2.0 4.0 102.3 1.9 8.7 92.5 
 
 
2.3.5 Determination of free MTX and 7OH-MTX 
Determination of in-vivo released MTX and the metabolite 7-OHMTX was 
accomplished by established methodology that involved liquid chromatography (LC) 
fractionation followed by post-column photochemistry ((PC(hv)) with fluorescence 
detection (FD)[35-38]. This approach allows for the separation and specific quantitation of 
MTX and various metabolites including 7O-HMTX and if necessary DAMPA. Since G5-
MTX-FA would only be dosed via intravenous injection, DAMPA was not an analytical 
target of the present effort. However, using the LC-PC(hv)-FD approach, the resulting 
methodology is such that DAMPA is not an interference with respect to MTX and 7OH-
MTX, and if required could be used for DAMPA determination. 
Separation of MTX and 7OH-MTX was conducted on a end-capped reversed 
phase C18 column. The selectivity factor of this column for the separation of MTX and 
7OH-MTX is not optimal, and as a result MTX and 7OH-MTX were only partially 
resolved, or lengthy analysis times are required in order to facilitate separation (figure 
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13A). It has been shown that the resolution between both compounds can be improved 
on a C18 column through the addition of dimethylformamide (DMF) to the mobile 
phase[36].  Using relatively small percentages of DMF as a mobile phase additive, 
typically 2.5% by volume, allowed for high separation selectivity with respect to the 
resolution of MTX and 7OH-MTX and an overall separation time of 10 minutes (figure 
13B, C, D). 
 
 
 
Figure 13. Separation of MTX and 7OH-MTX with A) no DMF in the mobile phase B) 1% 
DMF in the mobile phase C) 2.5% DMF in the mobile phase D) 5% DMF in the mobile 
phase. 
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Sensitive detection of both MTX and 7OH-MTX was achieved by optimization of 
the post column PTFE reaction coil length. Longer columns would allow for more 
sensitive detection of MTX, but lead to over oxidation of 7OH-MTX resulting in 
diminished detection sensitivity (figure 14). A compromise was made between both 
signals by using a reactor coil with a length of 1 meter, resulting in an 
exposure/residence time of the analytes in the photo reactor of about 4 seconds at a 
flow rate of 1.0 mL/min. This residence time maximizes the detection sensitivity of the 
MTX metabolite 7OH-MTX which is generally a present in lower concentrations that 
MTX itself in plasma, therefore maximizing the detection potential for this low abundance 
metabolite. 
 
Figure 14. Optimization of the fluorescence signal for MTX and 7OH-MTX by varying 
the reactor coil length and therefore reaction/residence time. 
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2.3.5.1 Determination of free MTX and 7OH-MTX out of rat plasma 
Sample preparation consisted of two straightforward steps. The analytes were first 
isolated in the supernatant obtained subsequent to perchloric acid mediated protein 
precipitation. In a second step the analytes were subjected to an SPE extraction, using a 
strong anion exchange (SAX) cartridge in order to reduce biological background (figure 
15A). The SPE step provided an interference free chromatographic window which was 
utilized for the isocratic separation of MTX and 7OH-MTX (figure 15B).  
 
Table 3. Intraday validation of free MTX in rat plasma 
Nominal MTX 
Concentration (µM) 
Mean observed 
concentration (µM) 
(n=6) 
Precision       
(RSD %) 
 Mean Accuracy            
of target value (%) 
15.3 15.2 2.0 99.3 
11.4 11.1 5.6 97.0 
7.6 7.8 7.3 102.9 
3.7 4.3 5.3 116.2 
1.5 1.4 11.3 96.6 
0.75 0.67 3.8 89.0 
0.15 0.14 6.1 94.4 
0.075 0.080 14.5 107.0 
 
Figure 15. A) Rat plasma interference removal by performing a SAX SPE extraction. B) 
rat plasma enriched with MTX and 7OH-MTX at various concentrations. 
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Assay specificity with regard to G5-MTX-FA associated MTX was investigated by the 
analysis of various spiked controls (concentrations as high as 0.1 mg/mL). G5-MTX-FA 
was not observed in any of the LC-PC(hv)-FD chromatograms, thus demonstrating the 
assay is specific for MTX and 7OH-MTX regardless of G5-MTX-FA concentrations. A 
limited validation (8 points calibration with 6 replications for each concentration) was 
performed since this methodology has been largely described in the literature (table 3 
and 4). The  limit of quantitation for MTX and 7OH-MTX  was determined to be 50 nM 
and 10 nM, respectively.  
 
2.3.5.2 Determination of free MTX and 7OH-MTX out of Beagle plasma 
As stated before in-vivo toxicology studies of G5-MTX-FA were also conducted in 
Beagle dogs. It was found that the free analyte method could be directly transferred from 
rat plasma to dog plasma without any alterations to the chromatographic system or 
sample preparation procedure. The method was validated according to a similar protocol 
Table 4. Intraday validation of free 7OH-MTX in rat plasma 
Nominal 7OH-MTX 
Concentration  
(µM) 
Mean observed  
concentration (µM) 
(n=6) 
Precision  
(RSD %) 
 Mean Accuracy  
of target value (%) 
2 2.0 3.4 101.10 
1.5 1.4 5.8 96.14 
1 1.1 7.6 105.04 
0.5 0.59 5.5 118.94 
0.2 0.18 9.4 91.49 
0.1 0.09 5.7 92.05 
0.02 0.020 4.9 99.62 
0.01 0.009 19.9 85.65 
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as in 2.3.5.1, running 6 replicates at 8 different concentrations (table 5 and 6). As 
illustrated by table 2 and 3 intra-day accuracy and precision are well within FDA 
guidelines for a bioanalytical assay, where deviations up to 20% are acceptable. 
 
Table 5. Intraday validation of free MTX in Beagle plasma 
Nominal MTX 
Concentration (µM) 
Mean observed 
concentration (µM) 
(n=6) 
Precision       
(RSD %) 
 Mean Accuracy            
of target value (%) 
15.3 14.5 3.6 94.5 
11.4 11.5 3.8 100.7 
7.6 8.1 0.7 106.1 
3.7 3.8 3.5 102.0 
1.5 1.3 4.1 89.8 
0.75 0.66 3.2 87.5 
0.15 0.13 5.4 83.3 
0.075 0.064 7.4 85.2 
 
 
 
 
 
Table 6. Intraday validation of free 7OH-MTX in Beagle plasma 
Nominal 7OH-MTX 
Concentration  
(µM) 
Mean observed  
concentration (µM) 
(n=6) 
Precision  
(RSD %) 
 Mean Accuracy  
of target value (%) 
2 1.9 3.3 95.2 
1.5 1.6 4.3 107.1 
1 1.2 2.4 119.1 
0.5 0.57 3.9 114.8 
0.2 0.22 4.3 108.6 
0.1 0.11 3.1 111.3 
0.02 0.019 3.2 95.4 
0.01 0.009 14.9 92.0 
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2.3.6 G5-MTX-FA Sample Preparation Issues 
Pre-column reduction for detection of G5-MTX-FA associated MTX is 
compromised by any (released) free MTX within the sample that will form the same 
fluorescent product upon degradation. In order to achieve specific detection of G5-MTX-
FA associated MTX, attempts were made to separate the nanodevice from free MTX. A 
variety of SPE sorbents including C18, SAX, WCX and PLEXA were explored in order 
to either retain the dendrimer conjugate with free MTX eluting in the void volume, or vice 
versa. The recovery of G5-MTX-FA after SPE extraction was found to be low, non-linear 
and highly irreproducible, with lower regions of the calibration curve affected more 
severely. Similar behavior of G5-MTX-FA was observed utilizing SEC and ultra-filtration 
materials. Significant analyte loss at low µM concentrations due to adsorption could be 
observed upon exposure of a standard solution of G5-MTX-FA to a glass surface. 
Previous work has reported that amine-terminated PAMAM dendrimers adsorb 
tenaciously to polar surfaces making chromatography on this class of compounds 
difficult[29]. In the present investigation, adsorption of a surface deactivated G5-MTX-FA 
dendrimer conjugate was observed, suggesting that the G5 PAMAM core may become 
partially exposed and available for interactions, perhaps due to an initial absorption and 
subsequent rearrangement of the three dimensional structure.  
 
2.3.7 Successful Sample Pretreatment of G5-MTX-FA 
Significant loss of G5-MTX-FA was encountered in all of the various sample 
preparation steps examined.  Reflecting upon this situation, these results are could be 
due to the numerous polar interaction sites of the macromolecule (numerous amide 
 
 
56 
 
moieties reside along each of the dendrimer arms), thus once a given untoward 
interaction occurs, a second and following interactions likely would occur, essentially 
providing a cascade of events leading to unwanted binding and loss of the 
macromolecule analyte.  However, as previously noted, reductive cleavage to provide a 
small molecule reporter was a highly successful approach to quantitation of G5-MTX-FA. 
If one subjected an untreated plasma sample to the reduction reaction, perhaps there 
would be a reproducible release of the reporter, which would remain in solution and not 
be subject to the various G5-MTX-FA loss processes previously observed. However, the 
consequence is that the total measured MTX concentration consists of G5-MTX-FA 
associated MTX and free MTX. Since free MTX can be determined accurately and 
independently of G5-MTX-FA associated MTX, one could perform both determinations 
and subtract the free MTX value from the apparent total to obtain G5-MTX-FA  
associated MTX.  As this strategy was devised, the in-vivo MTX release behavior of G5-
MTX-FA was not clear, but three scenarios could be expected. Category 1, none to very 
little (<1%) MTX is released from G5-MTX-FA. In this scenario free MTX could be 
determined accurately and the total MTX value obtained by the reductive method closely 
reflects G5-MTX-FA associated MTX with minimal correction required. Category 2, MTX 
release is significant but not the major product and total G5-MTX-FA requires correction. 
Category 3, there is a significant release of MTX from the nanodevice, with free MTX 
serving to dominate the total value as compared to G5-MTX-FA associated MTX.  
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*Concentrations of G5 associated MTX are based on the assumption that on spiked G5-average 
5.48 MTX molecules are attached. 
 
In order to analyze the feasibility of this approach, a number of cases with 
significant MTX release were simulated. Various samples were spiked with G5-MTX-FA 
and free MTX, divided into two separate aliquots, and analyzed by the reductive (total 
MTX obtained) and the LC-PC(hv)-FD method respectively (table 7). Analysis of the first 
3 cases in table 4  (falling in category 2) show that free MTX content was determined 
accurately and independently of G5-MTX-FA concentration. Subtraction of the free MTX 
content from the measured MTX total by the reductive method yielded the expected 
(known) G5-MTX-FA concentration, proving that subtraction is a viable method for 
category 2 cases. The last 3 cases could be assigned as category 3, having high free 
MTX content. Free MTX could again be determined accurately independently of G5-
MTX-FA content, however subtraction of free MTX content from the obtained MTX total 
did not result in accurate G5-MTX-FA associated MTX values. High standard deviations 
are however expected in this type of scenario, since a relatively large number (and its 
associated absolute standard deviation) is subtracted from a nearly equal number (with 
its standard deviation), resulting in a relatively small difference. A result observed for this 
Table 7. Method specificity and mathematical correction. 
MTX 
(µM)* 
Spiked Free 
MTX (µM) 
Total MTX in 
sample (µM) 
Total MTX 
Measured 
by 
reduction 
(µM) 
Free MTX 
measured 
(µM) 
Calculated 
G5 MTX 
content 
(µM) 
Mean 
Accuracy  
of G5-MTX 
value (%) 
23.0 3.9 26.9 25.9 3.9 22.0 95.6 
17.3 0.8 18.0 17.0 0.9 16.1 93.5 
11.5 1.6 13.1 13.2 1.6 11.7 101.5 
5.8 15.6 21.4 22.6 15.5 7.1 123.6 
2.3 7.8 10.1 9.5 7.7 1.8 79.9 
1.2 11.7 12.9 12.6 11.9 0.8 65.4 
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mathematical correction is a extremely large relative standard deviation, and thus 
imprecision associated with the G5-MTX-FA determination. As these results became 
available, information emerged indicating that category 1 describes the in-vivo fate of 
G5-MTX-FA for rats  (see the results provided in the application section), thus no further 
method development efforts were required. 
 
2.3.8 Stability 
Stability data is shown in table 8. The stability of G5-MTX-FA was studied at 
intermediate to high concentrations, so significant amounts of released MTX would be 
detectable. The derivatized product DAMP was found to be stable in the autosampler at 
room temperature for 24 hr illustrated by the small R.S.D. for repetitive analysis over this 
time course. All of the samples were analyzed within 24 hr this window. G5-MTX-FA 
spiked plasma samples were stable over three consecutive freeze-thaw cycles, and no 
free MTX due to ester cleavage could be detected. Prior work has described the stability 
of the MTX ester linkage to the nanodevice at pH 2.25 for 59 days at room temperature 
in highly aqueous media[30]. The percentage of released MTX was found to be less than 
1 percent, suggesting that the ester linkage not particularly labile. In order to 
demonstrate that the ester linkage is not hydrolyzed by esterases during sample 
processing, G5-MTX-FA spiked plasma samples were incubated at room temperature 
for 4 hours (exceeding standard processing time), and subsequently analyzed. Free 
MTX could not be detected, indicating that esterlinkage is stable in rat plasma during 
sample processing and handling. Samples from a pharmacokinetic study were stored for 
 
 
59 
 
a month before analysis occurred. G5-MTX-FA was found to be stable at -70 °C over 
this time frame (table 8). 
 
Table 8. Stability of G5-MTX-FA under various conditions (n=5) 
    
Storage condition 
G5-MTX-FA related MTX 
concentration (µg/mL) R.S.D. 
(%) 
Free MTX 
Free 7OH-
MTX 
  nominal measured measured measured 
Stability in autosampler 50 51.9 0.8 ND ND 
 
100 103.4 0.8 ND ND 
 
200 188.1 0.5 ND ND 
Freeze-thaw stability 50 47.5 10.1 ND ND 
 
100 102.9 3.9 ND ND 
 
200 198.9 4.0 ND ND 
Incubation at 25 °C (4h) 50 46.1 1.9 ND ND 
 
100 100.9 0.7 ND ND 
 
200 182.6 2.5 ND ND 
Stability at -20 °C (1 month) 50 54.6 4.5 ND ND 
 
100 104.2 7.7 ND ND 
 200 207.7 3.0 ND ND 
 
 
2.3.4 Reporter Chemistry for Determination of G5-MTX-FA Titer 
As noted in the introduction, characterization of the degree of surface modification 
of dendrimer conjugates is an analytical challenge. In order to determine an average 
MTX or FA titer of the G5-PAMAM derivatives, researchers have applied UV 
spectroscopy, gel permeation chromatography or have taken advantage of MTXs or FAs 
aromatic hydrogens on the para-aminobenzoic acid residue that appears downfield in a 
proton NMR spectrum[16]. The effectiveness of both strategies diminishes with increasing 
size, complexity and intermolecular interaction of dendrimer conjugates.  
The reductive release method demonstrated in the previous paragraph provides a 
potential complimentary strategy for determination of MTX titer. Assuming the yield of 
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reductive cleavage of the C9-N10 bridge in free MTX and G5 conjugated MTX is similar, 
the G5-MTX titer can be determined by running individual calibration curves. The 
difference in slope between individual calibration curves of free MTX and G5 conjugated 
MTX reveals the number of MTX molecules associated with G5 (equation 1).  
 
(Eq. 1) MTX loading = G5-MTX-FA related MTX slope / MTX std slope. 
 
Although not within the scope of method development, a similar argument could be 
made for determination of the FA loading of the nanodevice (equation 2).  
 
(Eq. 2) FA loading = G5-MTX-FA related FA slope / FA std slope. 
 
Various lots of G5-MTX-FA were supplied by Avidimer Therapeutics for valuation 
of MTX and FA titer (table 9). The MTX titer varied between 4.84 and 10.16 MTX 
molecules per nanoparticle. Lot 0505-001 of G5-MTX-FA was used for the analytical 
method development and was found to bear on average 5.15 molecules of MTX per G5 
PAMAM core unit, by the reductive method (table 9). Information provided by the 
supplier indicated approximately 5-6 MTX molecules per G5 PAMAM core unit could be 
expected, which is in substantial agreement with the present findings.  
 
 
 
 
 
 
 
61 
 
Table 9. G5-MTX-FA related MTX FA titer determination   
   
lot std [G5-MTX-FA] uM MTX area MTX - statistics 
MTX 
titer FA area FA - statistics 
FA 
titer 
123-34 
1 0.086 1411591 r^2: 0.998 
6.221 
69465 r^2: 0.993 
0.492 
2 0.171 3698321 228743 
3 0.342 6844653 
slope: 21571743 
334365 
slope: 953099 4 0.685 13581518 712390 
5 1.37 29421989 1217554 
0505-001 
1 0.081 1480690 r^2: 0.999 
5.151 
42701 r^2: 0.998 
0.322 
2 0.162 3197696 94691 
3 0.324 5768268 
slope: 17831219 
174527 
slope: 637559 4 0.6487 11721408 386135 
5 1.297 23257656 816670 
0147-135 
1 0.086 1718343 r^2: 0.998 
4.841 
40306 r^2: 0.998 
0.412 
2 0.172 4093268 142838 
3 0.346 7560776 
slope: 16741453 
287852 
slope: 792169 4 0.691 16051808 548374 
5 1.382 31118674 1085550 
06-02-0001 
1 0.089 1568317 r^2: 0.993 
5.901 
82331 r^2: 0.998 
0.492 
2 0.179 3781184 170311 
3 0.357 8095449 
slope: 20428177 
371968 
slope: 948106 4 0.714 14435970 706376 
5 1.428 - 1355976 
0083-112 
1 0.085 2681269 
r^2: 0.999 
10.161 
38670 
r^2: 0.997 
0.322 
2 0.169 5271335 97636 
3 0.338 11856236 
slope: 35184146 
204302 
slope: 618420 4 0.676 23316396 379370 
5 1.352 47191623 831796 
1 MTX standard curve statistics: r2: 0.999, slope: 3462379 
2FA standard curve statistics: r2: 0.986, slope: 1942248 
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G5-MTX-FA was found to bear on average 0.5 FA molecules per core unit, which 
was substantially different from the information supplied by the provider of G5-MTX-FA, 
which had indicated an average of 5 FA molecules covalently attached to the 
nanocarrier core. The nature of this discrepancy at this point is not understood, however 
the difference might be indicative of side reactions during coupling of FA or the 
introduction of structural modifications to the FA pteridine core in subsequent synthetic 
steps (reaction with glycidol and the addition of MTX). Detecting these minor FA 
modifications is challenging with the spectroscopic techniques described earlier in this 
introduction of this chapter. However, (slighty) structurally altered FA will behave 
differently upon reduction, possibly have different emission and excitation wavelengths, 
and will be separated by reversed phase chromatography, and thus (minor) variations 
chemical variations will lead to a diminished FA titer using this method.  
In order to investigate the effect of side reactions, the FA titer was determined on 
several isolated intermediates during the G5-MTX-FA synthesis procedure. The first step 
in the synthetic procedure is partial acylation of the PAMAM dendrimer core, followed by 
carbodiimide coupling of FA. Analysis of the FA coupled intermediate revealed by the 
reductive procedure indicated that 0.82 FA molecules were attached per dendrimer core 
unit, again significantly less than the suggested 5 FA molecules/dendrimer core unit 
(figure 16), but higher than the 0.32 FA/G5-MTX-FA measured on the final product. 
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 The next step in the synthetic procedure aims for derivitization of the remaining 
primairy amines on the surface of the PAMAM nanoparticle with glycidol (figure 17). 
Subjection of this 2nd intermediate to the reductive procedure reveals that there are 0.30 
FA molecules associated with the nanoparticle, indicating a further loss of roughly 2/3 of 
the FA molecules during this procedure. As suggested earlier in this paragraph, due to 
the high specificity of this method, a lower FA titer can also be observed due to covalent 
modifications on FA. Since characterization of G5-MTX-FA was not within the research 
scope, further studies to investigate the discrepancies between the various analysis 
methods were not conducted. However, it is important to note that the targeting vector of 
the nanodevice (FA) might have a covalently altered structure and largely presents itself 
in this fashion to the over expressed folate receptors on the cancer cell surface, rather 
than glutamyl linked native FA.  
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Figure 16. FA-titer determination (a) on a G5-MTX-FA intermediate (b) that has been 
partially acylated, followed by conjugation with FA. The FA-titer was determined at 0.82 
FA/core unit. 
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2.3.5 Application of the method 
The plasma reduction approach described above was utilized for analysis of 
plasma samples obtained form a toxicology study in rats. The rats were given doses of 
50, 200, 400 and 800mg/kg G5-MTX-FA by intavenous injection (IV). The early time 
point samples had to be diluted 1:10 prior to analysis (i.e after reduction) in order to 
reduce concentration and prevent detector over-ranging. G5-MTX-FA could be 
determined in all of the resulting plasma samples (Figure 18A). Free analytes, MTX and 
7OH-MTX, only could be detected in rats dosed at 800mg/kg. The MTX concentrations 
observed were low and quickly dropped below the limits of detection for the free analyte 
assay (Figure 18B). The plasma profile of MTX suggests, that at a given time point, the 
circulating free MTX mass accounts for ~0.06% of the total MTX mass. In prior work, 
stability of the MTX ester bond linkage to the nanodevice had been tested at pH 2.25 for 
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Figure 17. FA-titer determination (a) on a G5-MTX-FA intermediate that has been subjected 
to reaction with glycidol (b) The FA-titer was determined at 0.30 FA/core unit. 
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59 days at room temperature in highly aqueous media [30]. The percentage of released 
MTX was found to be less than 1 percent, suggesting that the ester linkage not 
particularly enzyme labile. In the present investigation, it appears that the ester bond is 
also stable in-vivo in the presence esterases and other endogenous compounds, 
however future work is needed to ascertain the hydrolysis rate constant in biological 
matrices. The presently described analytical methodology would allow for such a study, 
but is beyond the scope of the present work. 
Preliminary pharmacokinetic profiles of G5-MTX-FA in rats at dosages clinically 
more relevant were also obtained. Three animals received G5-MTX-FA at a dose of 65 
mg/kg by IV injection (Figure 18C), and three animals were treated with a similar dose 
by subcutaneous injection (SC) (Figure 18D). After IV injection, G5-MTX-FA appears to  
undergo a rapid distribution phase (Figure 18A, C) followed by rapid clearance from 
plasma, which is consistent with earlier reports [18]. G5-MTX-FA plasma concentrations 
observed,  when administered in the SC tissue, were typically much lower compared to 
the IV samples. The maximal G5-MTX-FA plasma concentration was observed 8 hours 
after administration (Figure 18D). For accurate pharmacokinetic modeling, an increased 
number of data points is required, especially with regard to the elimination phase. 
However, the sensitivity of the present analytical methodology was found adequate for 
the plasma analysis of G5-MTX-FA in rats and would support such a study. 
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Figure 18. A) G5-MTX-FA plasma PK profile of a 800mg/kg IV dosed rat. B) PK profile 
of G5-MTX-FA released MTX, same animal as shown in (A). C) G5-MTX-FA plasma PK 
profile of 65mg/kg IV dosed rats (n=3). D) G5-MTX-FA plasma PK profile of 65mg/kg SC 
dosed rats (n=3). 
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2.4 Conclusion 
  A bioanalytical assay is presented for the analysis of G5-MTX-FA associated 
MTX, released MTX and the major metabolite 7OH-MTX in plasma samples. Due to 
difficulties associated with various sample preparation approaches, a strategy was 
developed wherein the sample was divided into two aliquots with each being analyzed 
with differing but complementary methodology. The result was that one aliquot, without 
any other sample preparation steps, could be subjected to a reductive reaction to 
release a highly fluorescent reporter molecule. The second sample aliquot was used to 
determine any released MTX and the major metabolite 7OH-MTX after subjecting the 
sample to an appropriate SPE procedure followed by LC-PCR(hv)-FD. The analysis 
strategy for G5-MTX-FA associated MTX could not distinguish between conjugated and 
free MTX. However, it was demonstrated that the amount of MTX released in plasma by 
the nanodevice is insignificant, and as a result the presented strategy is specific for G5-
MTX-FA associated MTX. Free MTX and 7OH-MTX could be determined specifically, 
irrespective of the nanodevice concentration. The presented methodology was 
successfully used to establish a preliminary plasma pharmacokinetic profile of G5-MTX-
FA in rats. Finally, the reductive release method allows for the determination of glutamyl 
conjugated MTX titer of functionalized PAMAM polymers. 
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3.1 Introduction 
It has been shown that half life plays an important role in the effectiveness of 
dendritic nanoparticles[1-2]. The decline in blood concentration after nanoparticle 
administration results from elimination by the body. The elimination rate constant is 
predominantly a function of hepatic and renal clearance. The size of the dendritic 
nanoparticle plays an important role in its susceptibility towards renal clearance. There 
have been several recent reports that indicate that once the molecular weight of a 
spherical nanoparticle approaches 30,000 to 40,000 dalton, the renal excretion rate and 
the volume of distribution of the entity reduces significantly, resulting in longer circulation 
times and an increased half-life[3-4]. Based on size, it has been stated that the 
hydrodynamic radius of dendritic particles should at least approach that of a renal pore 
(~5 nm) to avoid elimination due to glomerular filtration[5]. The diameter of a generation 5 
PAMAM nanoparticle is about 5.3 nm, and the diameter of G5-MTX-FA will be slightly 
increased due to the additional surface modifications, placing it near the renal clearance 
cut-off values presented for these type of entities. The preliminary pharmacokinetic data 
presented in the previous chapter (Chapter 2, figure 18) revealed a relatively short half-
life of G5-MTX-FA, suggesting this nanoparticle is a candidate for renal clearance. 
Knowledge of the fraction of the drug excreted into urine is an important parameter in 
understanding how the human body handles the drug and provides useful information 
about the influence of renal disease. Accurate modeling of the fraction of the 
experimental therapeutic excreted into urine requires an analytical method for detection 
of the drug and its metabolites with a similar rationale presented in chapter 2.  
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The previous chapter described the reaction and chromatographic conditions for 
the detection of nanoparticle associated MTX and free MTX in plasma matrices. Initially 
it was believed that the method could be transferred with minor modifications (i.e. 
chromatographic conditions) towards urine analysis. However, it became apparent that 
besides a number of alterations to the chromatographic and sample preparation, the 
derivatization procedure did not proceed to desirable extent in urine. This chapter deals 
with the optimization of the derivatization reaction, sample preparation and 
chromatography of G5-MTX-FA in urine. 
 
3.2 Experimental 
3.2.1 Materials  
HPLC grade N,N-dimethylformamide (DMF), folic acid (FA), 30% solution of 
hydrogen Peroxide (H2O2), methotrexate (MTX), potassium permanganate (KMnO4), 
sodium dithionite (Na2O4S2), sodium hydroxide (NaOH) and TRIS-hydrochloride were 
obtained from Sigma-Aldrich. (St. Louis, MO).  potassium phosphate monobasic 
(KH2PO4), potassium phosphate dibasic (K2HPO4), ammonium acetate and HPLC 
grade solvents acetonitrile (ACN) and methanol (MeOH) were obtained from Fisher 
Scientific (Fair Lawn, NJ). 7-hydroxymethotrexate (7OH-MTX) was purchased from 
Synfine Research (Ontario, Canada). G5-MTX-FA was obtained from Avidimer 
Therapeutics (Ann Arbor, MI). Blank heparin stabilized rat plasma (Sprague Dawley) , 
blank heparin stabilized dog plasma (Beagle) and blank unfiltered urine was obtained 
from Bioreclamation, Inc (Westbury, NY).  
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3.2.2 Instrumentation and Apparatus 
G5-MTX-FA System: This system consisted of two Shimadzu LC6A solvent 
delivery modules that were operated through a Shimadzu SCL-6B system controller. 
Sample introduction occured by a Shimadzu SIL-6B autosampler equipped with a 50 μL 
injection loop. A Phenomenex Luna C18(2), 5 µm, 100 Å, 250 x 2.0 mm analytical 
column was guarded by a Supelcosil LC-8, 5 µm, 2 x 2.1 mm guard column and 
maintained at 30°C by a Shimadzu CTO-6A column oven. Detection occurred by a 
Shimadzu RT-10Axl fluorescence detector with excitation and emission wavelengths of 
367 nm and 463 nm, respectively. The data was collected using TurboChrom V4.1. The 
mobile phase used with this chromatograph consisted of solvent A: 15 mM tris-HCl 
adjusted to pH 6.8 by a 10% NaOH solution and solvent B: consisting of MeOH. The 
system was operated at a flow rate of 0.2 mL/min with 75% A and 25% B, unless stated 
otherwise. 
Post column photo oxidation system: Solvent was delivered by a Shimadzu LC6A 
binary pumping system that was operated through a Shimadzu SIL-6B system controller. 
The sample was introduced by a Shimadzu SIL-6B autosampler equipped with a 100 μL 
injection loop. The separation was conducted on a Phenomenex Intertsil C18 (150 x 4.6 
mm) column with 5 µm particles with a 100 Å pore size that was protected by a 
Supelcosil LC-8, 5 µm, 2 x 4.0 mm guard column. Two meters of transparent Teflon 
tubing (0.012” id x 0.030” od), one meter in the center braided, was used as reactor coil 
and connected to the outlet of the column (total reactor coil volume 0.14 mL). An in-
house fabricated online photochemical reactor was constructed using a GE Germicidal 
9W lamp as a light source inside of the photochemical reactor. Detection occurred by a 
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Jasco FP-920 Intelligent Fluorescence Detector (excitation: 360nm and emission: 
417nm) and data was collected by TurboChrom V4.1. The mobile phase used with this 
chromatograph consisted of solvent A: 975 mL 10 mM potassium phosphate buffer pH 
6.2, 25 mL DMF and 1.5 mL 30% solution of H2O2 and solvent B: consisting of 200 mL 
ACN, 800 mL H2O and 1.5 mL 30% solution of H2O2. The system was operated at a 
flow rate of 1.0 mL/min with 60% A and 40% B, or as stated otherwise.  
 
3.2.3 Reduction reaction of G5-MTX-FA  
An aliquot of 100 µL of (spiked/sampled) urine was diluted with a 1.0 M 
ammonium acetate solution to 800 µL in a (1.5 mL) plastic vial. If plasma was added to 
the vial as well, the 100 µL urine samples was diluted 1:1 with rat plasma, prior to further 
dilution by the ammonium acetate solution. Once all samples and calibrants were 
prepared they were placed in an in-house manufactured sample holder (details provided 
in supplemental section) that has the ability to lock the caps. Subsequently 200 µL of a 
freshly prepared 50 mM Na2O4S2 solution was added and the vials were closed and 
secured by the holder. The entire holder was then vortexed for 10 seconds and placed 
into a boiling water bath. After 15 minutes the holder was removed from the water bath 
and stored in a refrigerator for 30 minutes. The cooled samples were removed from the 
holder and placed into a centrifuge for 5 minutes at 10,000 rpm (1,000 g) to spin down 
denatured and precipitated plasma proteins. The supernatant was transferred into 1.0 ml 
autosampler vials and 50 µL was injected into the G5-MTX-FA LC-Fl HPLC system. 
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3.2.4 Preparation of Stock Solutions, samples and calibration  
Stock solutions of MTX and 7OH-MTX were prepared according to an earlier 
method presented by Steinborner et al. MTX was dissolved in 95% MeOH and 5% 
Formic acid. 7-OHMTX was dissolved in 50% DMSO, 50% H2O. G5-MTX-FA is freely 
soluble and was dissolved in H2O. The stock solutions were diluted with water to the 
desired concentration and spiked into a 100 µL blank plasma matrix to yield calibration 
standards. The linearity and reproducibility of the G5-MTX-FA methodology was 
assessed by the analysis of calibrants (n=6) spiked with 25, 50, 125, 250, 375 and 500 
µg/mL for rat urine analysis, and concentrations of 13, 25, 63, 125, 188 and 250 µg/mL 
were used in combination with dog urine. Samples spiked with similar concentrations 
were used to determine intra-day (six replicate) and inter-day (18 replicates analysis 
conducted over 3 separate runs) precision and accuracy. The linearity and 
reproducibility of the free MTX and 7OH-MTX methodology was assessed by the 
analysis of calibrants (n=6). MTX and 7OH-MTX were spiked in as a mixture and 
concentrations are given in table 3 and 4. Samples spiked with similar concentrations 
were used to determine intra-day (six replicates) precision and accuracy.  
 
3.2.5 Sample preparation for MTX and 7OH-MTX analyses 
Spiked urine sample (volume 100 µL) were diluted by addition of 900 µL of 100 
mM ammonium bicarbonate solution (pH 8.0). Aliquots (950 µL) of the diluted samples 
were subjected to Solid Phase Extraction (SPE). The recovered analytes were heated in 
40 °C water and evaporated to dryness under a gentle stream of nitrogen. The residue 
was reconstituted in 200 µL of 100 mM ammonium bicarbonate (pH 8.0). The solution 
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was transferred into a 1.0 mL autosampler vial with a 350 µL liner and 100 µL was 
injected onto the post column photo-oxidation HPLC system. 
 
3.2.6 Solid Phase Extraction (SPE) 
A 500 mg, 1.0 ml Varian Bond Elute Strong Anion Exchange (SAX) SPE device 
was activated with 1.0 ml of MeOH. The column was equilibrated with 1.0 ml of 100 mM 
ammonium bicarbonate solution (pH 8.0). To the equilibrated column, 950 µL of sample 
was applied. Interferences were washed from the column with 1.0 ml of 100 mM 
ammonium bicarbonate solution. The retained analytes were eluted by 1.0 ml consisting 
of 95% MeOH and 5% formic acid. During extraction the SPE cartridges were mounted 
in a Waters vacuum manifold and the vacuum was adjusted to maintain a flowrate of 
approximately 0.5 ml/min through the cartridge.  
3.3 Results and Discussion 
3.3.1 Chromatographic Method Development 
Initial rat urine method development involving the detection of G5-FA-MTX 
associated MTX was started by evaluating the methods performance towards the urine 
matrix, utilizing the previously established plasma analysis protocol (chapter 2). The pilot 
experiments demonstrated a more complex biological background in urine as opposed 
to plasma, including co-elution of the analytes derivatization product (DAMP) with an 
unidentified endogenous compound (figure 19A). The two compounds were resolved by 
reduction of the modifier strength at the consequence of increased analysis time and 
reduction of analytical throughput (figure 19B, C). Separate batches of rat urine 
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demonstrated variable interference patterns (figure 19C, D), with one batch 
demonstrating a interferent (1) requiring the previously discussed increase in 
chromatographic analysis time. However this interferent did not appear in any of the 
other samples (figure 19D). Peak purity was checked by analysis of various blank urine 
matrices and no co-eluting/interfering compounds were detected in the elution window of 
DAMP using the LC-FL system. 
 The interference pattern of dog urine was substantially different compared to rat 
urine, requiring an additional chromatographic method (figure 20A). Dog urine contained 
a co-eluting compound with the analyte being retained for about 20 minutes, a 
separation time that provided an adequate separation in rat urine analysis. The co-
elution of these compounds is indicative of a poor selectivity factor between the 
compounds using a C18 stationary phase and methanol as the organic modifier. The 
interferent and analyte could be baseline separated in a lengthy chromatographic 
procedure requiring an analysis time of about 50 minutes and an isocratic separation 
with 5% MeOH (Figure 20, B, C). The resulting procedure suffered from a lack of sample 
throughput and broad peaks that reduced the limit of detection. A substantial 
improvement selectivity factor was achieved when the organic modifier was changed 
from MeOH to tetrahydrofuran (THF). The increased selectivity factor resulted in a fast 
isocratic separation of DAMP from endogenous interferences within 15 minutes (figure 
20, D).  It is important to note that the elution order of the interferent and reduction 
product has reversed, something that proved to be favorable for trace analysis, where 
small amounts of DAMP would otherwise have to be detected on the shoulder of a 
dominant peak resulting from the interferent.  
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Figure 19. HPLC-FL chromatograms of G5-MTX-FA spiked rat urine (derivatized). (1) 
endogenous interferent, (2) G5-MTX-FA reporter (DAMP). (A) Chromatogram obtained at 
25% B, 1 and 2 co-elute. (B) Chromatogram obtained at 20% B, 1 and 2 co-elute. (C) 
Chromatogram obtained at 15% B, 1 and 2 are separated. (D) Chromatogram of G5-
MTX-FA spiked in a different batch of rat urine where the major endogenous interferent 
(1) is not present. 
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Figure 20. HPLC-FL chromatograms of G5-MTX-FA spiked dog urine (derivatized). (1) 
endogenous interferent, (2) G5-MTX-FA reporter (DAMP). (A) Chromatogram obtained 
at 15% B, 1 and 2 co-elute. (B) Chromatogram obtained at 10% B, 1 and 2 co-elute. (C) 
Chromatogram obtained at 5% B, 1 and 2 are separated. (D) Chromatogram obtained 
with THF instead of MeOH as modifier, note that the elution order of the peaks 1 and 2 
is inverted. 
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3.3.2 Matrice Influence on the Derivatization Procedure 
Once the chromatographic variables were established, the G5-MTX-FA 
associated MTX analysis procedure in rat urine was validated. Surprisingly, the 
derivatization reaction that proved to be useful for the plasma analysis did not perform 
adequately in the urine matrix, both from a sensitivity and reproducibility (within and 
between days) perspective (figure 21, red trace). Analysis of the regression line slope 
indicates a relative yield for the G5-MTX-FA reduction reaction of 5.1% in rat urine when 
compared against a similar protocol utilizing rat plasma (figure 21, black trace). One 
might argue that a loss of 20 fold in sensitivity of the analytical method is (at least partly) 
compensated for by the fact that compounds that are primarily eliminated through the 
renal clearance pathway accumulate into urine, reducing the need for optimal limits of 
detection. However, additionally the derivatization reaction also proved to be 
irreproducible, demonstrating relative standard deviations up to 47% in the linear range, 
vastly exceeding acceptable error tolerances for bioanalytical method development. The 
low yield of the reaction in rat urine as opposed to rat plasma suggests that there is a 
reaction mediating factor present in plasma, and/or an effective reaction quenching 
component in urine.  
Early in the plasma method development process it was observed that the 
relative derivatization yield in the plasma matrice was 2.5 (figure 21, blue trace) times 
higher when compared to a similar procedure utilizing water opposed to plasma, 
supporting the hypothesis of the presence of a reaction mediating/catalyzing compound. 
This increase in apparent yield of reaction was not further investigated at the time, 
however the importance of a consistet matrix throughout preparation of standards and 
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samples was pointed in the previous chapter. Despite the favorable properties of the 
plasma matrix on the reaction, it is also clear that the urine matrix reduces the extent of 
the derivatization reaction to an addition degree, demonstrated by a significant lower 
yield of the derivatization reaction in urine compared to water (figure 21).  
Based on an extensive screening of sample preparation stratagies, chapter 2 
concludes that derivatization has to occur directly within the biological matrix to yield 
reproducible results, before exposure to any sample clean-up procedures. Within these 
borders the key to a successful analysis strategy for urine analysis would be optimizing 
the urine derivatization reaction so it behaves comparable to the plasma derivatization 
reaction, rather than including an extensive clean-up procedure. Improving the 
derivatization procedure requires an extensive knowledge of the various chemical 
pathways, so the reaction could be directed to yield the desired products. The following 
section will present a plausible reaction mechanism based on data that has appeared in 
the literature. 
 
Figure 21. Individual G5-MTX-FA calibration curves in various matrices. rat plasma 
(black line), rat urine (red line), water (blue line). 
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3.3. 4 Mechanism of Reduction 
 
 
Figure 22. Hypothesized derivatization scheme of G5-MTX-FA associated MTX in the 
presence of dithionite (only the MTX related reactions are shown). 
  
The reduction of MTX to 2,4-diamino-6-methylpteridine (DAMP) is a multistep 
chemical cascade, involving multiple electron transfer steps. A reaction scheme has 
been proposed by R.C Gurira et al., based on results obtained by various analytical 
techniques and electrochemical reduction (figure 22). Whilst making the assumption that 
G5-MTX-FA behaves similar to free MTX under reductive conditions, these observations 
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would also hold for the derivatization procedure of the nanoparticle. In an initial reduction 
step, MTX undergoes a 2 electron, 2 proton reduction to 5, 8-dihydro-MTX. Depending 
on the pH of the solution 5,8-dihydro-MTX tautomerizes to the more stable 7,8-dihydro-
MTX or a proton catalyzed cleavage of the C(9)-N(10) bond to yield DAMP. 7,8-dihydro-
MTX can undergo a reductive cleavage of the C(9)-N(10) bond, to yield 2,4-diamine-6-
methyl-7,8 dihydropteride (7,8-dihydroDAMP), which upon subsequent (auto)oxidation 
step gives raise to the desired fluorescent reporter DAMP. At this time it is unclear which 
kinetic pathway is dominating in the G5-MTX-FA derivatization procedure at pH 6.0 with 
excess dithionite, but independent of the kinetic pathway DAMP is generated. R.C 
Gurira et al also report that at pH 3-9 MTX and DAMP have similar reduction potentials. 
Considering the fact that the derivatization procedure utilizes a large molar excess of 
dithionite, it should be expected that any DAMP formed by the protoncatalyzed cleavage 
of the C(9)-N(10) bridge of 5,8-dihydro-MTX will be rapidly reduced to 7,8-dihydroDAMP 
until the dithionite is depleted, and then auto-oxidation to DAMP will occur. An additional 
reduction of 7,8-dihydroDAMP is possible to 2,4-diamino-6-methyl-5,6,7,8-
tetrahydropteridine, however this reduction has a potential of - 1.31 V at pH 6 and 
therefore does not occur with dithionite as reducing agent (- 0.66 V at pH 7). To 
conclude, it appears that the sodium dithionite mediated reduction of MTX follows the 
following pathway, MTX  7,8-dihydro-MTX  DAMP  7,8-dihydroDAMP  DAMP.   
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3.3.5 Adapting the Urine Derivatization Reaction 
As mentioned before 7,8-dihydroDAMP is a highly unstable compound which is 
susceptible for auto-oxidation to DAMP. From a detection point of view this is a desirable 
process, and it appears that there is a component in plasma that facilitates this auto-
oxidation. Whilst the compound(s) in plasma responsible for this behavior are unknown, 
it was hypothesized that various metals in plasma are responsible for this redox 
behavior. These metals are present in both, a free, and protein bound form where they 
are released upon denaturation of the protein in the incorporated boiling stage, possibly 
providing a constant oxidation factor in the procedure. In an attempt to address this 
auto-oxidation factor in plasma, various concentrations (0, 0.1, 1, 10 mM) of Fe3+ were 
added to the aqueous buffer solution before the derivatization procedure was started. 
The presence of Fe3+ greatly influenced the apparent yield of reaction, reaching a 
maximal effect at 1 mM (figure 23).  
 
Figure 23. Effect of Fe3+ concentration on reaction yield (fluorescence response) 
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It is tempting to believe that Fe3+ aids in the re-oxidation of 7,8-dihydroDAMP to 
DAMP. If this were true, the addition of Fe3+ post reduction should yield similar results. 
An experiment was conducted where 1 mM of Fe3+ was added prior and post reaction 
(figure 24 A). Independent of the stage of Fe3+ addition a similar increase in formation of 
DAMP was observed compared to a reference derivatization reaction in buffer. It was 
also observed that the overall yield was about 70% of that obtained when derivatizing in 
a plasma matrix. In order to investigate if the addition of Fe3+ was beneficial for G5-MTX-
FA urine analysis, a comparable experiment was performed using a rat urine matrix. The 
presence of Fe3+ during the derivatization reaction had similar beneficial effects as 
reported before. However, the addition of Fe3+ post derivatization did not demonstrate 
any increase in apparent reaction yield (figure 24 B).  
 
Figure 24. The influence of the stage of Fe3+ addition, aqueous reference, reduction in 
the presence of 1 mM Fe3+, and an reduction followed by the addition of 1 mM Fe3+. (A) 
aqueous matrix (B) rat urine matrix. 
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Elucidating the reaction mechanism was beyond the scope of this work. However 
on a speculative basis it seems plausible that due to the addition of Fe3+ post reaction, 
competing nucleophiles present in the urine matrix have a time window to scavenge the 
unstable/partly reduced 7,8-dihydroDAMP.  Since urine contains large quantities of 
organic molecules with reactive sulfur and nitrogen functional groups, nucleophilic 
addition reactions are a possibility, trapping and depleting 7,8-dihydroDAMP levels 
before reoxidation to DAMP could occur upon the addition of Fe3+. With the discovery 
that the presence of an oxidation factor/mediator during reduction was important in the 
derivatization procedure, a validation experiment was performed, using Fe3+ during the 
reduction of G5-MTX-FA in rat urine. It was found that sensitivity of the method had 
increased, but the precision of the method was still poor when compared to validation 
result of similar measurements out of plasma (figure 25).  
 
Figure 25. Comparison between the various matrix compositions and instrument 
response. G5-MTX-FA in plasma (black line), G5-MTX-FA in urine + Fe3+ (red line), G5-
MTX-FA in urine + plasma (blue line), G5-MTX-FA in urine (green line). 
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Since the reduction of MTX to DAMP occurs in a reproducible fashion, and 
plasma being identified as an important component of the derivatization reaction, it was 
tempting to believe that the addition of an aliquot of plasma to a urine sample would lead 
to precise and reproducible MTX derivatization. The addition of plasma to urine 
however, adds numerous endogenous interferences to the already complex biological 
sample. However it was expected, based on the observation that since the derivatization 
reaction of MTX in plasma resulted in relatively clean LC-FL chromatograms, the 
addition of rat plasma would not further complicate the chromatogram. Chromatograms 
of G5-MTX-FA derivatized in a plasma/urine matrix are presented in figure 26. As 
illustrated by figure 26 A and C, the addition of plasma to the urine matrix did not result 
in more complex chromatograms, demonstrating the feasibility of plasma enrichment of 
the urine sample, to mediate the derivatization reaction. 
In order to investigate if the addition of plasma to the urine matrix would yield the 
desired increase in robustness of the method, a single day calibration involving the 
analysis of urine samples containing 6 different concentrations in 5 replicates was 
performed (figure 25, blue line). The experiment indicated that precision and 
reproducibility of G5-MTX-FA reduction in a combined urine plasma matrix was greatly 
improved when compared to derivatization in Fe3+ enriched urine (figure 25, red line).  
The yield of the plasma mediated urine derivatization reactions is overall about 70% of 
that compared to reduction plasma, indicating that competing kinetic pathwats, trapping 
reduced forms of MTX derivatives during their transformation pathway to DAMP are still 
partially active. 
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Figure 26.  HPLC-FD chromatograms of derivatized G5-MTX-FA in various urine matrix 
compositions. (A) Blank  rat urine spiked with G5-MTX-FA. (B) 1 mM Fe3+ enriched rat 
urine spiked with G5-MTX-FA (C) G5-MTX-FA spiked in blank rat urine that was 
combined with an aliquot of rat plasma. 
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3.3.6 Validation of the G5-MTX-FA Associated MTX Analytical Procedure 
 As it appeared that the procedure was repeatable when rat plasma was used as 
an oxidative mediator, an extensive validation procedure was started utilizing rat and 
dog urine as model systems. The linear range, precision and accuracy of the method 
were assessed by analyzing 6 different G5-MTX-FA concentrations in 6 replicates. The 
reproducibility of the method was addressed by repeating the experiment for three 
consecutive days. Intra- and inter-run validation data involving the rat urine matrix is 
demonstrated in table 10.  The precision of the method was in general < 10% except for 
the most concentrated value, where the inter-run precision was 19.7%. The accuracy of 
the method was also acceptable with values in general deviating <10% from the target 
value. At the low end of the calibration curve some larger deviations are seen, however 
not exceeding 15%. A typical intra-day calibration plot can be described by the equation: 
y = 3.903 * 107x + 2.259 * 105, where (y) is the instrument response and (x) is the 
concentration of G5-MTX-FA in rat urine in mg/mL). The lowest intra-day correlation 
coefficient obtained was R² = 0.9985, spanning a 500 fold change in concentration 
range (0.025 – 0.500 mg/mL). The limit of quantification for G5-MTX-FA associated MTX 
was around 0.025mg per mL of rat urine.  
Intra- and inter-run validation data in dog urine is summarized in table 11.  The 
precision of the method was in general < 10% except for the most dilute value, where 
the inter-run precision was 31.6%.The accuracy of the method was also acceptable with 
values deviating in general <10% from the target value. The limit of quantification for G5-
MTX-FA associated MTX was around 0.025mg per mL of dog urine. A typical intra-day 
calibration plot can be described by the equation: y = 7.907* 107x - 1.645 * 105, where 
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(y) is the instrument response and (x) is the concentration of G5-MTX-FA in dog urine in 
mg/mL). The lowest intra-day correlation coefficient obtained was R² = 0.9992. 
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3.7 Free MTX and 7OH-MTX Analysis in Rat and Dog Urine 
 
Figure 27. Chromatograms of MTX and 7OH-MTX in rat urine extracts (A) and dog urine 
SPE extracts (B). 
 
As demonstrated in chapter 2, minor amounts of MTX are hydrolysed from the 
G5-MTX-FA nanoparticle in vivo. Liberated MTX will be a candidate for hepatic 
metabolism, transforming MTX in 7OH-MTX. Both of these entities are largely excreted 
into urine. A detection strategy for free MTX and 7OH-MTX in plasma has been 
presented in the previous chapter and involved reversed phase separation combined 
with post column photo chemical derivatization and fluorescence detection. Sample 
preparation occurred by strong anion exchange (SAX) solid phase extraction (SPE), 
followed by an evaporation and reconstitution step in order to obtain an RP-HPLC 
compatible sample. In the process of obataining an analysis strategy for free MTX and 
7OH-MTX the plasma method was evaluated towards a dog and rat urine matix. The 
high ionic strength in the urine matrix led to break through of the 100 mg SAX SPE 
cartridge, leading to low recoveries (10-20%) and irreproducible results. The analyte 
breakthrough was eliminated by increasing the bed volume of the SAX SPE cartridge to 
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500 mg. The use of these 500 mg cartridges resulted in recoveries >90% for both 
analytes and reproducible results. Furthermore the application of these cartridges led to 
relatively “clean” chromatograms where the analytes could be separated within 15 
minutes (figure 27 A and B). There were some hydrophobic interferences observed that 
had long retention times. In order to prevent the carryover of these more hydrophobic 
entities in a subsequent analysis, a step gradient was incorporated at the end of each 
run in order to clean the column.  
 Since the detection of free MTX and 7OH-MTX has been largely described in the 
literature, a limited intra-day validation was performed, demonstrating the viability of the 
presented method. The Intra-day precision and accuracy of the free analyte assay was 
determined by analyzing 6 replicates of standards spiked with six different MTX and 
7OH-MTX concentrations in both rat (table 12, 13) and dog urine (table 14, 15). The 
intra-day precision did not exceed 11.6% and in was in general well below 10%, both for 
dog and rat urine. The accuracy of assay in rat urine did not exceed 20% deviation at 
the limit of detection (1.6 µM), and was well within the limits for a bioanlytical assay over 
the remaining part of the linear range. Similar observations were made in the analysis of 
MTX and 7OH-MTX in dog urine. 
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Table 12. Intra-day validation of free MTX in rat urine 
Nominal Concentration 
(µM) 
Mean observed 
concentration (µM) 
(n=6) 
Precision       
(RSD %) 
 Mean Accuracy            
of target value (%) 
31.1 30.6 3.6 98.2 
23.3 23.7 1.8 101.7 
15.6 16.1 6.1 103.7 
7.8 7.9 7.2 101.0 
3.1 2.9 4.8 94.2 
1.6 1.3 9.2 81.1 
 
Table 13. Intra-day validation of free 7OH-MTX in rat urine 
Nominal Concentration 
(µM) 
Mean observed 
concentration (µM) 
(n=6) 
Precision       
(RSD %) 
 Mean Accuracy            
of target value (%) 
5.9 5.8 4.8 98.0 
4.4 4.5 1.7 103.0 
2.9 3.0 5.6 101.7 
1.5 1.5 8.1 99.2 
0.59 0.57 2.8 96.9 
0.29 0.26 11.6 88.8 
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Table 14. Intraday validation of free MTX in dog urine 
Nominal Concentration 
(µM) 
Mean observed 
concentration (µM) 
(n=6) 
Precision       
(RSD %) 
 Mean Accuracy            
of target value (%) 
36.6 35.9 7.9 98.0 
27.4 28.6 3.9 104.0 
18.3 17.3 10.0 94.3 
9.2 9.3 6.5 101.9 
3.7 4.0 10.4 108.3 
1.8 1.7 12.2 91.1 
 
Table 15. Intraday validation of free 7OH-MTX in dog urine 
Nominal Concentration 
(µM) 
Mean observed 
concentration (µM) 
(n=6) 
Precision       
(RSD %) 
 Mean Accuracy            
of target value (%) 
8.2 8.2 9.8 100.4 
6.1 6.3 6.6 103.8 
4.1 3.6 8.6 89.3 
2.0 2.0 3.5 99.7 
0.82 0.90 3.2 110.5 
0.42 0.50 11.0 123.0 
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3.4 Conclusion 
 The analysis and characterization of G5-MTX-FA imposes an analytical 
challenge. The detection of this entity in biological matrices is even further complicated 
by the presence of a large number of endogenous compounds. Attempts at isolating G5-
MTX-FA from a sample matrix by common sample preparation techniques such as SPE 
extraction have failed to give reproducible results and linear responses. The sodium 
dithionite mediated reduction of G5-MTX-FA associated MTX to DAMP gives rise to a 
highly detectable small molecule entity that does not demonstrate any of the negative 
physical chemical properties complicating intact G5-MTX-FA analysis. Interestingly, the 
matrix plays an important role in the chemical degradation pathway of G5-MTX-FA 
conjugated MTX to DAMP. The highest and most reproducible derivatization yields are 
obtained when there is a plasma component within the derivatization matrix, possibly 
aiding in the re-oxidation of 7,8 –dihydroDAMP to DAMP. This observation proved to be 
useful for the analysis of G5-MTX-FA associated MTX in dog and rat urine. Precision, 
accuracy and sensitivity of the urine assay were significantly improved when the 
derivatization occurred in the presence of an aliquot of rat plasma. Chromatographic 
analysis of dog and rat urine samples was complicated by a larger number of 
endogenous interferents. Both dog and rat urine needed matrix individualized 
chromatographic procedures. A co-eluting compound in dog urine could not be 
separated in an acceptable time frame using MeOH as the modifier, however a 
separation could be accomplished when the selectivity factor of the assay was adapted 
by using THF as the organic modifier. 
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 Detection of free MTX and 7OH-MTX was relatively straight forward, utilizing SAX 
SPE, followed by HPLC separation and post column photochemical degradation and 
fluorescence detection. It was observed that the bed volume of the SPE cartridge 
needed to be increased when dealing with samples with an increased ionic strength. 
Whereas an SAX SPE cartridge with an 100mg bed volume was adequate for plasma 
analysis, the bed volume needed to be increased to 500mg per SPE cartridge in order to 
prevent the analyte from breaking through during urine analysis. The same isocratic 
chromatographic separation could be performed independent of the matrix composition, 
however the detection of free analytes out of urine required the addition of a step 
gradient at the end of each analysis in order to eliminate hydrophobic contaminants from 
the chromatographic media. 
 In the animal studies discussed in chapter 2 urine was not collected. Due to this 
absence of urine samples, the methods presented have not been applied to animal urine 
samples in order to detect G5-MTX-FA associated MTX and related analytes in urine. 
The renal clearance rate of G5-MTX-FA has therefore not been determent yet, and 
animals studies need to be performed in order to adequately answer this question. 
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4.1 Introduction 
In adult populations, methotrexate (MTX) is one of the most commonly prescribed 
drugs for the treatment of rheumatoid arthritis (RA)[1-2]. In contrast to non-steroidal anti-
inflammatory drugs used to relieve the symptoms of RA, MTX is categorized as a 
disease modifying anti-rheumatic drug, i.e. an agent that reduces disease activity and 
slows the progression of joint damage.  MTX also forms the therapeutic cornerstone for 
pediatric patients suffering from Juvenile Idiopathic Arthritis (JIA)[3]. The efficacy, safety 
and relatively low toxicity of weekly low dose MTX therapy in children with JIA has been 
shown in a number of clinical trials[4-6]. 
Despite the fact that MTX is one of the best tolerated disease modifying drugs, 
there is a large inter-patient variability in clinical response and toxicity that is poorly 
understood in both RA and JIA. The MTX dose that provides an acceptable level of 
disease control varies greatly, and studies have been published indicating the presence 
and absence of a dose-response relationship. Measurement of MTX plasma 
concentrations in low dose MTX therapy is of little value since there is a lack of 
correlation between serum concentrations and disease activity, mainly because MTX is 
largely cleared from plasma within 24 hours by glomerular filtration and tubular secretion 
or is stored intracellularly as MTX polyglutamates (MTXPGs)[7-8] (figure 28).  
MTX is transported into cells by the reduced folate carrier where it is converted by 
folylpolyglutamate synthase to MTXPGs by sequential addition of glutamic acid residues 
at the γ position of the terminal glutamate residue[9].  Polyglutamation results in an 
overall increase in net negative charge, providing a cellular retention mechanism.  
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Figure 28. Structure of methotrexate and its polyglutamates. The common m/z 308.10 
fragment obtained by collision induced dissociation is illustrated by the dotted line. 
 
A number of studies have indicated that MTXPGs are the bioactive form of MTX, with 
pharmacological action related to MTXPGs concentration and population distribution[9-
11].  The anti-inflammatory action of MTX results from inhibition of enzymatic pathways 
involved in de novo purine synthesis, leading to increased concentrations of adenosine, 
which has the ability to serve as an anti-inflammatory agent[12].  Since intra-cellular 
MTXPGs appear to form the therapeutically active bioavailable pool, these substances 
obviously constitute an interesting analytical target to monitor and potentially utilize as a 
basis for optimization of MTX therapy. 
With MTX historically being used in high dose as an anti-cancer agent, analytical 
methods were focused on the detection of MTX[13] and MTXPGs[14] in plasma and urine, 
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mainly by chromatographic methods, rather than intracellular levels of MTXPGs.  
Current methodology for the determination of MTXPGs in human red blood Cells (RBCs) 
can be categorized into methods that detect the sum of MTXPGs, and methods that are 
able to determine cellular levels of individual MTXPGs, typically MTXPG1-5. 
Chromatographic methods for total MTXPG are based on an pre-chromatographic 
enzymatic de-glutamation step that converts the MTXPGs back to MTX.  Total MTX is 
then determined by LC separation (isocratic[15] or gradient elution[16]) and a subsequent 
post-column photochemical[17-18] (PCR(hν)) or electrochemical[19] reaction to form a 
product(s) amenable to fluorescent detection (FD).  Other reported strategies involve the 
use of radiochemical-ligand binding[20], enzymatic[21] and fluorescence polarization 
immunoassays[22].  Individual MTXPGs have been measured by coupling a fractionation 
step to earlier reported assays[23-24], leading to complicated labor intensive assays. The 
specificity of these non-chromatographic detection methods has been questioned due to 
discrepancies observed for results obtained by LC based methods[25].  In 2003, Dervieux 
et al. reported a strategy utilizing reversed-phase liquid chromatography post-column 
photochemical reaction (LC-PCR(hν)−FD) for detection of MTXPG1-7 in a single run[16].  
Surprisingly to date, mass spectrometry detection (MS) of (intra-cellular) MTXPG levels 
has received little attention. Recently Chen et al. reported an LC tandem mass 
spectrometry assay (LC-MS/MS) for the measurement of MTXPG1-5 in Caco-2 cells, 
leading to improved selectivity and lower detection limits[26].  However, no reports of LC-
MS/MS based methods for the detection of MTXPGs in RBCs have appeared in 
literature.  
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Presently our laboratory is collaborating with colleagues at Children's Mercy 
Hospitals and Clinics (Kansas City, MO) to investigate the MTXPG state in combination 
with genomic assesment of children undergoing therapy for JIA.  In the present work we 
evaluated the performance of an LC-PCR(hν)-FD, which was found to be problematic. 
As a result we have subsequently developed LC-MS/MS based methodology that is 
highly sensitive and specific for the detection of MTXPGs and appears to be superior to 
all previously reported methods. 
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4.2 Experimental 
4.2.1 Materials 
LC grade solvents acetonitrile (ACN) and methanol (MeOH) were obtained from 
Fisher Scientific (Fair Lawn, NJ, USA). Ammonium bicarbonate, N, N-
Dimethylhexylamine (DMHA) and methotrexate were purchased from Sigma-Aldrich (St 
Louis, MO, USA). Methotrexate polyglutamation standards 4-amino-10-
methylpteroyldiglutamic acid (MTXGlu2), 4-amino-10-methylpteroyltriglutamic acid 
(MTXGlu3), 4-amino-10-methylpteroyltetraglutamic acid (MTXGlu4), 4-amino-10-
methylpteroylpentaglutamic acid (MTXGlu5), 4-amino-10-methylpteroylhexaglutamic 
acid (MTXGlu6), 4-amino-10-methylpteroylheptaglutamic acid (MTXGlu7) were 
purchased as the ammonium salts from Schircks Laboratories (Jona, Switzerland). 
Oasis HLB solid phase extraction (SPE) cartridges (30mg) were obtained from Waters 
(Milford, MA, USA). 
 
4.2.2 Preparation of erythrocyte (RBC) lysates 
Blood samples (~5 ml) obtained from patients were centrifuged at low speed 
(2000 rpm) in a Beckman tabletop centrifuge to pellet the RBCs. After recovery of the 
plasma, the RBCs were suspended in an equal volume of sterile normal saline, mixed by 
gentle inversion and subjected to a second low speed centrifugation. The supernatant 
was discarded and the wash procedure was repeated a second time. After discarding 
the supernatant, the packed RBCs were divided into four aliquots and stored at -70°C 
until use. 
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4.2.3 LC-PCR(hν)-FD  
The LC-PCR(hv)-FD system consisted of two Shimadzu LC6A solvent delivery 
modules that were operated through a Shimadzu SIL-6B system controller. The sample 
was introduced by a Shimadzu SIL-6B autosampler equipped with a 100 μL injection 
loop. The separation was conducted on a Phenomenex Intertsil C18 (150 x 4.6 mm) 
column with 5 µm particles with a 100 Å pore size, that was protected by a Supelcosil 
LC-8, 5 µm, 2 x 4.0 mm guard column. The column was coupled to an in-house 
manufactured online photochemical reactor. Two meters of transparent Teflon tubing 
(0.012” id x 0.030” od) with 1 meter in the center braided was used as reactor coil. A GE 
Germicidal 9W lamp, GBX9/UVC lamp was used as light source inside of the 
photochemical reactor. Detection was accomplished using a Jasco FP-920 Intelligent 
Fluorescence Detector (excitation: 274nm and emission: 470nm) with the data recorded 
by TurboChrom V4.1. The mobile phase used with this chromatographic system 
consisted of solvent A:  10 mM Sodium Phosphate buffer pH 6.2 with 1.5 mL/L 30% 
H2O2 and solvent B: 20% ACN with 1.5 mL/L 30% H2O2. The system was operated at a 
flowrate of 1.0 mL/min with a gradient elution program of 10% B to 55% B in 15 minutes, 
followed by an isocratic hold for 5 minutes. The column was allowed to re-equilibrate for 
10 minutes at the initial conditions. Sample preparation was conducted according to the 
procedure described by Dervieux et al[16].   
 
4.2.4 Sample preparation for LC-MS/MS analysis 
Packed RBCs obtained from patients were thawed prior to sample workup and 
analysis. A 200 µL aliquot was transferred into a plastic vial and subsequently 210 µL of 
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water was added to ensure complete lysis of the red blood cells. The vial was closed 
and vortexed for 10 seconds yielding a suspension. Protein precipitation was performed 
by addition of 40 µL of 70% perchloric acid, immediately followed by vortex mixing for 20 
seconds or until complete precipitation had visually occurred.  The precipitated 
suspension was centrifuged for 5 minutes at 13,000 RPM, resulting in a clear solution 
with an aggregate at the bottom of the vial. The solution was diluted by the addition of 
550 µL of water and subjected to SPE. The SPE procedure consisted of 5 steps.  First 
the cartridge was activated with 2 mL of MeOH.  Second, the cartridge was equilibrated 
with 2 mL of a 0.1% aqueous formic acid solution. Third, 950 µL of sample was applied 
to the cartridge. Fourth, the cartridge was washed with 2 mL of the equilibration buffer. 
Fifth, analytes were eluted with 4 mL of a MeOH:3% NH4OH (9:1) solution.  The flow 
through the cartridge was adjusted to approximately 1.0 mL per minute during all steps.  
The eluent was evaporated to dryness under a gentle stream of nitrogen, while heating 
at 40° C in a waterbath. Analytes were redissolved in 300 µL of mobile phase A, 
vortexed for 20 seconds and transferred to an auto-sampler vial with 250 µL liner. 
 
4.2.5 Preparation of standards 
Methotrexate (polyglutamation) standards were dissolved in 100 mM NH4HCO3 
buffer. Individual standards were combined and diluted to generate stock solutions 
containing each of the standards at a concentration of 1 µM, 100 nM and 10 nM.  Stock 
solutions were stored at -80 °C and prepared on weekly basis. In order to validate the 
method, six-point calibration plots were constructed by analyzing methotrexate 
(polyglutamation) standards with concentrations of: 0, 2.5, 5, 10, 50, 100 nM. These 
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standards were prepared by spiking the appropriate volume of stock solution in 200 µL 
of blank RBCs obtained from healthy individual RBC donors. A seven-point calibration 
(0, 0.5, 1, 5, 10, 50, 100 nM) was performed for the analysis of patient samples. The 
calibration standards were treated the same as patient samples, with the exception that 
the volume of water used to lyse the cells was lowered by the volume of stock solution 
used to spike the calibration standard. 
 
4.2.6 Liquid chromatography with MS detection 
Solvent was delivered either by a Waters Associates Alliance 2695 
Chromatographic System, or a Waters Acquity UPLC. Separation occurred on a 50 x 
1.00 mm Phenomenex Synergy Hydro-RP LC column, packed with 4 µm, 80 Å particles. 
The column was guarded by a Supelcosil LC-8, 5 µm, 2 x 2.1 mm cartridge in the 
appropriate Supelcosil holder. The mobile phase consisted of (A) 10 mM NH4HCO3 
buffer with 5 mM DMHA adjusted to pH 7.5 with HCO2H, (B) consisted out of ACN with 
5mM DMHA. The total flow rate was set to 200 µL/min. The solvent program for elution 
consisted of an isocratic hold at 90% A for 1 minute, followed by a linear gradient to 70% 
A in 9 minutes and was held for 2 minutes. The column was re-equilibrated for 8 minutes 
at 90% A. The injection volume using a Waters Associates Alliance 2695 
Chromatographic System was 100 µL. Needle wash solution for this chromatograph 
consisted out of a basic solution of 50% 0.1 M NH4OH: 50% MeOH. A Waters Acquity 
UPLC was equipped with a 20 µL loop and 100 µL sample syringe. Strong needle wash 
consisted out of 70% MeOH: 30% H2O, weak needle was consisted out of 5% MeOH: 
95% H2O. 
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4.2.7 Mass Spectrometry 
Instrumentation was a  Micromass Quattro Ultima “triple” quadrupole mass spectrometer 
(Manchester UK) equipped with an electrospray ionization source. The instrument was 
operated in positive ion mode. Source parameters, including the cone voltage for each 
analyte were optimized by maximizing the area under the curve of multiple LC runs of 
the standard mixture at various programs. The probe capillary was optimized at 3.0kV, 
and the desolvation and source temperatures were set to 400 °C and 125 °C, 
respectively. The cone voltage was optimized by maximizing the area under the curve 
for each individual analyte by repetitive IP-LC runs varying the cone voltage. The cone 
gas flow rate was optimized at 80L/hr, the desolvation and nebulizer gas flow rate was 
adjusted for maximum signal of analyte. Argon was used for collision induced 
dissociation (CID) and the cell vacuum was set at 2.4 x 10-3 mbar.  Q1 and Q3 were set 
to transmit ions with a resolution of 0.8 u FWHH.  Multiple Reaction Monitoring (MRM) 
parameters (table 16) including precursor ions, product ions and collision energy were 
optimized by direct infusion of the individual analytes dissolved in 80% A and 20% B at 
10 µM, closely resembling chromatographic conditions. 
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Table 16. MRM parameters used for the LC/MS/MS analysis of MTXPGs. 
Analyte 
Precursor ion 
(m/z) 
Product ion 
(m/z) 
Cone Voltage 
(V) 
Collision energy 
(V) 
MTXGlu1 455.2 308.10 20 20 
MTXGlu2 584.3 308.10 20 26 
MTXGlu3 713.3 308.10 20 33 
MTXGlu4 842.3 308.10 20 40 
MTXGlu5 971.3 308.10 20 48 
MTXGlu6 1100.4 308.10 20 56 
MTXGlu7 1229.4 308.10 20 64 
 
4.3 Results and Discussion 
4.3.1 Performance of the LC-PCR(hν)-FD Method 
Dervieux et al. presented the use of LC-PCR(hν)-FD for the detection of MTXPGs in 
2003[16]. To date, this is still the only published chromatographic method for the 
detection of individual MTXPG species. The authors claimed the method to be sensitive 
and to exhibit the required selectivity with minimal biological interferences.  However, the 
authors do note that the method lacks the ability to robustly separate and quantify long-
chain MTXPGs. When the published methodology was implemented in-house in order to 
analyze RBCs obtained from JIA patients on MTX therapy, the results of Figure 29 were 
observed. Improvements over the Dervieux method were achieved by utilizing a 
Phenomenex Intertsil C18 column instead of the reported Waters Terra MS C18 column 
with similar dimensions. A baseline separation with improved chromatographic efficiency 
and peak symmetry (note the similar time frame for the separation with narrower peaks, 
i.e. improved efficiency) of a 50 nM spiked MTXPG1-7 mixture in water is demonstrated 
in Figure 29A).  
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Figure 29. Chromatograms of calibrators in water, blank RBCs and a patient. A) 
Chromatogram of  MTXPG standards spiked at a final concentration of 50nM/each in 
water. This chromatogram is presented in B, C and D as the dotted line for reference 
purpose. B) Example chromatogram of a RBC blank from an individual donor with  an 
endogenous interferent in the elution window of MTXPG4. C) Example chromatogram of 
a RBC blank from an individual donor with an endogenous interferent in the elution 
window of MTX. D) Example chromatogram of RBCs from a patient on low dose (7.5mg) 
MTX.  
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However, even with improved chromatographic performance, blank RBCs collected from 
eight healthy individuals showed a variety of endogenous interferences with variable 
retention times. The chromatograms of two of these individuals are shown in Figure 29B 
and 29C. Figure 29B shows a chromatogram of a blank RBC lysate from a healthy 
donor containing a significant interference that would, based on its retention time, falsely 
identify and quantitate as MTXPG4. This individual also has another peak eluting near 
the MTXPG2 standard that could be misinterpreted as MTXPG2 and thus lead to over 
estimation. Another chromatogram of a healthy RBC donor is shown in Figure 29C, 
demonstrating a contaminant that would be falsely identified as MTX by this method. A 
chromatogram of a patient on weekly low dose (7.5 mg) MTX therapy is presented in 
Figure 29D. By comparing Figures 29B, 29C and 29D, it is obvious that these interfering 
peaks can significantly influence measured concentrations of individual MTXPGs, 
leading to a gross over estimation of MTXPGtotal and skew the MTXPG “fingerprint” 
within the RBC. Despite the fact that the original work reported quantitation of MTXPGs 
in individual patients on MTX therapy, it appeared blank RBCs were obtained from a 
blood bank and pooled before preparation of the RBC calibration standards. The use of 
pooled RBCs could have led to an average blank RBC picture, disguising individual 
analyte variations due to dilution.   
The nature of these interferences is unknown at this point, but likely to be folate 
related since a number of folates share the same chromatographic behavior and 
fluorescent spectroscopic properties as MTX under these conditions[27-28]. MTX as a 
folate antagonist has been shown to interfere with the folate cycle by blocking key 
enzymes, which could lead to a buildup of oxidized folate (polyglutamated) species[10-11].  
In a worst case scenario, this could lead to false identification and over estimation of 
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MTXPGs in patients on MTX therapy, as compared to situation presently demonstrated 
by the individual RBC blanks (figure 29B and 29C). These observations dictated the 
need for development of a more specific and sensitive method for the present research. 
The approach taken was based on LC separation followed by tandem mass 
spectrometry detection. 
 
4.3.2 Chromatographic conditions for mass spectrometry  
The chromatographic performance of several supports (Waters Atlantis T3,  
Altech Alltima and Phenomenex Synergy) was screened for the separation of MTXPGs 
in the reversed phase mode. The Phenomenex Synergy Hydro RP column provided the 
highest selectivity factor together with symmetrical peaks for the MTXPGs, especially for 
MTPG5-7, analytes that were poorly resolved by the other columns, likely due to 
unfavorable secondary retention mechanisms. In order to separate MTXPGs a pH > 5.0 
(resulting in proportionally higher anionic character for longer PGs) was required, 
resulting in elution inversely proportional to polyglutamation number.  The highly anionic 
character of the MTXPGs in this pH range led to poor retention, leading to organic 
concentrations at the low limit (i.e. a 0.5%-3% B gradient was used). The highly aqueous 
elution conditions were found to suppress overall ionization efficiency, with the most 
severe effects observed for the longer polyglutamates. 
Garratt et al. presented the use of DMHA as volatile ion-pair reagent in reversed-
phase ion-pair (IP) chromatography mass spectrometry for the analysis of a broad 
spectrum of folate polyglutamates[29]. In the present case, a similar concentration of 
DMHA (5 mM) led to improved retention and successful separation of MTXPG1-7 within 
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10 minutes. The elution order of MTXPGs was observed to be directly proportional to the 
number of glutamate residues. The pH of the mobile phase was buffered at 7.5, the pH 
limit at which the column was reported to be stable and thus maximizing ionization of the 
glutamate carboxylates.   
 
4.3.3 LC-MS/MS conditions 
MTXPG standards were screened in positive and negative ion ESI mode, in the 
presence and absence of DMHA. In contrast to folate polyglutamates being reported to 
have an overall more favorable signal-to-noise ratio in negative ion mode, MTXPGs 
were found to ionize more efficient in positive ion mode. In the absence of DMHA (in 
reversed phase LC-mode), it was found that longer polyglutamates formed increasingly 
higher multiple charged species (i.e. doubly and triply charged), that were more 
susceptible to formation of unfavorable sodium clusters (Figure 30A, 30B and 30C). The 
use of DMHA as the ion-pairing reagent, led to the nearly exclusive formation of the 
singly charged species, [M+H]+. MTX was susceptible to the formation of a 
[M+DMHA+H]+ cluster (Figure 30D), an effect that was significantly reduced in longer 
MTXPGs (Figure 30E and 30F). Interestingly the observed instrument response 
between the singly charged species of the individual MTXPGs was found to be virtually 
identical, with MTX being slightly lower due to formation of the [M+DMHA+H]+ cluster. It 
was found that a low cone voltage was optimal for all MTXPGs (table 16).  
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Figure 30. Ionization characteristics comparison of MTXPGs in reversed phase 
chromatography (left) and ion-pair chromatography (right). A) MTX under reversed 
phase conditions forms a singly charged ion. B) MTXPG4 forms a singly and doubly 
charged ion under reversed phase conditions. C) MTXPG7 forms under reversed phase 
conditions the singly charged ions, doubly charged ions that form sodium adducts, and 
triply charged ions. D) MTX forms mainly the singly charged species and a DMHA 
adduct in IP-mode. E) MTXPG4 forms an exclusively singly charged molecule in IP-
mode. F) MTXPG7 forms an exclusively singly charged molecule in IP-mode. 
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Collision induced dissociation of MTX and the polyglutamates yielded a consistant 
pattern of product ions (figure 31) including an abundant product ion at m/z 308.10, 
corresponding to the 4-amino-10methylpteroyl fragment (figure 28). This m/z 308.10 
fragment was selected as product ion for all of the MTXPGs in multi reaction monitoring 
(MRM). The collision energy was optimized for the product ion by infusion of the 
individual analytes (table 16) and was found to proportionally increase with glutamation 
number. 
 
 
 
Figure 31. Product ion spectra of MTX (A) and MTXPG4 (B). 
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4.3.4 Sample preparation from erythrocytes 
The most commonly used sample preparation for the LC analysis of MTXPGs out 
of RBCs involves addition of an aliquot of water to assist in lysis of RBCs, followed by a 
perchloric acid protein precipitation step and direct injection of the supernatant. This 
procedure results in diluted samples of high ionic strength that are incompatible with 
LC/MS. In an effort to desalt, clean-up and pre-concentrate MTXPGs from RBCs the 
performance of silica based reversed phase C18 and strong anion-exchange (SAX) 
solid-phase extraction phases were investigated.  It was found that higher order PGs 
were not retained by the C18 cartridge, whereas their recovery was incomplete and 
inconsistent from the SAX cartridge. Reproducible recovery and strong retention of all 
MTXPGs was obtained by the use of a Oasis HLB SPE cartridge (30 mg), that has a 
polymeric stationary phase. Clean extracts were eluted and evaporated to dryness and 
reconstituted in a small volume, effectively reducing dilution of the samples prior to 
analysis. 
Ideally, the use of an isotopically labeled internal standard is preferred in this 
multistep sample preparation procedure. However, d3-MTX is extremely costly to 
purchase or synthesize[30], and isotopically labeled MTXPGs are not commercially 
available. As an alternative internal standard, the anti-folate aminopterin (AMP) is 
used[26]. It was found that AMP is poorly retained under LC-IP conditions, suffering from 
matrix effects, and as a result was found unsuitable as internal standard. With a suitable 
internal standard not being readily available, the method was performed with external 
calibration. 
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Table 17. Intra- and inter-day precision, accuracy and analyte recovery results 
      Intra-run (n=5) Inter-run (n=20) 
Analyte 
Nominal RBC 
Concentration 
(nM) 
Precision       
(RSD %) 
Mean 
observed 
concentration 
(nmol/L) 
 Mean 
Accuracy            
of target 
value (%) 
Precision       
(RSD %) 
Mean 
observed 
concentration 
(nmol/L) 
 Mean 
Accuracy            
of target 
value (%) 
MTXPG1 2.5 12.6 2.5 100.0 19.2 2.2 88.6 
 
5 11.3 4.8 96.8 16.3 5.4 107.2 
 
10 17.1 10.7 106.6 15.4 10.8 107.8 
 
50 15.2 50.8 101.6 10.3 51.0 102.0 
 
100 11.9 98.7 98.7 11.8 101.1 101.1 
MTXPG2 2.5 11.9 2.6 102.4 19.1 2.3 93.0 
 
5 8.4 5.0 99.2 11.4 5.0 100.1 
 
10 10.7 9.4 94.2 10.6 10.6 106.3 
 
50 7.9 52.3 104.5 12.5 51.2 102.4 
 
100 9.1 98.3 98.3 9.6 99.0 99.0 
MTXPG3 2.5 19.3 2.4 95.2 23.7 2.5 99.6 
 
5 8.8 5.1 101.6 12.9 5.0 99.1 
 
10 9.5 11.0 109.8 11.9 10.5 105.4 
 
50 14.9 50.0 100.0 10.2 50.1 100.2 
 
100 9.0 98.8 98.8 10.2 99.4 99.4 
MTXPG4 2.5 14.2 2.56 102.4 14.5 2.4 94.8 
 
5 3.0 5.04 100.8 11.6 5.2 103.4 
 
10 4.0 9.28 92.8 12.0 10.5 105.0 
 
50 4.6 52.18 104.4 11.9 51.3 102.6 
 
100 6.8 98.5 98.5 9.0 98.1 98.1 
MTXPG5 2.5 20.0 2.4 95.2 16.9 2.3 93.0 
 
5 8.1 5.1 102.4 10.4 5.1 102.9 
 
10 11.4 9.5 94.8 11.4 10.6 106.4 
 
50 7.7 53.2 106.5 12.0 51.2 102.4 
 
100 7.2 97.2 97.2 8.5 98.1 98.1 
MTXPG6 2.5 15.4 1.9 76.8 20.7 2.2 89.0 
 
5 13.8 5.1 101.0 14.5 5.2 103.1 
 
10 12.2 10.1 100.8 10.8 10.8 107.9 
 
50 6.8 52.2 104.3 10.9 50.8 101.7 
 
100 5.8 97.1 97.1 8.9 98.1 98.1 
MTXPG7 2.5 20.6 2.6 102.4 15.5 2.4 95.6 
 
5 6.9 4.9 97.2 9.7 5.1 102.4 
 
10 3.2 9.5 95.2 9.2 10.4 104.4 
 
50 7.6 54.2 108.5 10.5 51.1 102.3 
  100 6.6 96.3 96.3 7.2 98.4 98.4 
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4.3.5 Method performance 
Simultaneous MRM analysis of blank RBCs from different individual donors, 
demonstrated that endogenous compounds contributed minimal background noise 
(Figure 32A). Standards spiked at low concentration (5 nM) in RBCs eluted free of 
interferences (Figure 32B). Initially the method was developed and validated on a 
Waters Acquity UPLC platform equipped with a 20 µL sample loop. Table 17 
summarizes the intra- and inter-day precision and accuracy of the analytical assay at 
MTXPG concentrations spiked at 2.5 nM, 5 nM, 10 nM, 50 nM and 100 nM in 200 µL of 
RBCs respectively. Mean extraction recoveries for the total procedure (protein 
precipitation + SPE and evaporation with reconstitution) were 31.2% for MTXPG1, 
33.4% for MTXPG2, 39.6% for MTXPG3, 44.2% for MTXPG4, 43.0% for MTXPG5, 
50.6% for MTXPG6 and 47.8% for MTXPG7. Low, but reproducible recoveries were 
mainly attributed to the protein precipitation step, that has reported recoveries of around 
60%[16]. The intra-run precision was within an RSD of 3.0 and 20.0% and the inter-run 
precision was between 7.2 and 23.7% (table 17). Lower Limits of quantitation (LLOQ) 
were determined as the lowest concentration that resulted in a RSD ≤ 20% for intra-day 
precision. As a result the LLOQs were found to be about 2.5 nM for all of the individual 
MTXPGs using a 20 µL loop volume in combination with a Waters Acquity LC platform. 
At the LLOQ the signal to noise ratio was between 15:1 and 25:1 depending on the 
analyte. The Limit of detection (LOD) was derived from the LLOQ according to the 
equation LOD = (0.33*LLOQ). LODs were 0.8 nM for all of the individual MTXPGs. 
Regression analysis of various calibrants spiked with MTXPG concentrations ranging 
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from 2.5 to 100 nM, spanning the anticipated concentration range in patients, revealed a 
linear relationship between instrument response and analyte concentration (table 18).  
Finally, in order to further improve sensitivity the method was transferred from a 
Waters Acquity to a Waters 2695 platform that would allow for 100 µL injection volumes 
(over 20 µL) effectively yielding a factor of five increase in sample loading. It was found 
that an 100 µL injection volume could be successfully focused on the head of 
chromatography column leading to an increase in sensitivity of a factor five without the 
loss of separation efficiency (Figure 32B and 32C), note that the detected mass is 100 
fmol in both cases), resulting in LLOQs of 0.5 nM for individual MTXPGs. LOD for each 
MTXPG were determined to be 0.2 nM. However, it was found that the use of the 2695 
platform was prone to carryover, and as a result extensive needle cleaning steps and 
the use of blank wash injections had to be included in order to eliminate carryover.  
 
 
Table 18. Inter-day variation in calibration lines for MTXPG standards 
Analyte Slope ± SD R2 ± SD 
MTXPG1 1.012 ± 0.060 0.9993 ± 0.0007 
MTXPG2 0.991 ± 0.020 0.9993 ± 0.0005 
MTXPG3 0.999 ± 0.010 0.9993 ± 0.0007 
MTXPG4 0.982 ± 0.013 0.9992 ± 0.0005 
MTXPG5 0.982 ± 0.013 0.9992 ± 0.0005 
MTXPG6 0.981 ± 0.010 0.9991 ± 0.0010 
MTXPG7 0.986 ± 0.012 0.9986 ± 0.0019 
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Figure 32. A) Representative Blank RBC standard for different lots of RBCs. B) Low 
concentration (5nM) calibrant in the RBC analyzed by the Waters Acquity platform (20 
µL injection, injected mass 100 fmol). C) Low concentration (1 nM) calibrant in the RBC 
analyzed by the Waters 2695 Alliance platform (100 µL injection, injected mass 100 
fmol).  
 
Using large volume injections, an unidentified endogenous compound was observed 
that exhibits the same m/z as MTX and forms a 308.10 fragment, resulting in a peak in 
the MTX channel (Figure 32C). This molecule was separated from MTX and as a result 
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does not interfere with the analysis. The presence of such a compound has been 
reported in LC-MS/MS analysis of MTXPGs in Caco-2 cells as well[26]. Since the mono-
isotopic mass of DMHA is equal to that of a glutamyl residue (129 Da), the formation of 
DMHA clusters led to the appearance of a lower MTXPGn in the MRM channel of a 
MTXPGn+1. The intensity of this DMHA adduct is most abundant for MTX and 
significantly lower for the other MTXPGs (Figure 30 and 32C). DMHA clusters were 
found to not affect quantitative analysis since all PGs are baseline separated and 
clusters formed from lower laying MTXPG are easily identified since they have identical 
retention times. The use of N,N-dimethylpentylamine or N,N-dimethylheptylamine as ion-
pairing reagents will be explored in the future in an effort to circumvent this issue.  
 
4.3.6 Clinical application of the method 
The LC-MS/MS methodology was used to analyze the MTXPG distribution in 
RBC samples from 100 JIA patients on MTX therapy, in an effort to develop correlations 
to genomic variations (the object of a separate investigation) and potentially serve as the 
basis for the rational development of individualized therapeutic regimens. The Waters 
2695 platform was calibrated between 0.5 nM and 100 nM for each MTXPG. A typical 
patient chromatogram and resulting RBC MTXPG concentrations obtained by this 
method are shown in figure 33A and 33B. MTXPG3 was determined to be the major 
species in most of the samples, which is consistent with a prior publication[31]. The 
improved sensitivity of the LC-MS/MS method led to the observation and low nano molar 
detection and quantitation (<1 nM) of long chain MTXPG6-7 in a high number of samples. 
These MTXPGs were not observed in patient RBCs by earlier methods consistent with 
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reported 2 nM detection limits.  Since no standards are available for MTXPG8 nor higher 
polyglutamates, samples with high levels of MTXPGtotal were tentatively reanalyzed for 
the presence of MTXPG8-12 using the common product ion and extrapolated collision 
energies. Despite various efforts, MTXPG8-12 were not detected in any patient RBC 
samples. The detection and quantitation of long chain MTXPGs5-7 at low concentration 
is of particular clinical interest since these species are associated with increased 
potency over short chain MTXPGs. The sensitivity of this newly developed method 
would also allow for pharmacokinetics analysis of long chain MTXPGs. In a study by 
Dalrymple et al., using LC-PCR(hv)-FD, the elimination half-life of MTXPG4-5 could not 
be accurately determined due to a lack of sensitivity for these species[32].  
 
 
Figure 33. A) Typical total ion current LC/MS/MS chromatogram obtained from RBCs of 
a patient on MTX therapy. B) Individual MRM channels used to construct (A) for the 
seven MTXPGs. 
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4.3.7 Post analysis clean-up from ion pair agent 
DMHA cluster ions in the mass spectrometer [DMHA+H]+, [DMHA+CH3CN+H]+, 
and [DMHA+HCl+H]+, persist well after the DMHA solvent reservoirs are removed from 
the chromatograph.  A significant reservoir is the chromatograph itself, requiring 100’s of 
mLs of organic solvent with 1% FA to purge (using the wet prime function on the 2695) 
the system. Attention to washing the large stainless steel fritted filters in the solvent 
bottles speeds up removal of DMHA derived ions from the chromatograph. ESI source 
contamination is quickly reduced by flowing about 50 mL of clean solvent (e.g. not 
through the chromatograph),  reducing the [DMHA+H]+ ion to  about 2-3 times the most 
abundant ion in the typical low m/z ESI “solvent blast”. Complete removal of this 
background ion requires source block and first hexapole cleaning on the Quattro Ultima 
source. 
 
4.3.8 Patient data 
The method presented in this chapter was used for  MTXPG profiling of more 
than 100 JIA patients on low dose MTX. The MTX polyglutamation distribution is given in 
table 19. Data analysis was performed by our collaborators at Children’s Mercy 
Hospitals (Kansas City, MO) and results are published (appendix 1 and 2). Appendix 1 
also describes the patients demographics of this study. To summarize our findings, the 
route of MTX administration was a determining factor upon MTX polyglutamation 
distribution (appendix 1). The MTXPG chain length increased when patients received 
MTX in the subcutaneous tissue, as opposed to oral dosage. We have also 
demonstrated that longer MTXPGs are associated with liver toxicity, one of the common 
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adverse effects in MTX treatment in RA and JIA (appendix 2). A full discussion of all the 
results is beyond the scope of this dissertation, but readers are encouraged to review 
appendix 1 and 2. 
 
4.4 Conclusions 
The measurement of MTXPGs in RBCs is challenging due to the presence of 
endogenous interferences, low concentrations within RBCs and poor chromatographic 
behavior of longer polyglutamates, typically MTXPG5-7. The use of an improved sample 
preparation strategy for clean up and sample pre-concentration followed by an 
innovative chromatographic procedure with tandem mass spectrometry detection led to 
the robust separation and detection of MTXPG1-7 within 10 minutes in patient RBC 
samples. The use of DMHA as an ion-pairing agent was beneficial in both, 
chromatographic separation and mass spectrometry detection. Triple quadrupole mass 
spectrometers have become widely available and are currently routinely applied in 
clinical settings for therapeutic drug monitoring, thus allowing for widespread adaption of 
the described methodology. The new analytical approach should enhance knowledge of 
MTX metabolomics by providing a quantitative MTXPG “fingerprint” in patient RBCs. 
Such information has the potential to aid in individually optimized MTX dosing. This 
could result in reduction of side effects and provide valuable information in regard to 
interpretation of MTX pharmacogenomical data, a field that is currently receiving 
increased attention.  
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Table 19. JIA patient MTXPG profile 
      MTXPG concentration (nM) 
Patient MTXPG1 MTXPG2 MTXPG3 MTXPG4 MTXPG5 MTXPG6 MTXPG7 
1 28.4 14.5 50.1 21.9 6.7 0 0 
2 17 12.7 26.1 4.7 1 0.4 0 
3 27.8 12.9 36.2 8.9 1.5 0 0 
4 11.6 6.3 10.6 2.3 0.7 0.1 0 
5 33.4 17.3 35.5 10.6 2.2 0.4 0 
6 17.1 15.2 23.6 3.5 0.7 0.3 0 
7 20.4 19.5 80.4 32.6 9 0.3 0.4 
8 11.7 6.4 4 0.9 0.5 0 0 
9 3 8.2 9.7 1.5 0.4 0.1 0 
10 21.7 18.3 50.8 19 4.7 0.3 0 
11 16.1 11.2 14.8 2.4 0.5 0.1 0 
12 17.7 18.1 76.7 32.7 9.6 0.4 0.2 
13 5.9 8.5 24.1 10 3.1 0.1 0 
14 3.8 3 29.1 22.2 11.8 0.2 0 
15 76 13.4 38.9 13.2 3.8 0.2 0 
16 2.6 6 19.1 8.3 2.1 0.1 0 
17 42.4 18.4 64.5 28.7 8.3 0.3 0 
18 24.8 13.6 47 22.7 8.7 0.2 0 
19 15.3 16.6 21.8 2.8 0.6 0.1 0 
20 4 7.5 41.4 21.7 6.3 0.1 0 
21 0.1 0.6 7.6 3.7 1.4 0.1 0 
22 15 13.4 22.2 4 0.8 0 0 
23 13.7 11.2 40.7 13.8 3.1 0.1 0 
24 14.4 11.3 18.5 2.2 0.5 0 0 
25 1.3 2 6.3 2.1 0.4 0 0 
26 25.8 25 37.1 6.6 1.1 0 0 
27 9.6 10 20.8 4.8 0.8 0 0 
28 24.1 18.8 60.7 19.9 4.7 0.2 0 
29 3.7 7.1 44.3 25.2 8.8 0.1 0 
30 22.3 12.9 46 16.6 4.4 0.6 0 
31 11.3 9.8 47.2 29 10.8 0.4 0 
32 0.4 0.7 11.5 5.9 2 0.1 0 
33 27.9 15.9 77.4 42.4 14.8 0.4 0 
34 6.3 4.4 13.6 8.1 3.4 0.1 0 
35 15.2 11.1 48.4 32.6 15.6 0.4 0 
36 12.2 14.6 35.9 12.8 3.4 0.3 0 
37 20.4 11.5 6.3 0.4 0.3 0 0 
38 11.5 6.7 27.6 14.6 5 0.3 0 
39 46.1 20 51.5 16.7 4.7 0.3 0 
40 19.5 13.4 40 19.8 6.7 0 0 
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Table 19. continued 
      MTXPG concentration (nM) 
Patient MTXPG1 MTXPG2 MTXPG3 MTXPG4 MTXPG5 MTXPG6 MTXPG7 
40 19.5 13.4 40 19.8 6.7 0 0 
41 6.5 12.5 27.9 7.7 1.8 0.1 0.2 
42 10.8 12.8 36.8 9 1.8 0.1 0 
43 30.5 16 44.8 18 4.3 0.5 0 
44 32.3 3.7 3 0.3 0.7 0.1 0 
45 49.8 28.3 79.5 39.8 12.4 0.5 0 
46 1.1 0.6 12.2 7.9 3.1 0.2 0 
47 4.9 8.9 36 22.8 12.6 1 0 
48 6.2 7.1 61.2 39.1 15 0.3 0 
49 11.6 10.1 48.1 23 6.6 0.2 0 
50 23.5 12.4 25.9 9.1 2.7 0.3 0.3 
51 17.5 15.9 18.6 2.2 0.5 0.2 0.1 
52 14.8 9.1 32.2 10.5 2.3 0.2 0 
53 4.2 8.6 31.1 20.3 10.6 0.1 0 
54 7.8 6.9 26.8 7.9 1.6 0.2 0.1 
55 3.8 5.6 19 5.4 1.5 0.2 0 
56 28 18.6 42.1 12.6 2.6 0.2 0.2 
57 24.7 13.6 47.6 19.1 5.9 0.2 0 
58 21 17.6 17.8 3.6 0.6 0 0.1 
59 22.4 20.8 53.1 14.6 3 0.2 0.1 
60 14.7 10.4 64.5 42.6 20.3 0.6 0.1 
61 24.7 15.6 27.5 10.3 3 0.1 0.4 
63 23.2 16.3 20.8 2.3 0.5 0 0 
64 18 8.4 27.4 8.6 2.1 0.2 0 
65 25 18.5 13.7 1.1 0.2 0.1 0 
66 19.1 14.1 24.5 3.9 0.6 0.1 0 
67 2.8 5.8 19.2 7.1 1.8 0 0 
68 3.1 6.3 19.3 8 2.2 0.1 0.1 
69 44.2 11.7 29.9 7.9 1.5 0.1 0 
70 5.9 5.4 8.4 1.6 0.1 0.1 0 
71 18.2 13.3 33.8 8.7 1.4 0.1 0 
72 17.2 11.5 62.9 32.3 9.8 0.2 0 
73 0.7 0.8 0.7 0.9 0.9 0.8 0 
74 15.5 20.2 83.2 41.6 13.7 0.4 0 
75 13.1 16.8 45.9 19.3 5.7 0.2 0 
76 13.9 12.5 43.7 16.2 4.2 0.3 0 
77 15.5 8.5 32.5 15 5.2 0 0 
78 16.3 6.7 4.9 0.5 0.2 0 0 
79 18.9 15.4 34.4 7.6 1.1 0.1 0 
80 24.5 18.4 52.8 23.3 6.6 0.4 0 
81 19.7 9 2.2 0 0 0 0 
82 
       83 9 13.1 50.7 21.8 7.9 0.3 0 
84 12.7 15.4 73.1 31.3 9.3 0.2 0.1 
85 17.6 12.9 67.6 38.7 17.2 0.5 0.1 
86 0.1 4.9 15.7 3.5 1 0.1 0 
87 13.1 10.1 9.2 1 0.2 0 0.1 
 
 
132 
 
Table 19. JIA patient MTXPG profile 
      MTXPG concentration (nM) 
Patient MTXPG1 MTXPG2 MTXPG3 MTXPG4 MTXPG5 MTXPG6 MTXPG7 
88 15.1 9.3 56.2 8.3 0 0 0 
89 7.6 12.6 89.7 26 6.3 0.3 0 
90 18 15.7 103.1 52.8 23.8 0.5 0 
91 9.7 8.4 21.2 3.5 0.7 0 0 
92 5.4 4.3 27.3 12.3 4.5 0 0 
93 6 6.6 11.7 1.6 0.3 0 0 
94 12.7 19.4 114.1 40.8 13.6 
  95 19.6 14.6 42.9 7.6 1.3 0.2 0 
96 28.2 19.2 63.3 12.4 2.3 0.2 0 
97 17.9 11.2 87.1 61.6 39.8 0.7 0.2 
98 23.1 9.5 26.2 5.9 1.2 
  99 21.5 13.1 84.9 38.5 14.2 0.3 0 
100 19.4 18 60 19.4 4.9 0.2 0 
101 40.8 19 48 7.3 1.1 0 0 
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5.1 Introduction 
In chapter 4 a novel LC/MS/MS method for the detection of MTXPGs in human 
erythrocytes was presented[1]. Whilst the performance of the method was adequate for 
reliable analysis of a limited amount of patient RBC samples in an academic research 
setting, the throughput of the entire analytical procedure is too low for routine operation 
in a clinical environment. First, the method relied on a laborious sample preparation 
strategy using multiple clean-up stages. In an initial work up step the sample was 
exposed to perchloric acid to facilitate protein precipitation and release MTXPGs from 
the biological matrix. As a result the pH and ionic strength of this solution were 
incompatible with the RP-IP chromatographic method. Furthermore the high ionic 
strength of the sample was also problematic for mass spectrometric detection, and as a 
result a lengthy SPE desalting procedure was incorporated. A multistep sample 
preparation is undesirable in a clinical environment as it significantly increases the 
chance of error. As errors are unavoidably introduced in every operation, the total error 
is a reflection of the error introduced by the individual components. Additionally 
complicated sample preparation schemes are prone to gross error introduced by the 
laboratory operator. A single and simple sample preparation procedure is therefore of 
high interest by the clinical laboratory. 
 The second disadvantage of the method presented in chapter 4 is that as a result 
of the use of N,N-dimethylhexylamine as an ionparing agent in the mobile phase cross 
talk between the various SRM channels was observed. Since DMHA is isobaric with the 
addition of a  glutamate residue, the MTXPGn + DMHA adduct will cause crosstalk in the 
higher order MTXPGn+1 SRM channel. In the previous chapter it was hypothesized that 
the use of an IP-agent with a differentiating mass would eliminate this adverse effect. 
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The use of N,N-dimethylpentylamine (DMPA) and N,N-dimethylheptylamine (DMHPA) 
were suggested as examples of such compounds. Additionally the elimination of 
crosstalk would negate the need for baseline separation as the various MTXPGs could 
be separated in the gas phase. A shortened chromatographic procedure is of great 
clinical interest as it would increase throughput and reduce the occupancy of the 
procedure on costly equipment (e.g. mass spectrometers).  
 A third disadvantage of the method is that due to the lack of a suitable internal 
standard external calibration was performed. The use of external calibration in the 
analysis of samples from biological samples by LC/MS/MS is undesirable since it does 
not account for signal alterations (ion suppression) induced by a varying matrix 
composition (matrix effects).   In this chapter the various aspects of the assay that need 
to be altered to facilitate clinical MTXPG methodology are investigated and discussed. 
Improvements are presented in sample preparation, chromatographic and calibration 
procedures.  
Additionally the question was raised if the MTX metabolite, 7OH-MTX could be 
measured and observed in RBCs. A pair of reports by Baggott et al. demonstrate the 
presence of 7OH-MTX in the urine of RA patients on MTX therapy[2-3]. The urine 
concentration of 7OH-MTX was found to be highly variable (14 fold) over a small patient 
population and it was hypothesized that patients that extensively catabolize MTX to 
7OH-MTX would have a less efficacious response to MTX therapy. The researchers 
continue and hypothesize that based on a small amount of data a phenotype exists that 
is able to produce large amounts of 7OH-MTX. Since the metabolite is also subject to 
polyglutamation by polyglutamaylsynthase, this metabolite would be competing with 
MTX, limiting its polyglutamation and therefore enhancing MTX excretion. Finally the 
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researchers hypothesize: “The variability of MTXPGs concentrations in RBCs could be a 
function of MTX catabolism to 7OH-MTX; 7-OH-MTX could also displace MTX from the 
active site of other folate metabolizing enzymes” (quote). 
Interestingly it has been demonstrated that concentrations of 7OH-MTX in the 
bone marrow are about 3-10 times higher in children receiving low-dose oral MTX[4]. As 
the RBCs develop in the bone marrow and are metabolic inactive after erythropoiesis[5], 
these cells are considered to be representative of the (anti)-folate status within the bone 
marrow[6-7]. Therefore it is tempting to believe 7OH-MTX is present in RBCs, and if so, is 
there a correlation between interpatient MTXPG variability and the ability of these 
patients to catabolize MTX to 7OH-MTX? 
  The presence and detection of 7OH-MTX in its native or polyglutamated form in 
human erythrocytes has not been described in the literature. The detection of this class 
of MTX metabolites is complicated by the fact that 7OH-MTX is available on a limited 
commercial basis and the family of polyglutamates cannot be purchased from a 
commercial source. At the end of this chapter a strategy is presented for the detection of 
7OH-MTXPGs in human RBCs. The focus of the assay was to answer the question: is 
7OH-MTX(PGs) present in significant levels in RBCs? Rather than presenting a full 
quantitative assay that would require the synthesis of the various standards, this chapter 
presents a semi-quantitative approach. The development of a more quantitative 
approach would be the obvious next step if RBCs were found to be a suitable biomarker 
for this biotransformation. 
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5.2 Experimental 
5.2.1 Materials 
LC grade solvents acetonitrile (ACN) and methanol (MeOH) were obtained from 
Fisher Scientific (Fair Lawn, NJ, USA). Ammonium bicarbonate, N, N-
Dimethylpentylamine (DMPA), N, N-Dimethylhexylamine (DMHA), N,N-
Dimethylheptylamine (DMHPA) and methotrexate were purchased from Sigma-Aldrich 
(St Louis, MO, USA). Methotrexate polyglutamation standards 4-amino-10-
methylpteroyldiglutamic acid (MTXGlu2), 4-amino-10-methylpteroyltriglutamic acid 
(MTXGlu3), 4-amino-10-methylpteroyltetraglutamic acid (MTXGlu4), 4-amino-10-
methylpteroylpentaglutamic acid (MTXGlu5), 4-amino-10-methylpteroylhexaglutamic 
acid (MTXGlu6), 4-amino-10-methylpteroylheptaglutamic acid (MTXGlu7) were 
purchased as the ammonium salts from Schircks Laboratories (Jona, Switzerland). 7-
hydroxymethotrexate (7OH-MTX) was obtained from Synfine Research (Ontario, 
Canada). 
 
5.2.2 Preparation of erythrocyte (RBC) lysates 
Blood samples (~5 ml) obtained from patients were centrifuged at low speed 
(2000 rpm) in a Beckman tabletop centrifuge to pellet the RBCs. After recovery of the 
plasma, the RBCs were suspended in an equal volume of sterile normal saline, mixed by 
gentle inversion and subjected to a second low speed centrifugation. The supernatant 
was discarded and the wash procedure was repeated a second time. After discarding 
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the supernatant, the packed RBCs were divided into four aliquots and stored at -70°C 
until use. 
 
5.2.3 Sample preparation for LC-MS/MS analysis 
Packed RBCs obtained from patients were thawed prior to sample workup and 
analysis. A 200 µL aliquot was transferred into a plastic vial and subsequently 200 µL of 
a modified “Wilson and Horne” extraction buffer was added to ensure complete lysis of 
the red blood cells. The buffer was a 50 mM HEPES/CHES buffer at pH 7.85. The vial 
was closed and vortexed for 10 seconds yielding a suspension. The closed vials were 
placed in the in-house fabricated sample holder (chapter 2) and “sandwiched” to lock the 
lids. The entire sample holder was placed in boiling water for 5 minutes and after 
removal from the waterbath allowed to cool for 30 minutes. The boiled vials were placed 
into a centrifuge and spun at 13,000 RPM for 5 minutes. The supernatant was 
transferred to an auto-sampler vial with 250 µL liner. 
  
5.2.4 Preparation of standards 
Methotrexate (polyglutamation) standards were dissolved in 100 mM NH4HCO3 
buffer. Individual standards were combined and diluted to generate stock solutions 
containing each of the standards at a concentration of 1 µM, 100 nM and 10 nM.  Stock 
solutions were stored at -80 °C and prepared on weekly basis. In order to validate the 
method six-point calibration plots were constructed by analyzing methotrexate 
(polyglutamation) standards with concentrations of: 0, 1, 5, 10, 50, 100 nM. These 
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standards were prepared by spiking the appropriate volume of stock solution in 200 µL 
of blank RBCs obtained from healthy individual RBC donors. A seven-point calibration 
(0, 0.5, 1, 5, 10, 50, 100 nM) was performed for the analysis of patient samples. The 
calibration standards were treated the same as patient samples, with the exception that 
the volume of water used to lyse the cells was lowered by the volume of stock solution 
used to spike the calibration standard. 
 
5.2.5 Liquid Chromatography with MS detection 
Solvent was delivered by a Waters Acquity UPLC. A Waters Acquity UPLC was 
equipped with a 50 µL loop and 250 µL sample syringe. Strong needle wash consisted 
of 70% MeOH: 30% H2O, weak needle consisted of 5% MeOH: 95% H2O. Separation 
occurred on a 50 x 1.00 mm Waters BEH C18, packed with 1.7 µm particles. The 
column was guarded by a Waters Vanguard pre-column, 2.1 x 5 mm. The mobile phase 
consisted of (A) 10 mM NH4HCO3 buffer with 5 mM of the desired ion-pair adjusted to 
pH 7.5 with HCO2H, (B) consisted out of ACN with 5mM of the desired ion-pairing agent. 
The total flow rate was set to 200 µL/min. Various gradient elution profiles were used, 
the details are given in the text. Re-equilibration occurred by a step gradient to initial 
conditions followed by a equilibration time of 2 minutes.  
 
5.2.6 Mass Spectrometry 
Instrumentation was a  Micromass Quattro Ultima “triple” quadrupole mass 
spectrometer (Manchester UK) equipped with an electrospray ionization source. The 
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instrument was operated in positive ion mode. Source parameters, including the cone 
voltage for each analyte were optimized by maximizing the area under the curve of 
multiple LC runs of the standard mixture at various programs. The probe capillary was 
optimized at 3.0kV, and the desolvation and source temperatures were set to 400 °C 
and 125 °C, respectively. The cone voltage was optimized by maximizing the area under 
the curve for each individual analyte by repetitive IP-LC runs varying the cone voltage. 
The cone gas flow rate was optimized at 80L/hr, the desolvation and nebulizer gas flow 
rate was adjusted for maximum signal of analyte. Argon was used for collision induced 
dissociation (CID) and the cell vacuum was set at 2.4 x 10-3 mbar.  Q1 and Q3 were set 
to transmit ions with a resolution of 0.8 u FWHH.  Multiple Reaction Monitoring (MRM) 
parameters (table 20) including precursor ions, product ions and collision energy were 
optimized by direct infusion of the individual analytes dissolved in 80% A and 20% B at 
10 µM, closely resembling chromatographic conditions. 
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Table 20. MRM parameters used for the LC/MS/MS analysis of the various pteroyl based entities. 
Analyte Molecular Formula 
Precursor ion 
(m/z) 
Product ion 
(m/z) 
Cone 
Voltage (V) 
Collision 
Energy (V) 
ESI 
mode 
MTXGlu1 C20H23N8O5+ 455.2 308.1 20 20 + 
MTXGlu2 C25H31N9O8+ 584.3 308.1 20 26 + 
MTXGlu3 
C30H39N10O11
+ 713.3 308.1 20 33 + 
MTXGlu4 
C35H47N11O14
+ 842.3 308.1 20 40 + 
MTXGlu5 
C40H55N12O17
+ 971.3 308.1 20 48 + 
MTXGlu6 
C45H63N13O20
+ 1100.4 308.1 20 56 + 
MTXGlu7 
C50H71N14O23
+ 1229.4 308.1 20 64 + 
       7OH-MTX C20H23N8O6+ 471.1 324.3 15 20 + 
       7OH-MTX C20H21N8O6- 469.1 340.1 25 24 - 
7OH-MTXGlu2 C25H29N8O9- 598.1 340.1 30 31 - 
7OH-MTXGlu3 C30H37N8O12- 727.2 451.1 40 32 - 
7OH-MTXGlu4 C35H45N8O15- 856.2 451.1 50 37 - 
7OH-MTXGlu5 C40H53N8O18- 985.3 451.1 55 45 - 
7OH-MTXGlu6 C45H61N8O21- 1114.4 451.1 60 50 - 
7OH-MTXGlu7 C50H69N8O24- 1243.4 451.1 70 59 - 
       FA C19H20N7O6+ 442.2 295.1 30 20 + 
FAGlu2 C24H28N7O9+ 571.2 295.1 30 26 + 
FAGlu3 C29H36N7O12+ 700.2 295.1 30 33 + 
FAGlu4 C34H44N7O15+ 829.3 295.1 30 40 + 
FAGlu5 C39H52N7O18+ 958.3 295.1 30 48 + 
FAGlu6 C44H60N7O21+ 1087.4 295.1 30 56 + 
FAGlu7 C49H68N7O24+ 1216.4 295.1 30 64 + 
       FA C19H18N7O6- 440.2 311.1 25 24 - 
FAGlu2 C24H26N7O9- 569.2 311.1 30 31 - 
FAGlu3 C29H34N7O12- 689.2 422.3 40 32 - 
FAGlu4 C34H42N7O15- 827.3 422.3 50 37 - 
FAGlu5 C39H50N7O18- 956.3 422.3 55 45 - 
FAGlu6 C44H58N7O21- 1085.4 422.3 60 50 - 
FAGlu7 C49H66N7O24- 1214.4 422.3 70 59 - 
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5.3 Results and Discussion 
5.3.1 Column selection 
 As described in Chapter 4, the Waters UPLC platform, including autosampler with 
peak needle had to be utilized to avoid carry-over of the longer chain polyglutamates. 
The UPLC pumps can generate up to 15,000 psi of pressure, which allows 
chromatographers to overcome the high backpressures associated with the use of small 
particles. The use of chromatographic columns packed the stationary phase dispersed in 
small particles is highly advantages in chromatography as it minimizes chromatographic 
band broadening associated with using high linear velocities. These high linear velocities 
are desirable in chromatography as they minimize gradient delay and allow for swift 
separation of the analytes.  As the goal of this chapter was the development of a 
MTXPG LC/MS/MS assay with increased throughput tailored for clinical use, these small 
particle chromatography columns in combination with the UPLC demonstrate 
tremendous potential. In an attempt to use the UPLC to its fullest potential the method 
was transferred to a Waters 1.7 µm BEH C18 column. This column was selected due to 
its close resemblance to the previously used Phenomenex material, in an attempt to 
minimize change in retention/separation mechanism. The BEH columns are based on a 
trifunctional ligand bonding chemistry, resulting in elevated stabilities in basic media (up 
to pH 11). Due to the relatively high pH of the separation (pH 7.5 - 8.0) this extra stability 
in the basic pH range is desirable if one wishes to operate this assay on a day to day 
basis handling a large amount of samples and automated data handling requiring fixed 
retention times. The exact method transfer will be discussed in the following sections. 
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5.3.2 Ion-pair selection 
 
Figure 34. Properties of the various ion-pair reagents evaluated for LC/MS/MS analysis 
of MTXPGs. 
As mentioned in the introduction N,N-dimethylpentylamine (DMPA) and N,N-
dimethylheptylamine (DMHPA) were evaluated as alternatives to DMHA in an attempt to 
eliminate crosstalk between the various MTXPG channels (figure 34). DMPA varies from 
the previously used DMHA by a one carbon shorter alkyl-chain, resulting in a lower 
boiling point and less hydrophobic character. The inverse is true for DMPHA. A low 
boiling point of the IP-agent is generally considered to be advantageous in IP-mass 
spectrometry, since milli-molar concentrations in the mobile phase need to be 
desolvated and evaporated by the ESI-source. The lower boiling DMPA is however 
significantly less hydrophobic compared to DMHPA. The hydrophobicity of the IP-agent 
plays an important role in RP-IP chromatography, as the IP-agent has to dynamically 
load the hydrophobic chromatographic media. This process is driven by the equilibrium 
constant between the IP-agent and the hydrophobic solid support. In other words, a 
more hydrophobic IP-agent will be present at a higher concentration on the solid phase 
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and therefore introduce more chromatographic selectivity in the separation method (if 
mobile phase concentration is kept constant). To conclude, the ideal IP-agent from a 
mass spectrometric point of view would be DMPA  DMHA  DMHPA, and from a 
chromatographers stand point DMHPA  DMHA  DMPA (disregarding the crosstalk 
when DMHA is used). In order to identify the ideal IP-agent chromatograms were 
obtained by analyzing 100 nM aqueous mixtures of MTPG1-7. The concentration of the 
IP in the mobile phase was fixed to 5 mM independent of the IP-agent used. A 
concentration of 5 mM DMHA was found to be optimal by Garrett and colleagues[8] for 
the separation of folate polyglutamates, and further optimization was not attempted. 
Note that this concentration is typically one to two orders of magnitude below of 
commonly used IP concentrations in LC-UV/FL type of assays, due to adverse effect in 
ESI at elevated concentrations. Isocratic separations of MTXPG1-7 with DMPA (figure 
35A), DMHA (figure 35B) and DMHPA (figure 35C) are demonstrated in figure 35. In 
accordance with the hypothesis, it was observed that DMPA demonstrated the lowest 
selectivity factor (i.e note the separation of the various analytes) and analytes were 
retained fairly poorly, requiring only 10% organic for an isocratic separation of all of the 
analytes within a time-frame of 10 minutes. DMHPA demonstrated the highest selectivity 
factor of the IP-agents under investigation, and yielded the sharpest and most 
symmetrical peaks. A gradient separation was developed for both IP-agents with an 
emphasis on achieving rapid separation (figure 36). A gradient separation of MTXPG1-7 
using DMPA as IP agent is show in figure 36A. The gradient consisted out of an isocratic 
hold of 10%B for 1 minute in order to focus the analytes on the head of the 
chromatography column.  
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Figure 35. Isocratic separations of aqueous mixtures of MTXPGs demonstrating 
selectivity differences between the ion pair reagents. Each chromatogram is obtained 
with the IP concentration fixed at 5 mM. (A) Separation obtained with DMPA, (B) 
Separation obtained with DMHA, (C) Separation obtained with DMHPA. 
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The isocratic hold was followed by a linear gradient with a steepness of 1.8% min-1 
increase in B concentration. Using these settings, analytes were separated in a 
timeframe of 3.5 minutes following analyte introduction. A gradient program was also 
developed for the separation of MTXPG1-7 with DMHPA as the IP agent (figure 36B). 
The initial analyte focusing step that was required using DMPA as IP agent could be 
circumvented by using a weak mobile phase composition (but still higher eluting strength 
when compared to DMPA) during injection (17.5% B), followed by a “ballistic” gradient of 
8% min-1 increase in B concentration. The high selectivity factor observed in the assay 
with DMHPA as IP-reagent results in a baseline separation of aqueous MTXPG1-7 within 
2.5 minutes. Again peaks were sharper using DMHPA as the IP agent under gradient 
conditions. The signal to noise ratio was also more favorable for (MRM) signals obtained 
from a 100 nM MTXPG1-7 mixture, probably as a result of the beneficial effects obtained 
by the increased organic modifier strength required for timely elution of the MTXPGs 
(note signal intensities in figure 36A and B). The expected negative effect using DMHPA 
upon MS-ionization was not observed, but could be disguised by the increase in modifier 
strength. Nevertheless the effect can be neglected and chromatographic advantages 
obtained using DMHPA outweigh other considerations. 
 Whilst the timeframe separation time of 2.5 minutes for the seven MTX 
metabolites was desirable from the throughput perspective, chromatographic peaks 
widths became narrow and challenged the data acquisition rate of the Ultima mass 
spectrometer (note the beveled peaks in figure 36). It was found that the average 
amounts of scans during the peak was about 5 (figure 37A), where a minimum amount 
of 9 datapoints through the peak is generally considered to adequate.  
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Figure 36. Gradient profiles used to achieve a fast separation of the various MTXPGs. 
The gradient steepness is illustrated by the redline. (A) Gradient separation using 
DMPA. (B) Gradient separation using DMHPA. (note the differences in gradient 
steepness). 
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Figure 37. Width of the MTX peak in the chromatogram based on a “scan number” axis, 
illustrating the number of datapoints through the chromatographic peak.  
 
The amount of scans through the peak could be increased by slowing the “ballistic” 
gradient down to a more moderate 4% change in B per min (figure 37B). The more 
shallow gradient doubled the amount of scans through the peak, allowing for about 10 
scans through the peak. As a consequence the analysis time was increased to 4.5 
minutes per sample (figure 38F). Whereas the scan rate of the Waters Ultima triple 
quadrupole mass spectrometer is the bottle neck for sample throughput in this 
procedure, the current generation of modern mass spectrometers have shorter cycle 
times and will be able to operate under the more demanding rapid elution conditions. As 
a result there is a tremendous increase in the data acquisition rate and thus these type 
of detectors would for the fast separations presented earlier.  
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Figure 38. Illustration of crosstalk between the various SRM channels. (A) MTX DMHA 
adduct appears in MTXPG2 MRM channel. (B) MTX channel, (C) TIC using DMHA as 
ion-pair reagent. (D) Using DMHPA no signal is generated by the lower MTX SRM 
channel. (E) MTX channel, (F) TIC using DMPHA as the ion-pair reagent. 
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 With the establishment of DMHPA as the preferred IP-agent, the effect of adduct 
formation on the LC/MS/MS assay using MRM monitoring was investigated. The DMHA 
method demonstrated crosstalk from a MTXPGn channel (figure 38B) in the “next” 
MTXPGn+1 channel (figure 38A). As hypothesized this interference due to adduct 
formation was not observed once DMHPA was used as the IP reagent (figure 38D, E). It 
can therefore be concluded that when analyzing sequential metabolites (in this case 
polyglutamates), the mass of the IP-agent in LC/MS/MS should not be isobaric with the 
molecular change of the analyte due to metabolism.  
 
5.3.3 Sample preparation 
 A major drawback of the MTXPG analysis method presented in chapter 4 was the 
laborious procedure required to render the biological sample into a solution that could be 
introduced into the chromatograph. Chapter 4 describes the various strategies that had 
been explored in order to obtain a viable sample preparation strategy. All strategies 
explored as alternatives to the acid protein precipitation followed by SPE extraction were 
found to be ineffective. However, heat extraction, a sample preparation strategy that was 
applied successfully in G5-MTX-FA analysis was not explored. Additionally heat 
extraction has been presented in prior literature to extract various folate(polyglutamates) 
from a number of tissues at pH 7.85 [9-10]. The fact that MTXPGs are structural 
analogues of folatePGs suggests this technique could be useful for the extraction of 
MTXPGs in a simple step. An extraction in a single step at physiological pH would be 
highly desirable in this IP-LC/MS/MS analysis procedure as it would result in a mobile 
phase compatible sample that could be directly inject able into the HPLC system without 
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the need for additional sample workup.  The heat extraction of folates requires a very 
specific buffer, consisting of ascorbic acid as the anti-oxidant, mercaptoethanol to 
scavange formaldehyde released by ascorbic acid, and a HEPES/CHES buffer system 
that fixes the pH at 7.85. In the field of folate analysis commonly referred to as the 
“Wilson and Horne” buffer, named after the scientists that demonstrated the 
effectiveness of this buffer system for the stabilization of folate extracts (more about this 
buffer system will be presented in chapter 7). Since MTXPGs are more (redox) stable 
compared to the various folates, a modified buffer was explored where ascorbic acid and 
mercaptoethanol were excluded from the buffer. This buffer proved to be successful for 
the extraction of MTXPGs from RBCs. Overall recovery based on a limit study (n=1) 
appears to be around 60% for the individual MTXPGs, similar to acid mediated 
extraction.  
A full validation is presented in the next section of this chapter, demonstrating the 
reproducibility of this procedure.The advantage of the presented heat extraction 
procedure is the fact that protein bound analytes are liberated and proteins are 
precipitated simultaneously in one operation. After centrifugation a clear, sometimes 
slightly red supernatant (figure 39C, D) can be recovered and injected into the 
chromatograph without any deterioration in chromatographic of the analytical column for 
several hundreds of injections (guard columns were changed at 100 injection intervals, 
due to a slight increase in backpressure). The pH of the extraction solution was found to 
be important parameter to control, if the pH differentiated significantly from 7.85 a 
blackish slurry was obtained upon heat extraction (figure 39A, E). The slurry could not 
be separated by centrifugation and is obviously incompatible with HPLC/UPLC systems 
(figure 39B, F).  
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Figure 39. The influence of the pH during sample preparation (boiling). An aliquot of 200 
µL of RBCs were combined with 200 µL of buffer. (A) A solution with a pH of 6.0 was 
boiled, leading into a blackish sludge. (B) The sludge could not be separated by 
centrifugation. (C) Boiling at pH 7.85 leads to reddish “pudding”. (D) Centrifugation lead 
to separation, with the debris at the bottom the vial. (E) Boiling at pH 10.0 lead to similar 
results as pH 6.0, forming a sludge. (F) Again the sludge could not be separated. 
 
 
158 
 
5.3.4 Selection of internal standards 
 The validation results presented in chapter 4 for the MTXPG LC/MS/MS method 
revealed a precision that was in general between 10-15%, approaching the acceptable 
limits set by FDA guidelines for a bioanalytical assay[11].  It was therefore hypothesized 
that calibration relative to an internal standard could result in a reduction of the analysis 
error (i.e. improvement of the precision) and therefore would be beneficial. Furthermore 
the sample preparation approach presented in this chapter lacks the additional cleanup 
step provided by SPE extraction, making this faster and easier method more susceptible 
to matrix effects. The magnitude of suppression of the ion formation due to matrix effects 
was assessed by post column infusion of an aqueous MTXPG1-7 solution. During the 
infusion a representative, (blank) boiled RBC extract was injected in the 
chromatographic system and the change in signal intensity was monitored throughout 
the gradient elution profile. Ion suppression due to endogenous components in the 
worked up RBC matrix will result in a reduction of the analyte signal (figure 40A) (For a 
review on these techniques please refer to Annesley[12].). RBC samples from different 
individual donors (n=5) were analyzed using this strategy. A chromatographic window 
(between 4-5 minutes) was identified that demonstrated significant ion-supression, 
affecting the analysis of MTXPG1 and MTXPG2. (figure 40A and B, red area) (Please 
note that these experiments were conducted using a significantly slowed gradient, 
improving resolution aiding in the visualization of the areas of interest). The longer chain 
MTXPGs3-7 eluted in a chromatographic window where signal intensity was relatively 
stable and did not seem to be affected by matrix effects in any of the RBC samples 
screened (figure 40A and B, green area).  
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Figure 40. The influence of matrix effects on the quantitation of MTXPGs. (A) a constant 
infusion of MTXPGs1-7. Dips in the signal are indicative of suppression of ion formation. 
(B) MTXPGs enriched RBC extract. (C) Separation of aqueous FAPGs standards 
allowing for retention time comparison. The red area illustrates a part of the 
chromatogram where matrix effects were observed. The green part illustrates a relatively 
unaffected part of the chromatogram.  
 
 
160 
 
 As discussed earlier, the use of isotopically labeled internal standards mimicking 
the structure of the analytes is a hallmark in bio-analytical mass spectrometry[13]. 
However obtaining and synthesizing these internal standards is not always trivial, as is 
the case for MTXPGs. Synthesizing a deuterated (d3) version of MTX is for instance 
more complicated than one would expect at a first glance[14], and the complexity 
increases rapidly as the polyglutamates are required as well. Based on the observed ion 
suppression pattern it was hypothesized that the assay would benefit from the 
incorporation of minimally two internal standards; one internal standard representative of 
the suppressed chromatographic window affecting MTX and MTXPG2, and another 
internal standard serving the more stable signal area of the chromatogram where 
MTXPG3-7 are eluting.  
 Since the elution window of MTX and MTXPG2 is the most extensively effected, 
an isotopically labeled standard for these analytes would be highly desirable. As d3-MTX 
is commercially available and d3-MTXPG2 is not, d3-MTX was purchased and used as in 
internal standard for both MTX and MTXPG2. The remaining polyglutamates (MTXPG3-
7) are in a relatively stable region of the chromatogram, justifying the use of a pseudo 
internal standard. Folic acid is available in its polyglutamates commercially and several 
reports suggest that FA in its native or polyglutamate is absent in RBCs. Assuming there 
is no endogenous background of FAPG(s) this series would be a good candidate to 
serve as a internal standard due to its related structure to MTX. As a result of the 
chromatographic methods selectivity towards increasing anionic character with 
increasing polyglutamate chainlenght, the longer chain FAPGs(4-7) eluted closely to the 
MTXPGs(4-7) (figure 40, B and C). Since MTXPG3-7 are in a relatively clean area of the 
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chromatogram, (i.e. free from ion suppression) FAPG4 was selected to serve as internal 
standard for MTXPG3-7.  
 In order to check if FAPGs are present endogenously within RBC cells, RBCs 
from various donors (n=10) were screened for FAPGs (figure 41B, C, D). A number of 
RBC donors showed the presence of FAPG5-7, in contrast to what various publications 
suggest (measuring deglutamated FA). The highest concentrations measured were 
however low and FAPG4 was not detected in any samples, suggesting that this 
molecule was suitable for use as an internal standard. An additional safety level was 
however added to the method by fixing the concentration of FAPG4 at a slightly elevated 
level (50 nM) to negate effects of unexpected low endogenous concentrations of 
FAPG4.  
 Today, validation is considered essential component of the development of a 
clinical bio-analytical assay before it is applied to patient care[15].The newly described 
method, including heat extraction and fast chromatographic separation (see figure 43 for 
a representative chromatogram) was validated in a similar fashion as described in 
chapter 4. The data of the validation on four consecutive days is presented in table 21. 
The precision of the method was significantly increased as a result of the reduction of 
the number of sampling handling steps and the incorporation of internal standards. 
Overall the method was precise and accurate to 1 nM, with the exeption of the longer 
polyglutamates (MTXPG5-7). Correlations of the individual analytes were found to 
approach an R2 of 0.999, similar to earlier reported values.  
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Figure 41. Chromatograms of folic acid polyglutamates separations. (A) separation of an 50nM 
aqueous mixture of FAPG1-7. (B) JIA patients on MTX therapy with no detected FA in the 
donated RBC sample. (C) JIA patient with FAPG5-6 detected in concentrations <2.5 nM. (D) 
Chromatogram of an RBC sample from a JIA patient with FAPG5-7 detected at concentrations 
<10 nM. 
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Table 21. Intra- and inter-day precision and accuracy results 
      Intra-run (n=5) Inter-run (n=20) 
Analyte 
Nominal RBC 
Concentration 
(nM) 
Precision       
(RSD %) 
Mean 
observerd 
concentration 
(nmol/L) 
 Mean 
Accuracy            
of target 
value (%) 
Precision       
(RSD %) 
Mean 
observerd 
concentration 
(nmol/L) 
 Mean 
Accuracy            
of target 
value (%) 
MTXPG1 100 7.5 100.6 100.6 5.1 100.3 100.3 
 
50 4.6 50.1 100.1 6.7 50.3 100.6 
 
10 2.7 9.4 93.5 4.9 9.5 95.5 
 
5 7.6 4.9 97.6 10.9 4.8 96.7 
 
1 10.8 1.1 106.0 18.4 1.0 102.5 
MTXPG2 100 2.2 101.5 101.5 5.4 101.3 101.3 
 
50 5.3 48.6 97.2 8.3 49.7 98.1 
 
10 2.6 9.8 97.5 6.4 9.7 96.9 
 
5 13.6 5.1 102.0 11.4 4.9 98.9 
 
1 11.2 1.0 98.0 14.0 1.0 101.5 
MTXPG3 100 4.4 98.9 98.9 5.0 100.7 100.7 
 
50 11.4 51.9 103.8 8.0 50.2 100.3 
 
10 1.9 9.1 91.3 7.8 9.2 91.9 
 
5 3.8 4.8 96.8 6.3 4.9 97.2 
 
1 11.0 1.0 104.0 14.7 1.1 106.5 
MTXPG4 100 1.1 98.8 98.8 5.3 100.4 100.4 
 
50 11.3 52.0 104.0 8.1 50.5 101.0 
 
10 4.5 9.0 90.3 6.9 9.2 92.5 
 
5 3.7 4.9 98.8 5.8 4.7 94.4 
 
1 11.2 1.0 102.0 14.9 1.1 108.0 
MTXPG5 100 1.6 98.6 98.6 5.3 100.2 100.2 
 
50 11.8 51.8 103.6 8.3 50.8 101.5 
 
10 3.3 9.5 94.8 7.5 9.2 91.9 
 
5 6.2 4.9 98.8 14.2 4.6 92.8 
 
1 30.3 1.1 108.0 31.4 1.1 113.0 
MTXPG6 100 2.7 99.5 99.5 7.0 99.2 99.2 
 
50 11.0 51.3 102.6 8.6 51.3 102.7 
 
10 5.0 9.1 90.5 7.6 9.5 94.9 
 
5 9.3 4.8 96.8 9.4 4.8 96.1 
 
1 8.6 1.0 104.0 32.7 1.1 107.0 
MTXPG7 100 2.1 97.9 97.9 8.2 96.7 96.7 
 
50 10.5 52.5 105.1 8.7 52.9 105.9 
 
10 5.0 9.8 97.8 8.7 10.1 100.6 
 
5 7.4 4.6 92.0 18.7 4.8 96.1 
  1 22.1 1.1 108.0 60.1 1.1 105.5 
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5.3.5 Detection of 7OH-MTX 
 
 
Figure 42. An injection of a 10nM 7OH-MTX aqueous solution in both positive ion mode (A) and 
negative ion mode (B). Mass spectrometry setting can be found in table 1. 
 
As discussed in the introduction 7OH-MTX is a degradation product resulting from 
MTX catabolism. The measurement of these species might give provide addition insight 
of the MTX/folate metabolism of the individual RA patient and therefore provides a more 
extensive picture of all entities competing for enzymes that are responsible for folate 
biotransformation. 
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 The development of an analytical strategy for 7OH-MTXPGs is complicated by 
the fact that polyglutamyl standards are not commercially available and synthesis is not 
straight forward due to the nature of the glutamyl-linkage, where individual glutamate 
building blocks are connected through the amino acid side chain (gamma-carboxylate). 
However based on the fragmentation pattern of these type of species one could 
tentatively scout for these entities using specific SIM detection schemes by the triple 
quadrupole mass spectrometer. Such a study would not allow for reliable and robust 
quantitation but should demonstrate the presence or absence of this group of MTX 
metabolites within RBCs and could be followed up by more sophisticated studies if 
desired. 
 Initial method development was initiated by investigating the ionization behavior 
of 7OH-MTX.  Interestingly it was found that in contrast to MTXPGs, 7OH-MTX (as the 
parent) was ionized more efficiently in negative ion-mode. Using MRM monitoring 
negative ion-mode was also found to more sensitive (figure 42B) as opposed to positive 
mode (figure 9 A) when applied to the detection of 10 nM aqueous 7OH-MTX standards. 
In order to estimate the fragmentation behavior of 7OH-MTXPG in negative ion-mode, a 
study was conducted using folic acid polyglutamates (FAPG1-7). Folate acid 
polyglutamates are commercially available and based on the assumption that 7OH-
MTXPGs have similar gas phase properties as FAPGs one could extrapolate MS-SRM 
settings such as parent m/z, daughter m/z, cone voltage and collision energy. The 
results of the study are presented in table 20. The most dominant fragment was the for 
PG1-2 loss of the glutamate chain, whereas the fragmentation of higher order 
polyglutamates (PG3-7) were forming predominantly the monoglutamate fragment. This 
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was different to what was reported by Garrett et al, who had indicated the glutamate 
fragment with an m/z of 127.8 was the dominant fragment[8].  
 Using these extrapolated settings for 7OH-MTXPGs, erythrocyte samples from 
JIA patients on MTX therapy were screened for the presence of 7OH-MTXPGs. Since 
the hypothesis was that the presence of high amounts of 7OH-MTXPGs could enhance 
the excretion of MTX(PGs) patient samples were selected (n=10) with low-intermediate 
amounts of MTXPGtotal and screened for the presence of 7OH-MTXPGs. None of the 
patients out of the group tested positive for the presence of 7OH-MTXPGs. As the 
absence of 7OH-MTX could also be the result of poor MTX absorption in general by the 
individual, patients with high intracellular levels of MTXPGtotal were also screened for the 
MTX metabolites (n=10). Again none of the patients tested positive for the presence of 
7OH-MTX within donated RBC samples. An example is given in figure 43, figure 43A 
shows a baseline signal indicating the absence of 7OH-MTXPGs. The various MTXPGs 
are demonstrated in figure 43B. The fact that 7OH-MTX was not observed in any of the 
analyzed RBC samples suggest that this MTX metabolite is not present in RBCs. Based 
on the earlier reported high abundance of this metabolite in the bone marrow this is 
surprising. One could argue that 7OH-MTX was not observed could be due to a vast 
difference in fragmentation behavior in ESI- between 7OH-MTXPGs and FAPGs, and 
setting extrapolation fails. To appropriately address this concern one would need 
isolated standards of the 7OH-MTXPGs and optimize MS/MS settings by infusion of 
these compounds. However, the success of extrapolating MS/MS settings is proven 
using structurally related compounds in the final data chapter of this thesis dealing with 
folate analysis. Furthermore, the analytical strategy presented in the following chapter 
for the expedient detection of MTXPGtotal was not able to detect 7OH-MTX as well. 
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Based on these observations it is tempting to conclude that 7OH-MTX is not present (in 
significant amounts) within erythrocytes of JIA patients on weekly low dose MTX 
therapy.  
 
 
Figure 43. Example RBC chromatograms of a JIA patient on MTX therapy. (A) Chromatogram 
of 7OH-MTX(PGs) (B) Chromatogram of MTXPGs 
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5.4 Conclusion 
The analytical methodology presented in the previous chapter (chapter 4) has 
been adapted for clinical use. Significant improvements were made on a number of 
facets of the assay. First, an improved sample preparation strategy was presented 
where the analytes were liberated using heat extraction. Proteins were denatured in the 
same step, and thus after centrifugation, a supernatant was obtained that could be 
introduced in the chromatograph. Second, DMHPA was found to be a more suitable ion-
pairing agent when compared to DMHA and DMPA. Using DMHPA, chromatographic 
resolution between the analytes was increased, peak shape improved and fast gradient 
elution could be applied to separate the analytes within 4.5 minutes. Faster separation is 
chromatographically possible, but will need a mass spectrometer that clears the “ion 
path” faster than the Waters Ultima triple quadrupole mass spectrometer, such as the 
newer Xevo TQ. Third, the incorporation of d3-MTX and FAPG4 as internal standards 
(together with a less complicated sample preparation procedure) resulted in an improved 
precision, when compared to the assay that used solely external calibration.  
 An assay was developed for the detection of 7OH-MTX using electrospray 
ionization in negative ion mode. Due to the absence of polyglutamation standards the 
mass spectrometry settings were extrapolated based on the behavior gas phase 
behaver of FAPG homologues. RBC samples obtained from a number of JIA patients 
that displayed low, intermediate and high intracellular concentrations of MTXPGs were 
screened for the presence of 7OH-MTX. Interestingly, no 7OH-MTX in its native or 
polyglutamated form could be detected.  
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6.1 Introduction 
The antifolate methotrexate (MTX) (4-amino-10-methylpteroylglutamic acid) 
administered in low dose, on a weekly basis, is widely used for the treatment of 
rheumatoid arthritis (RA) [1] and juvenile idiopathic arthritis (JIA) [2]. MTX is the first-line 
therapy for RA patients exhibiting inadequate disease control from treatment with non-
steroidal anti-inflammatory drugs [3]. In low-dose this disease-modifying drug is generally 
well tolerated and considered safe, however there is a substantial percentage of patients 
who have poor response to MTX or develop adverse reactions [4]. This can be partly 
explained by a poorly understood inter-patient variation in the dose of MTX required to 
achieve a desirable level of disease control, making it difficult to optimize and 
individualize therapy. It has recently been shown that the measurement of MTX and its 
polyglutamate metabolites (MTXPGs) in red blood cells (RBCs), an easily accessible 
space thought to reflect the intra-cellular state, could be a useful tool in individualizing 
MTX therapy [5-8].  
Whilst the exact mechanism of action of MTX in RA/JIA is poorly understood [9-10], 
its therapeutic effect is attributed to the various MTXPGs rather than MTX itself  [11-13]. 
Various methods to measure intra-cellular levels of MTXPGs have appeared recently in 
the literature. These strategies can be categorized as methods that measure the total 
amount of polyglutamated MTX (i.e. as a total pool) (MTXPGtotal) and methods that 
measure and quantify each MTXPG individually, up to the hepta-glutamate. Individual 
concentrations of MTXPGs in RBCs have been measured by HPLC with a post-
separation photochemical (PCR(hv)) derivatization followed by fluorescence detection 
(FD) [6], and more recently by an ion-pair HPLC method followed by tandem mass 
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spectrometry (LC/MS/MS) [14]. Currently, the LC/MS/MS method is the most specific and 
sensitive assay for detection of MTXPGs. Whilst these methods give a detailed 
presentation of the intra-cellular MTX metabolome, calibration is required for each 
MTXPG, necessitating the use of expensive standards.  Further, gradient elution 
separation is required to compensate for differences in chromatographic behavior of the 
different MTXPGs, typically resulting in a relatively long run and re-equilibration times. 
Clinically, the relevance of individual MTXPG concentrations or population distribution is 
not fully understood, and as a result the various polyglutamates are often summed to a 
total or alternatively, grouped as short chain (MTXPG1-2) and long chain (MTXPG3-5) [5-6] 
pools.  
MTXPGtotal methods utilize the plasma enzyme ɣ-glutamyl hydrolase to 
deglutamate the various MTXPGs into MTX (in a similar fashion as folate 
polyglutamates) [15]. Typically, an aliquot of human plasma is added to a RBC lysate as a 
source of ɣ-glutamyl hydrolase, followed by a lengthy incubation period ranging from 6 to 
14 hours at 37 °C. The amount of MTX after deglutamation (reflecting the MTXPGtotal) is 
generally measured by HPLC- PCR(hv)-FD [6, 16]. The post column oxidative degradation 
used by these methods generates a fluorescent pteridine derivative by cleaving the C9-
N10 bond of MTX(PGs) [17-18] (figure 44a). Hence, the only function of the elaborate 
deglutamation procedure is to circumvent chromatographic resolution between the 
various polyglutamates.  
We hypothesized that a precolumn derivatization strategy leading to cleavage C9-
N10 bond of MTX(PGs) would circumvent the tedious deglutamation step and as a result 
increase sample throughput, reduce the number of sample preparation steps and avoid 
the addition of blank human plasma and the ensuring incubation period. The presently 
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proposed analytical method would possess the attributes of being rapid and economical, 
an attractive alternative for the routine monitoring of total intra-cellular MTX related 
species in JIA and RA patients, while still providing a quantitative basis for 
individualization of MTX therapy.  
 
 
177 
 
6.2 Materials and Methods 
6.2.1 Chemicals and reagents 
Methotrexate (MTX) was purchased from Sigma Aldrich (St. Louis, MO, USA) and 
methotrexate polyglutamates (MTXPG) 2-7 were purchased from Schircks Laboratories 
(Jona, Switzerland). 2,4-diamino-6-methylpteridine (DAMP) was obtained from ChemDiv 
(San Diego, CA). HPLC grade methanol (MeOH), sodium phosphate monobasic and 
ammonium bicarbonate were purchased from Sigma Aldrich (St. Louis, MO, USA). 
Ammonium acetate and sodium phosphate dibasic were acquired from Fisher Scientific 
(Fairtown, NJ, USA). Sodium dithionite was purchased from Riedel – de Haën (Seelze, 
Germany). Demineralized water was produced by Labconco Waterpro PS (Labconco 
Corporation, Kansas City, MO, USA). Blank Red blood cells (RBCs) were drawn from 
healthy volunteers on site. 
6.2.2 Chromatographic separation 
Solvent was delivered by a binary pumping system containing two Shimadzu 
LC6A pumps. The sample was introduced by a Shimadzu SIL-6B auto injector equipped 
with a 50µL injection loop and a 50% water/50% ACN wash solution. Detection was 
accomplished by a Shimadzu RF-10Axl fluorescence detector using an excitation - 
emission wavelength of 367 nm and 463 nm, respectively, with a bandwith of 15nm. 
Chromatography was performed using a Phenomenex Inertsil ODS-3 analytical column 
(150 x 4.6mm) packed with 5µ 100 Å particles.  The analytical column was guarded 
using a Supelcosil LC-8 guard column (5µ, 2 x 4.0mm). Mobile phase A consisted of 10 
mM ammonium acetate in water and mobile phase B was 100% methanol. An isocratic 
mobile phase containing 30% B at a flow rate of 1 mlmin -1 was used for the separation.  
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6.2.3 Stock solutions and buffers 
Phosphate buffers (1.0 M) of pH 5.5, 6.0, 6.5, 7.0 and 7.5 were obtained by 
blending a 1.0 M monobasic sodium phosphate solution with a 1.0 M dibasic sodium 
phosphate solution to achieve the targeted pH. MTX and MTXPGs were dissolved 0.10 
M  ammonium bicarbonate buffer to prepared 1.0 mM master stock solutions. The 
working stock solutions containing the appropriate concentrations of the analytes were 
created by further dilution of the master stocks solutions with water. All stock solutions 
were prepared daily prior to each experiment.  
 
6.2.4 Preparation of erythrocyte (RBC) lysates 
Blood samples (~5 ml) obtained from patients were centrifuged at low speed 
(2000 rpm) in a Beckman tabletop centrifuge to pellet the RBCs. After removal of 
plasma, the RBCs were suspended in an equal volume of sterile normal saline, mixed by 
gentle inversion and subjected to a second low speed centrifugation. The supernatant 
was discarded and the wash procedure was repeated a second time. After discarding 
the supernatant, the packed RBCs were divided into aliquots and stored at -70° C until 
use. 
 
6.2.5 Derivatization protocol 
A general derivatization procedure was established. An 100 µL aliquot of patient 
or blank RBCs was transferred to an Eppendorf reaction vial and was spiked with one of 
the analytes. The volume was adjusted to 200 µL using deionized water and/or aqueous 
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calibration solutions of MTX to obtain spiked RBCs of the appropriate concentration. The 
remaining mixture was subsequently homogenized via vortex mixing for 5 seconds. The 
pH of the homogenate was adjusted by the addition of 600 µL of pH 6.0 phosphate 
buffer followed by an additional 5 second vortex step. The samples were placed in an in-
house constructed sample holder that was able to pressure seal the caps of the 
Eppendorf reaction vials. The total reaction volume was brought to 1.0 mL by addition of 
200 µL of a freshly prepared solution of 10 mg/mL sodium dithionite. After sodium 
dithionite addition to each vial, the lids were closed and the entire holder inverted 5 
times, then vortexed for 10 seconds to ensure complete mixing (this step was found to 
be extremely important in obtaining reproducible results). The sample holder was then 
placed in boiling water for 15 minutes to facilitate the reduction reaction and precipitate 
proteins. After the reaction period, the sample holder was refrigerated at 7° C for 30 
minutes. The reaction vials were subjected to centrifugation (13,000 rpm for 5 minutes), 
and the resulting supernatant transferred to a 1.0 mL autosampler vials for subsequent 
determination.  
 
6.2.6 Yield determination and validation 
In order to determine the yield of the reduction, 100 µL  of RBCs (n=5) were spiked with 
MTX to 1.0 µM and subjected to the derivatization procedure. The reduction yield was 
obtained by comparing the spiked RBC samples to an aqueous DAMP standard 
calibration curve (0.1, 0.5, 1.0, 1.5, 2 µM) . Method validation consisted of determination 
of MTX spiked RBCs at 10, 25, 50, 100, 250 and 500 nM in 5 replicates on four 
consecutive days.  
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6.3 Results and discussion 
6.3.1 Selection of the Derivatization Reaction and Format 
The order of operations within an overall methodology has significant analytical 
implications.  For example, the conduct of a derivatization reaction in the pre- versus 
post-column format defines the nature of the data obtained. Conduct of a post-column 
derivatization reaction allows for separation of the various analytes of interest prior to 
formation of an analytical reporter product.  In contrast, pre-column derivatization of a 
family of analytes may lead to the formation of a common product and thus loss of 
analytical identity.  As noted previously, there are clinical situations where determination 
of the total concentration of all related species is sufficient and desirable, rather than 
determination of each individual analytical species. 
 
 
 
Figure 44. The labile C9-N10 bond in MTX can be cleaved in oxidative (A) and reductive 
(B) environments. The resulting fluorescent derivative is either carboxylated or 
methylated at the C6 position, depending on the chemistry selection. 
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Continuing with the concept of total analyte determination, as previously noted, the C9-
N10 bond in methotrexate is chemically labile to oxidative [6, 16-18] and reductive [19] 
environments to yield fluorescent pteridine derivatives (figure 44). These different 
processes lead to different products, with oxidative cleavage leading to the formation of 
2,4-diaminopteridine-6-carboxylic acid (DAPC) (figure 44a) while reduction cleavage 
leads to 2,4-diamino-6-methylpteridine (DAMP) (figure 44b). A prior publication suggests 
that the reductive product DAMP exhibits more favorable fluorescence properties as 
compared to the oxidative product DAPC, with a yield of approximately 70% being 
realized when the analyte is present in plasma [19]. 
In previous studies (Chapter 2 and 3), it was found that sodium dithionite 
reductive mediated reductive cleavage of the C9-N10 bond may be extended to the 
situation where  MTX is conjugated to a macromolecular carrier via the glutamyl residue.  
The apparent generality of this reaction lead to the present hypothesis that sodium 
dithionite reductive mediated reduction could be used to measure MTXPGtotal (DAMP 
serves as a common reporter molecule for each MTXPG).  In another consideration with 
respect to the choice of an oxidative versus reductive process to mediate C9-N10 
cleavage, the previous investigation had also shown the reductive procedure to result in 
significantly less chromatographic interferences as compared to the oxidative procedure. 
With any bioanalytical method, simplistic and efficient sample preparation is a hallmark 
of a robust method. In the present case, it was observed that by conducting the 
reductive procedure directly in plasma (reaction for 15 minutes in boiling water), efficient 
protein denaturation was accomplished, and after centrifugation, the supernatant could 
be directly analyzed by HPLC-FL. When this procedure was investigated for the analysis 
of MTXPGtotal in human RBCs, the chromatograms of figure 45 were obtained. A DAMP 
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reference standard dissolved in water was used to optimize chromatographic conditions 
(figure 45a). Blank human RBCs showed no significant interference originating from 
endogenous molecules during the elution window of DAMP (figure 45a). Due to the low 
background a rapid isocratic separation was possible, leading to an analysis time of just 
7 minutes per sample. In order to validate the hypothesis that the various MTXPGs 
would yield the same product (DAMP), the various individual MTXPGs were spiked in 
similar concentrations and derivatized in human RBCs obtained from individuals not 
treated with MTX. Identical chromatograms were generated regardless of the derivatized 
MTXPG (figure 45b).  
 
 
 
Figure 45.  (A) Illustration of a blank RBC chromatogram (black line), showing no 
endogenous interference during the elution of the DAMP derivatization product (blue 
line). (B) 7 individual chromatograms of RBC samples, each spiked with a different 
MTXPG standard (1-7). 
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6.3.2 Yield Optimization and Comparison 
Deen and coworkers stated in their plasma method that no increase in fluorescent 
signal was observed after 15 minutes of reaction time and/or an increase in dithionite 
concentrations[19]. Similar observations were made with the reaction in the RBC matrix. 
The influence of the pH on the reduction reaction of MTX with an RBCs matrix was 
investigated at pH 5.5, 6.0, 6.5, 7.0 and 7.5 (table 22). The highest fluorescence was 
obtained at pH values of 5.5 and 6.0. In order to maximize the buffer capacity of the 
phosphate buffer, a pH of 6.0 was selected. It has been shown that patients on MTX 
therapy show large inter-patient variability in MTXPG distributions (short-chain or long-
chain MTXPGs being dominant). Since MTXPGtotal is calculated as the sum of all 
glutamation species from MTXPG1 (parent) to MTXPG7, it was essential that 
derivatization of the various MTXPGs proceed with similar yields in order to avoid 
analytical bias due to differences in the MTXPG population distribution. MTXPG1-7 were 
individually (n=5) spiked at 1.0 µM in the RBC matrix and subjected to the reductive 
procedure (table 23). The average yield of reaction was 61.6% yield, with MTXPG2 
giving the highest (65.1%) and MTXPG7 lowest (56.6%) yield.  
 
Table 22. pH influence on reaction yield 
pH Relative yield Precision (RSD %) 
5.5 1.00 1.5 
6.0 0.96 3.2 
6.5 0.74 2.2 
7.0 0.56 3.4 
7.5 0.41 3.3 
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The MTXPG7 reduction yield was significantly lower than the mean using the student t-
test at the 95% convidence interval. However, this standard is very hygroscopic and had 
visually picked up some water during storage. Therefore it was concluded that reaction 
yield between the different MTXPGs was identical, with observed differences being 
caused by minor variations in the purities of the commercially obtained MTXPG 
standards. As a result, the analytical method can be calibrated with reference to MTX 
thus avoiding the need for specialized expensive MTXPG standards. 
Table 23. Reduction Yields of various MTXPGs 
  
  Concentration (µM) Found (µM) 
Yield 
(%) RSD (%) 
MTX 1.00 0.62 62 1.8 
MTXPG2 1.00 0.65 65 1.4 
MTXPG3 1.00 0.61 61 1.1 
MTXPG4 1.00 0.64 64 2.0 
MTXPG5 1.00 0.63 63 0.6 
MTXPG6 1.00 0.59 59 1.3 
MTXPG7 1.00 0.57 57 2.8 
 
6.3.3 Matrix influence 
During method development it was observed that sodium dithionite-mediated 
reduction to yield DAMP was matrix dependent. Unexpectedly, in aqueous solutions the 
reaction was less efficient (absolute yield was about 5-10%) as compared to RBC matrix 
(yield about 62%). As this variation was of considerable concern, further experimentation 
was conducted in an effort to establish the nature of this variability and to define 
conditions leading to reproducibility.  RBCs from four separate individual donors were 
spiked (n=5) with an equal amount of MTX and subsequently analyzed (table 24). The 
various lots of RBCs did not significantly affect the derivatization yield and as a result the 
ability of the method to quantitate MTXPGtotal in individual RBC samples is not 
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compromised. Since the derivatization proceeds more efficiently in RBCs than water, it 
was established that it is very important to keep RBC volumes between calibrants and 
samples constant during the derivatization process, or in other words an identical matrix 
must be maintained for all samples, unknowns or standards, being subjected to sodium 
dithionite reduction.  
Table 24. Yield of reaction in various individual RBC donors. 
RBC Donor Spiked (nM) Found (nM) Yield (%) RSD (%) (n=3) 
1 100 109.5 109.5 11.4 
2 100 107.7 107.7 1.5 
3 100 111.7 111.7 4.3 
4 100 107.8 107.8 1.6 
 
6.3.4 Method Validation 
Using MTX the method was validated on four consecutive days at six different 
concentrations from 10-500 nM, representing a clinically relevant MTXPGtotal range 
reported in RBCs (table 25). The intra-run mean accuracy of the target value was 
between 98.1 % and 106.0 %. The intra-run precision was between 1.2 % and 8.8 %. 
The limit of quantification was determined to be 10 nM MTXPGtotal. The limit of 
detection, defined as 3 times the signal to noise ratio, was 4 nM MTXPGtotal. Four 
different calibration curves at different days revealed a linear relationship between peak 
area and concentration of the prepared RBC standards, with correlation coefficients r2 > 
0.999 for each day. A typical calibration curve was described by the following linear 
equation: y = 376.7x + 832.1, where y is peak area and x is concentration added in 
nMThe derivatization procedure results in a 10-fold sample dilution, however limits of 
quantification were within assay requirements, so no effort were made to preconcentrate 
the sample prior to injection. 
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6.3.5 Stability 
The stability of the reporter molecule (DAMP) was investigated at three different 
concentrations (10.0, 50.0 and 250.0 nM). After sample processing the samples were 
placed in the autosampler and analyzed 24 hours later (table 26). Sample deterioration 
was not observed, indicating that the processed samples are stable for at least 24 hours 
at room temperature, which is sufficient for analysis. The freeze-thaw stability was 
investigated in a similar manner (table 26). Recently, Hroch et al have reported sample 
instability when multiple freeze-thaw cycles were applied (method of detection was 
enzymatic deglutamation followed by HPLC-(PCR(hv)-FD) [16]. A significantly lower value 
(47%) was observed, especially after the third free-thaw cycle. This instability was not 
observed when these freeze-thaw cycled samples were analyzed by the presented 
methodology. 
 
 
 
 
Table 25. Intra- and inter-day precision and accuracy results  
  Intra-run (n=5)   Inter-run (n=20) 
Nominal RBC 
MTXPG 
concentration 
(nM) 
Mean 
observed 
concentration 
(nmol/L) 
Mean 
Accuracy 
of target 
value (%) 
Precision 
(RSD %)   
Mean 
observed 
concentration 
(nmol/L) 
Mean 
Accuracy 
of target 
value (%) 
Precision 
(RSD %) 
10 10.6 106.0 5.6 
 
10.0 99.7 9.6 
25 25.7 102.7 2.3 
 
24.8 99.2 7.5 
50 50.0 100.0 8.8 
 
49.6 99.2 6.1 
100 98.1 98.1 3.2 
 
98.7 98.7 4.1 
250 250.6 100.2 2.6 
 
253.2 101.3 2.1 
500 500.0 100.0 1.2   498.7 99.7 1.6 
 
 
187 
 
Table 26. Freeze-thaw stability and stability of the derivatization product  
 Storage condition Concentration of MTXPGtotal in nM R.S.D. (%) (n=3) 
  nominal measured 
Stability in autosampler (24h) 10 10.0 13.4 
 
50 50.2 6.1 
 
250 250.2 5.8 
Freeze-thaw stability (3 cycles) 10 9.4 24.4 
 
50 48.3 13.3 
  250 242.3 5.9 
 
6.3.6 Patient samples analyzed by the MTXPGtotal assay and LC/MS/MS 
 
Figure 46. Chromatograms of a patient with a relative high concentration of MTXPGtotal 
(black line) and a patient with lower MTXPGtotal (blue line) are demonstrated. A worked 
up RBC blank is included for reference purposes (red line). 
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Patient samples were analyzed by the MTXPGtotal method (figure 46) and compared 
with our previously reported LC/MS/MS methodology (figure 47). The LC/MS/MS 
method was specific for each MTXPG, leading to quantification of individual MTXPGs 
which were added to provide MTXPGtotal.  Results obtained by the different methods 
correlated well (R2 = 0.983) and therefore respond comparable to changes in 
intracellular levels of MTXPGtotal within patient RBCs. The relationship between the 
methods could be described by the following equation: y = 1.32x + 5.3, where y is the 
response in nM measured by the reductive method and x is the response in nM 
measured by the LC-MS/MS method.  
 
Figure 47. Correlation between MTXPGtotal concentrations in 10 patients obtained by  
LC-MS/MS and the presented reductive method. 
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Analysis of the equation reveals that the reductive procedure yields on average a 32% 
higher MTXPGtotal value when compared to LC/MS/MS. It has been shown that another 
MTX metabolite, 7OH-MTX, can accumulate to a significant extend in bone marrow and 
certain tissues[20]. Since red blood cells are generally considered to be a biomarker for 
the (anti)folate status in the bone marrow[21], it was hypothesized that these elevated 
levels could be due to the presence of 7OH-MTX in RBCs. In order to check the 
specificity of the reductive method towards 7OH-MTX, RBCs were spiked with MTX and 
7OH-MTX respectively. It was found that the reductive method was less sensitive 
towards 7OH-MTX and more importantly was able to distinguish between the 7OH-MTX 
and MTX (figure 48), eliminating the possibility of measuring elevated MTXPGtotal levels 
due to the presence of 7OH-MTX in the patient samples. While the nature of the 
discrepancy between the reductive method and LC/MS/MS remains unknown, it is to be 
noted that interfering backgrounds have been observed when HPLC-FL was used in 
conjunction with the post-column photochemical derivatization. As a result, when 
comparing and reporting absolute MTXPGtotal concentrations the analysis strategy 
should be taken into account, but despite the absolute value attained, the approach 
provides a clear indication of MTXPGtotal that should be of clinical value.  
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Figure 48. Chromatogram of MTX and 7OH-MTX enriched RBCs. The reductive 
products DAMP and 7OH-DAMP were baseline separated.  
 
6.4 Conclusion 
The measurement of RBC MTXPGs has potential to aid in optimization and 
individualization of MTX therapy in JIA and RA. Despite the clinical advantages of 
monitoring RBC MTXPGs this tool is currently not commonly used. Analytical methods 
that allow for the determination of intra-cellular MTXPGs are rather labor intensive 
and/or require the use of specialized equipment. Furthermore, the throughput of these 
methods is low and cost of analysis is high, thus making their implications in a clinical 
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environment challenging. In this report a method is presented for rapid analysis of 
MTXPGtotal status in human RBCs. The analytical procedure is a simple “one pot” pre-
column reaction involving reagent addition and heating for 15 minutes. After 
centrifugation the supernatant is introduced into a conventional HPLC system equipped 
with a fluorescence detector, without the need for further workup. By performing the 
derivatization reaction pre-column, a time consuming (6-14h) commonly used de-
glutamation procedure utilizing blank human plasma, becomes obsolete. Using the 
described procedure the total sample preparation time for a 50 sample run should not 
exceed 1-1.5 hours. The chromatographic run time per sample is 7 minutes using 
isocratic elution conditions. The rapid chromatographic procedure in combination with 
the uncomplicated sample preparation procedure should allow for same day sample 
determinations. Clinical results obtained by the reductive procedure correlated well with 
an earlier published LC/MS/MS method, however obtained absolute RBC MTXPGtotal 
concentrations were on average 30% higher, likely due to the enhanced selectivity 
accorded with the more elaborate and expensive instrumentation required for LC/MS/MS 
determinations. 
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7.1 Introduction 
7.1.1 The MTX folate relationship 
Following analytical method development, our group has identified patterns of MTXPGs 
that are associated with MTX toxicity, but not response (see chapter 4, 5, 6 for 
analytical method development and appendix 1 and 2 for the clinical discussion of the 
results). Whilst predictors of drug induced toxicity are of great clinical value, MTX 
therapy would further benefit from the identification of biomarkers that are indicative of 
drug response. During RBC MTXPG analysis it was realized an important part of the 
cellular milieu was not taken into account, namely the cellular folate content and 
polyglutamation distribution of this folate pool.  
The role that folate (supplementation) plays in MTX efficacy and toxicity has been 
a subject of debate across disciplines.  As a potent anti-folate drug, side-effects of MTX 
are also consistent with symptoms of folate deficiency, and baseline plasma and RBC 
folate concentrations have been shown to be negatively correlated with MTX toxicity 
scores[1]. Folate supplementation for the treatment of MTX related side-effects has been 
shown to be effective in diminishing MTX toxicity in vitro [2] and in vivo [1, 3], however, the 
effect that supplemental folic acid has upon MTX efficacy is still unclear.  Although a 
small number of clinical studies designed to investigate folic acid supplementation in JIA 
have suggested no substantial effect upon drug efficacy [3-4], studies in psoriasis have 
shown greater improvement in skin scores in subjects on MTX monotherapy [5].  This 
same study also showed that the percent improvement in skin scores correlated with an 
increased MTXPG / Plasma folate concentration ratio, suggesting more effective folate 
inhibition may result in improved drug response. Recently (2010) L. Stamp et al. also 
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reported the lack of correlation between disease outcome and MTXPG concentrations 
in adult rheumatoid arthritis[6]. However, in the same study it was noted that erythrocyte 
folate content (measured by a standardized clinical assay) was significantly higher in 
patients with higher disease activity, suggesting a link between folate levels and disease 
activity. Interestingly (not noted by Stamp), the association between MTX and declining 
intra-cellular folate concentrations has been drawn in various in vitro[7-9] and in vivo[10] 
studies. Despite a number of encouraging clinical observations, there remains a 
substantial lack of clarity on the effect that cellular folate status may have upon MTX 
response. 
As mentioned in the introduction (chapter 1) MTX(PGs) alters the activity of 
multiple enzymes within the folate cycle and therefore it is likely that regular intracellular 
folate metabolism will be distorted (figure 49). Since total folate content seems to be 
correlated to MTX efficacy, the next question to be answered is: how much of each 
folate isoforms is present (i.e. redox/methylation forms), what is its polyglutamation 
population distribution and how does MTX therapy affect this folate metabolism? In 
order to address this research question a folate control group and a group of JIA 
patients on MTX therapy were established. The folate control group included 100 JIA 
patients that were not on MTX therapy, and the MTX group consisted of the 110 
patients that were analyzed earlier for MTXPGs. Whole blood samples were drawn from 
all patients for the purpose of comprehensive RBC folate analysis (i.e. quantitation of 
folate isoforms and polyglutamation distribution). The comprehensive folate analysis of 
RBCs is however complicated by the fact that such an analysis strategy has not 
appeared in the literature yet.  
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Figure 49. Cellular folate pathway with both folic acid and MTX represented. Red lines 
represent known inhibition of target enzymes with MTX. (figure reproduced with 
permission from PharmGKB and Stanford University). 
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7.1.2 RBC folate content 
 Until a decade ago it was believed that the only folate form present in RBCs was 
the polyglutamyl form of 5-MTHF[11]. More recent studies have indicated that an 
important exception are subjects homozygous for C677T polymorphism in the 
methylenetetrahydrofolate reductase (MTHFR) gene[12-13]. Individuals that display this 
single nucleotide polymorphism (SNPs) produce a thermolabile version of MTHFR, 
where an alanine residue is substituted by valine. The thermolabile variant losses about 
50% of its activity, impairing the reduction of 5,10-methyleneTHF to 5-MTHF. As a 
consequence, subjects with the 677 TT genotype have increased amounts of non-
methylTHFs (i.e. 5-FTHF, 10-FTHF, 5,10-MTHF and THF) within their RBCs, when 
compared to 677 CT or CC genotypes[11, 13-14]. The introduction of more sensitive and 
specific detectors such as LC-MS/MS has revealed that non-methylTHFs are also 
present in 677 CC and CT genotypes, but concentrations are typically low (i.e. <10% of 
total folate content)[13]. Analytical techniques for the measurement of folates in RBCs 
should therefore be able to discriminate between various folate isoforms and 
polyglutamation state. 
 
7.1.3 Analyte selection 
Folate isoforms continuously interconvert in the biological system, donating 
methyl groups and changing redox states, mostly by reversible but sometimes 
irreversible pathways (figure 49). Since the barriers for interconvertion are generally low, 
one has to be aware of the stability, or lack of stability of the folates of interest. Folate 
stability therefore directly influences analytical method development; it determines what 
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species could be measured and in some cases the measured folate form might be 
indicative of an entire subset of closely related folate isoforms. Detailed studies (using 
LC-MS/MS) of folate stability and interconversion have recently appeared in the 
literature[15]. The following section will discuss the consequences and implications of 
stability results presented by these papers in regard to folatepolyglutamyl analysis out of 
RBCs.  
 A chemical view of the folate cycle is demonstrated in figure 50. Folic acid (fully 
oxidized pterine ringsystem) is a synthetic form of folate, used for folic acid fortification in 
foods due to its high chemical stability. Low amounts of this folate form have been 
reported in RBCs, but generally this folate is not measured. Folic acid gets reduced by 
dihydrofolate reductase (DHFR) to dihydrofolic acid. Dihydrofolic acid (DHF) is highly 
unstable and has therefore not been measured human RBCs. About 50% of DHF 
reoxidizes to FA during folate extraction, and thus measured FA reflects the sum of the 
“oxidized folate forms” (FA + degraded DHF)[16]. DHF is further reduced by DHFR to 
tetrahydrofolate (THF), which is the entry to the biologically active folates, however no 
biological activity has been reported for THF itself. THF is unstable, but can be assayed 
for if acidic conditions are avoided. THF can be stabilized in the analytical procedure by 
the use of the Wilson and Horne buffer (pH 7.85, containing ascorbic acid and 
mercaptoethanol)[17-18]. Significant levels of THF have been reported in MTHFR 677 TT 
genotypes[11, 13-14, 16, 19-20]. In biological systems THF is formylated to 10-
formyltetrahydrofolate (10-FTHF) and interconverts to the much more stable 5-
formyltetrahydrofolate (5-FTHF)[15]. In biological systems formylated folates are utilized 
or further reduced to 5,10-MTHF, an interconversion that is also pH dependent. At acid 
pH (<1.5) the 5,10-MTHF form is exclusively formed, at basic pH values (≥ 8.5), 
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hydration occurs to 10-FTHF which slowly interconverts to 5-FTHF. Usually 
chromatographic mobile phases are acidic and therefore formylated species are 
measured as 5,10-MTHF. As a result of this rapidly established equilibrium, 5-FTHF, 10-
FTHF and 5,10-MTHF are grouped together as “non-methylTHFs” [11-14, 16, 19-20]. In 
biological systems 5,10-MTHF gets reduced to 5,10-METHF, a highly unstable 
compound that has not been observed in RBCs[19]. Next to instability it also has been 
suggested that the compound is readily used within the cell, therefore no significant 
buildup occurs. METHF is irreversibly reduced to 5-MTHF, the dominant form of folates 
in RBCs. 5-MTHF is considered the most stable of the reduced folates[21]. 
 Based on stability, detectability and biological occurrence, it was concluded that 
the desired analytical assay would be able to measure the polylgutamation status of the 
following folate isoforms: FA (representing the partly oxidized folates: FA and DHF), 
THF, 5-FTHF or 5,10-MTHF (representing the non methyl folates: 5-FTHF, 10-FTHF and 
5,10-MTHF) and 5-MTHF. 
   
7.1.4 Analytical methods for RBC folate measurement 
Clinical methods for the determination of folate consist of the microbiological 
assay[22-23] and various immunoassays or competitive protein binding assays[24-25]. 
Although sensitive, these assays only measure total folate concentrations, and therefore 
do not differenciate between folate isoforms or polyglutamation distribution[11]. The 
presence of antifolates, including MTX, may inhibit bacterial growth and therefore lead 
to underestimation of folate concentrations in patients on MTX therapy[26], limiting its 
usefulness for a comparative folate study of JIA patients on and off MTX therapy. 
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Furthermore, results obtained by these methods demonstrate considerable variability [27-
28]. More recently, various HPLC methods have appeared for the measurement of 
folates in biological matrices. The performance of these methods for folate analysis has 
been extensively reviewed by Quinlivian et al[26]. Briefly, these chromagraphic based 
assays demonstrate improved specificity when compared to the microbiological assay 
and immunoassay, but they often lack sensitivity. More sensitive folate measurement 
can be achieved by LC with fluorescence detection, however not all folates demonstrate 
intrinsic fluorescence and therefore this strategy does not allow for comprehensive 
folate determination[29].  
The sensitivity of these assays can be increased by using a folate affinity 
precolumn and a multi-channel electrochemical detector. This strategy allows for the 
measurement of the various folate isoforms, and additionally polylgutamation chain 
length[30]. Disadvantages are that folate affinity columns are unstable (lifetime of 48 h) 
and binding efficiencies are based on folate isoform, an issue that is further complicated 
by the absence of reliable internal standards for this technique. Gas chromatography-
mass spectrometry methods have for folate analysis have also been presented. These 
techniques require complex sample preparation schemes, where folates are treated 
with acid to cleave the different polyglutamated species to para-
aminobenzoylglutamates[31-32].  
Unfortunately, many of the discussed methods have limited utility for rigorous 
population studies due to complex sample pretreatment, loss of folate identity and do 
not compensate appropriately for folate interconversion and degradation during sample 
analysis. The use of stable isotope dilution LC-MS/MS eliminates many of the earlier 
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described problems and recently, the first HPLC mass spectrometry based methods for 
the detection of folates in human plasma[14, 20, 33-35], whole blood[11, 14, 16, 19, 35] and 
urine[35] have appeared in the literature. Folates are quantitated in the monoglutamated 
form using [13C5]-labeled internal standards, mimicking the exact structure of the folate 
species of interest. Erythrocyte folate is typically not directly measured as the various 
folates are present in the polyglutamated form and extraction is challenging. Whilst 
some of the aforementioned publications may suggest that erythrocyte folate is 
measured, these methods in fact measure whole blood folate content after 
deglutamation[11, 16, 19]. The folates originating from the RBCs can be calculated after 
correction for the plasma folate content. These strategies have demonstrated accurate 
quantitation of whole blood/erythrocyte folates, but as a result of the deglutamation 
procedure, the polyglutamation distribution is lost.  
Semi-quantitative comprehensive folate measurement (including polylgutamation 
status) has been reported for spinach using ion-pair LC-MS/MS[36], and using 
hydrophilic interaction chromatography for folate profiling of bacteria[37]. Whilst these 
methods illustrate the ability of LC/MS/MS for the measurement of folate 
polyglutamates, the absence of (internal)standards renders these methods unsuitable 
for the reproducible, comprehensive measurement of folates present in RBCs in a large 
clinical cohort. A method for quantitative comprehensive RBC folate measurement has 
not appeared in the literature, but as illustrated by a number of recent publications, 
LC/MS/MS analysis clearly has the required sensitivity and specificity for the detection 
of the various folate isoforms, including their polyglutamation distribution. This chapter 
deals with analytical method development of a comprehensive folate detection strategy 
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in patient RBCs. The presented method has to be applicable for the analysis of large 
data sets and should demonstrate robustness and reproducibility to the extent that 
biological variations induced by MTX therapy can be accurately quantitated. 
 
 
 
 
Figure 50. The folate cycle from a chemical perspective. 
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7.2 Experimental 
7.2.1 Materials 
LC grade solvents acetonitrile (ACN) and methanol (MeOH) were obtained from 
Fisher Scientific (Fair Lawn, NJ, USA). Ammonium bicarbonate, Ascorbic acid, 2-
mercaptoethanol (MCE), N, N-dimethylheptylamine (DMHPA) and methotrexate (MTX) 
were purchased from Sigma-Aldrich (St Louis, MO, USA). Methotrexate polyglutamation 
standards 4-amino-10-methylpteroyldiglutamic acid (MTXPG2), 4-amino-10-
methylpteroyltriglutamic acid (MTXPG3), 4-amino-10-methylpteroyltetraglutamic acid 
(MTXPG4), 4-amino-10-methylpteroylpentaglutamic acid (MTXPG5), 4-amino-10-
methylpteroylhexaglutamic acid (MTXPG6), 4-amino-10-methylpteroylheptaglutamic acid 
(MTXPG7) were purchased as the ammonium salts from Schircks Laboratories (Jona, 
Switzerland). Folates obtained from this source were folicacid/pteroicacid (FA), 
pteroyldiglutamic acid (FAPG2), pteroyltriglutamic acid (FAPG3), pteroyltetraglutamic 
acid (FAPG4), pteroylpentaglutamic acid (FAPG5), pteroylhexaglutamic acid (FAPG6), 
pteroylheptaglutamic acid (FAPG7),  5-formyl-5,6,7,8-tetrahydropteroic acid (5-FTHF), ),  
5-formyl-5,6,7,8-tetrahydropteroyldiglutamic acid (5-FTHFPG2), 5-formyl-5,6,7,8-
tetrahydropteroyltriglutamicacid (5-FTHFPG3), 5-formyl-5,6,7,8-tetrahydropteroyl-
tetraglutamic acid (5-FTHFPG4), 5-formyl-5,6,7,8-tetrahydropteroylpentaglutamic acid 
(5-FTHFPG5), 5-formyl-5,6,7,8-tetrahydropteroylhexaglutamic acid (5-FTHFPG6), 7,8-
dihydrofolate (DHF), 5,6,7,8-tetrahydrofolate (THF), 5-methyltetrahydrofolate (5-MTHF), 
5,10-methenyltetrahydrofolate (5,10-MTHF), 5,10-methylenetetrahydrofolate (5,10-
METHF).  
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 [13C5]-folicacid ([13C5]-FA), [13C5]-tetrahydrofolicacid ([13C5]-THF), [13C5]-5-
methyltetrahydrofolate ([13C5]-5-MTHF) and [13C5]-5-formyltetrahydrofolate ([13C5]-5-
FTHF) were obtained from Merck Eprova (Schaffhausen, Switzerland).  
 
7.2.2 Preparation of erythrocyte (RBC) lysates and plasma 
Blood samples (~5 ml) obtained from patients were centrifuged at low speed 
(2000 rpm) in a Beckman tabletop centrifuge to pellet the RBCs. After recovery of the 
plasma, the RBCs were suspended in an equal volume of sterile normal saline, mixed by 
gentle inversion and subjected to a second low speed centrifugation. The supernatant 
was discarded and the wash procedure was repeated a second time. After discarding 
the supernatant, the packed RBCs were divided into four aliquots and stored at -70°C 
until use. 
 
7.2.3 Analysis of folate polyglutamation distribution 
Folate polyglutamates were determined using packed RBC samples. An aliquot of 
200µL of packed RBCs was diluted 1:1 with a pH 7.85 HEPES/CHES buffer containing 
1% Ascorbic acid and 10 mM MCE, in order to ensure complete RBC lyses and stabilize 
released folates. Following lyses the RBC extracts were placed in boiling water for 5 
minutes to induce protein denaturation. The denatured proteins were packed on the 
bottom of the vial by centrifugation, using a similar protocol as presented in chapter 5. 
The supernatant was transferred to an autosampler vial with a 300 µL liner and analyzed 
by IP-LC-MS/MS.  
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7.2.4 Whole blood preparation 
Prior to analysis, a 5 µL internal standard solution (I.S.) containing 1000 nM of 
each (anti)folate isoform [13C5]-FA, [13C5]-THF, [13C5]-5-MTHF, [13C5]-5-FTHF and D3-
MTX was added to a 50 µL aliquot of whole blood, resulting in an I.S. concentration of 
100 nM in whole blood. The sample was further diluted to 250 µL with a solution of 1% 
ascorbic acid at pH 4.0. The pH of the resulting solution was determined to be 4.7. 
Folates(PGs) in the solution were deglutamated by incubating the solution for 3 hours at 
37 ˚C. The deglutamated lysates were further worked up by the SPE method of Huang 
et al[19] (unsuccessful), or by performing a protein precipitation with 40 µL of a 70% 
perchloric acid solution (successful). Proteins were separated by centrifugation, 
following the protocol presented in chapter 5. The supernatant was transferred into an 
autosample vial with a 300 µL liner and analyzed by LC-MS/MS. 
 
7.2.5 Plasma analysis 
Sample preparation for plasma folate LC/MS/MS analysis occurred according to 
Huang et al[19]. Briefly, To each plasma sample (300 µL) was added Wilson and Horne 
buffer (200 µL) containing 1% ascorbic acid and 10 mM 2-mercaptoethanol. After the 
addition of 30 µL internal standard solution (I.S. contained 100nM of each anti-folate 
isoform [13C5]-FA, [13C5]-THF, [13C5]-5-MTHF, [13C5]-5-FTHF and D3-MTX) the samples 
were thoroughly mixed (the resulting I.S. concentration is 10nM for each analyte). Water 
(1 mL) containing 1% ascorbic acid and 1% methanol was added prior to purification 
using C18 SPE columns. Please refer to Huang et al. for SPE protocol[19].  
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7.2.6 Chromatographic analysis 
Analysis of folate polyglutamation distribution: using the mobile phases and 
chromatographic system (i.e. column, guard column etc.) as described in chapter 5. An 
altered gradient elution profile was used. First analytes were focused on the head of the 
column for 2 minutes at 5% B. A linear gradient was used to 35% B in 8 minutes. A step 
gradient was used to return to initial conditions, and the column was allowed to re-
equilibrate for 3 minutes, resulting in a total runtime of 13 minutes per injection. During 
the analyte focusing phase, flow from the analytical column was diverted to waste, to 
prevent non-volatile materials from entering the mass spectrometer. Each sample was 
analyzed in duplicate, first the various 5-MTHF(PGs) were measured, and in a second 
injection 5-FTHF(PGs) were measured. Each 25 patients (50 injections) a 50nM 
MTXPG1-7 mixture was analyzed to monitor sensitivity drifts of the mass spectrometer. 
 
Analysis of plasma and whole blood folate distribution: The chromatographic 
system was as described in chapter 4 and 5. Chromatography was conducted on a 50 x 
2.1 mm Phenomenex kinetex column using C18 core-shell particles. Mobile phase A 
consisted out of water containing 5% acetic acid, and mobile phase B was a blend of 
72.5% ACN, 22.5 % MeOH and 5% acetic acid. Gradient elution was used for the 
separation of the various mono-glutamate folates, starting with an isocratic hold for 1 
minute at 1% B, followed by a linear increase to 40% B for 5 minutes. Directly after the 
elution gradient, a step gradient was used to return to initial conditions and the column 
was allowed to re-equilibrate for 2 minutes. Analysis volumes were 50 µL for both, 
plasma and whole blood extracts.  
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7.2.7 Mass Spectrometry 
The instrumentation utilized was a  Micromass Quattro Ultima “triple” quadrupole 
mass spectrometer (Manchester UK) equipped with an electrospray ionization (ESI) 
source. The instrument was operated in positive ion mode. Source parameters, including 
the cone voltage for each analyte were optimized by maximizing the area under the 
curve of multiple LC runs of the standard mixture at various programs. The probe 
capillary was optimized at 3.0 kV, and the desolvation and source temperatures were set 
to 400 °C and 125 °C, respectively. The cone gas flow rate was optimized at 80 L/hr, the 
desolvation and nebulizer gas flow rate was adjusted for maximum signal of analyte. 
Argon was used for collision induced dissociation (CID) and the cell vacuum was set at 
2.4 x 10-3 mbar.  Q1 and Q3 were set to transmit ions with a resolution of 0.8 u FWHH.  
Multiple Reaction Monitoring (MRM) parameters (table 27) including precursor ions, 
product ions and collision energy were optimized by direct infusion of the individual 
analytes dissolved in 80% A and 20% B at 10 µM, closely resembling chromatographic 
conditions. 
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Table 27. MRM parameters used for the LC/MS/MS analysis of the various pteroyl based entities. 
Analyte 
Molecular 
Formula 
Precursor 
ion (m/z) 
Product ion 
(m/z) 
Cone 
Voltage (V) 
Collision 
Energy (V) 
ESI 
mode 
FA C19H20N7O6+ 442.2 295.1 30 20 + 
FAGlu2 C24H28N8O9+ 571.2 295.1 30 26 + 
FAGlu3 C29H36N9O12+ 700.2 295.1 30 33 + 
FAGlu3 C34H44N10O15+ 829.2 295.1 30 40 + 
FAGlu5 C39H52N11O18+ 958.3 295.1 30 48 + 
FAGlu6 C44H60N12O21+ 1087.4 295.1 30 56 + 
FAGlu7 C49H68N13O24+ 1216.4 295.1 30 64 + 
       FA C19H18N7O6- 440.2 311.1 25 24 - 
FAGlu2 C24H26N8O9- 569.2 311.1 30 31 - 
FAGlu3 C29H34N9O12- 689.2 422.3 40 32 - 
FAGlu4 C34H42N10O15- 827.3 422.3 50 37 - 
FAGlu5 C39H50N11O18- 956.3 422.3 55 45 - 
FAGlu6 C44H58N12O21- 1085.4 422.3 60 50 - 
FAGlu7 C49H66N13O24- 1214.4 422.3 70 59 - 
       5-FTHF C20H24N7O7+ 470.2 327.1 30 20 + 
5-FTHFGlu2 C25H32N8O10+ 603.2 327.1 30 26 + 
5-FTHFGlu3 C30H40N9O13+ 732.3 327.1 30 33 + 
5-FTHFGlu4 C35H48N10O16+ 861.3 327.1 30 40 + 
5-FTHFGlu5 C40H56N11O19+ 990.3 327.1 30 48 + 
5-FTHFGlu6 C45H64N12O22+ 1119.4 327.1 30 56 + 
5-FTHFGlu7 C50H72N13O25+ 1248.4 327.1 30 64 + 
5-FTHFGlu8 C55H80N14O28+ 1377.5 327.1 30 70 + 
5-FTHFGlu9 C60H88N15O31+ 1506.5 327.1 30 76 + 
5-FTHFGlu10 C65H96N16O34+ 1635.5 327.1 30 82 + 
5-FTHFGlu11 C70H104N17O37+ 1764.5 327.1 30 88 + 
       5-FTHF C20H22N7O7- 468.2 315.0 25 20 - 
5-FTHFGlu2 C25H30N8O10- 601.2 315.0 35 26 - 
5-FTHFGlu3 C30H38N9O13- 730.3 454.2 40 33 - 
5-FTHFGlu4 C35H46N10O16- 859.3 454.2 50 40 - 
5-FTHFGlu5 C40H54N11O19- 988.4 454.2 60 48 - 
5-FTHFGlu6 C45H62N12O22- 1117.4 454.2 70 56 - 
5-FTHFGlu7 C50H70N13O25- 1246.5 454.2 80 64 - 
5-FTHFGlu8 C55H78N14O28- 1375.5 454.2 90 70 - 
 
 
214 
 
Table 27. continued 
Analyte 
Molecular 
Formula 
Precursor 
ion (m/z) 
Product ion 
(m/z) 
Cone 
Voltage (V) 
Collision 
Energy (V) 
ESI 
mode 
5-MTHF C20H26N7O6+ 460.2 313.1 30 20 + 
5-MTHFGlu2 C25H34N8O9+ 589.2 313.1 30 26 + 
5-MTHFGlu3 C30H42N9O12+ 718.3 313.1 30 33 + 
5-MTHFGlu4 C35H50N10O15+ 847.3 313.1 30 40 + 
5-MTHFGlu5 C40H58N11O18+ 976.4 313.1 30 48 + 
5-MTHFGlu6 C45H66N12O21+ 1105.4 313.1 30 56 + 
5-MTHFGlu7 C50H74N13O24+ 1234.4 313.1 30 64 + 
5-MTHFGlu8 C55H82N14O27+ 1363.5 313.1 30 70 + 
5-MTHFGlu9 C60H90N15O30+ 1492.5 313.1 30 76 + 
5-MTHFGlu10 C65H98N16O33+ 1621.5 313.1 30 82 + 
5-MTHFGlu11 C70H106N17O36+ 1750.6 313.1 30 88 + 
       THF C19H24N7O6+ 444.2 299.1 30 20 + 
THFGlu2 C24H32N8O9+ 575.2 299.1 30 26 + 
THFGlu3 C29H40N9O12+ 704.3 299.1 30 33 + 
THFGlu4 C34H48N10O15+ 833.3 299.1 30 40 + 
THFGlu5 C39H56N11O18+ 962.4 299.1 30 48 + 
THFGlu6 C44H64N12O21+ 1091.4 299.1 30 56 + 
THFGlu7 C49H72N13O24+ 1220.4 299.1 30 64 + 
THFGlu8 C54H80N14O27+ 1349.5 299.1 30 70 + 
THFGlu9 C59H88N15O30+ 1478.5 299.1 30 76 + 
THFGlu10 C64H96N16O33+ 1607.5 299.1 30 82 + 
THFGlu11 C69H104N17O36+ 1736.6 299.1 30 88 + 
       DHF C19H22N7O6+ 442.2 297.1 30 20 + 
       5,10-MTHF C20H22N7O6+ 456.2 412.1 25 32 + 
       13C5-FA C19H20N7O6+ 447.2 295.1 30 20 + 
13C5-THF C19H24N7O6+ 451.2 299.1 30 20 + 
13C5-5MTHF C20H26N7O6+ 465.2 313.1 30 20 + 
13C5-5,10-MTHF C20H22N7O6+ 461.2 416.1 25 32 + 
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7.3 Results and discussion 
7.3.1 The development of a quantitative assay (rationale) 
7.3.1.1 The folate standard problem 
Table 28. Commercial availability of various folate standards 
     
Folate (methylation/redox state) 
Length of the glutamyl-chain 
Source if available 
1 2 3 4 5 6 7 
Folic acid X X X X X X X Schircks  
7,8-Dihydrofolate X - - - - - - Schircks  
5,6,7,8-Tetrahydrofolate X - - - - - - Schircks  
5-Methyltetrahydrofolate X - - - - - - Schircks  
5-Formyltetrahydrofolate X X X X X X - Schircks  
10-Formyltetrahydrofolate O - - - - - - Schircks  
5,10-Methylenetetrahydrofolate X - - - - - - Schircks  
5,10-Methenyltetrahydrofolate X - - - - - - Schircks  
13C5-Folic acid X - - - - - - Merck Eprova 
13C5-Tetrahydrofolate X - - - - - - Merck Eprova 
13C5-5-Formyltetrahydrofolate X - - - - - - Merck Eprova 
13C5-5-Methyltetrahydrofolate X - - - - - - Merck Eprova 
13C5-5,10-Methenyltetrahydrofolate O - - - - - - Merck Eprova 
X = commercially available and purchased, - indicates that compounds were not commercially available, 
O = indicates commercially available but the compound was not obtained 
 
The development of a comprehensive folate detection strategy (i.e the detection of 
redox, methylation and polyglutamation state) within RBCs is complicated by the limited 
availability of standards. Whilst (13C5-labelled) folates are generally available in the 
various methylation and redox states as the monoglutamates, their polyglutamated 
forms are in general unavailable on a commercial basis (table 28). The only 
polyglutamated folate species that could be obtained in a sequential series were the folic 
acid polyglutamates (1-7) and 5-formyltetrahydrofolate polyglutamates (1-6). As 
discussed earlier one would expect 5-methyltetrahydrofolate as the dominant folate 
species within RBCs donated by individuals that were genotyped as MTHFR 677 CC 
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homozygotes or CT heterozygotes (accounting for 90% of the Caucasian population). 
Significant levels of THF and 5-formylTHF/5,10-methenylTHF (depending on pH of the 
analyzed solution) have been reported in individual that were classified as MTHFR 677 
TT homozygotes. With the exception of 5-formylTHF, that is available up to the 
hexaglutamyl chain, standards of the most biologically relevant polyglutamated folates of 
interest for this research are commercially unavailable. The absence of these standards 
complicates the development of a quantitative analytical assay. First the mass 
spectrometer cannot be tuned for the specific compounds, and second the absence of 
standards eliminate the possibility to appropriately calibrate the analytical procedure.  
 The synthesis of the commercially unavailable folate polyglutamation standards is 
a complicated task, and requires the use of cell culture methodology or a partially 
purified folylpolyglutamase enzyme. The purification of the various folates is further 
complicated by the fact that different redox-forms readily can readily interconvert 
depending on pH and/or the presence of oxygen. Furthermore one has to realize that 
the measurement of folates in human erythrocytes is even further complicated by the 
endogenous nature of folates. Even if folate standards were available or obtained, 
external calibration would still be impossible since folate depleted (i.e. blank) RBCs are 
not available. Quantification using these standards could however occur by the standard 
addition method. The standard addition quantification method relies on enrichment 
(addition) of a number of aliquots of the sample with known amounts of calibrants. After 
analysis of these samples, an analyte concentration can be obtained through 
extrapolation. Since basically each sample is calibrated in its own matrix, standard 
addition is rather labor intensive and due to the fact that sample splitting has to occur a 
much larger sample size is required. As RBC sample size was limited (100 – 200 µL of 
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RBCs depending on the sample) together with the level of difficulty involving synthesis of 
the standards, this strategy was abandoned. While the synthesis of stable isotope 
enriched folate standards would eliminate the need for standard addition quantification, 
this solution requires a complex and costly synthetic procedure. As the implications and 
applications of comprehensive folate are not yet understood this strategy was not 
pursued either. Based on these various considerations it was concluded that analytical 
method development had to occur with the use of commercially available standards, 
despite certain limitations. 
 
7.3.1.2 A (semi-)quantitative assay for the measurement of the folateome in RBCs 
 Since the goal of analytical method development was the comprehensive 
measurement of folates within the RBCs of JIA patients, in order to measure variations 
in folate (polylgutamation) status, we designed a (semi)-quantitative analysis strategy 
staying within the constraints that commercially available standards had to be used. 
Recently a number of LC-MS/MS have been presented for the quantitative “indirect” 
measurement of intracellular folate concentrations within RBCs. Whilst each publication 
presented a unique sample preparation method, the analysis strategy was common and 
relied on a folate deglutamation procedure using a whole blood sample of the patient 
(details will be presented in section 7.3.3.2. of this chapter). As a result of the 
deglutamation procedure utilizing whole blood, the folates are quantitated as the 
monoglutamate species and represent whole blood folate content, rather than RBC 
concentrations of the individual. Since whole blood is largely composed of a plasma and 
RBC components, the measured concentration is the result of the sum of the folate 
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contribution by each individual component. Thus if the folate plasma concentration is 
known besides whole blood folate concentration, RBC folate content can be calculated 
according to the method of Lamers et al.[38] (eq. 3).  
 
hematocrit
hematocritxfolatePlasmaxfolatebloodwholefolateRBC ))100(()100( −−=       Eq. 3 
  
The advantage of this strategy is two-fold. 1) Deglutamation liberates the various 
polyglutamates and measurement of deglutamated species reduces number of folate 
metabolites that have to be tracked by LC-MS/MS. An additional advantage is that the 
redox/methylation status remains unaltered during this process, effectively converting a  
distribution of metabolites (i.e. polyglutamates) to a single measurable species, and thus 
enhancing its detectablility. 2) Stable isotope labeled monoglutamyl-folate standards of 
all of the folates of interest are commercially available (table 28), allowing for accurate 
quantification using stable isotope dilution LC-MS/MS. 
There are also disadvantages to this strategy, such as the requirement for an 
additional assay, detecting plasma folate content. However, because of the similarities in 
whole blood and plasma folate measurement this development is reasonably 
straightforward. A more severe disadvantage of the strategy presented in the previous 
paragraph is loss of the polyglutamation distribution fingerprint within the RBC, an 
essential component of our desired assay.  
It was hypothesized that this information could be obtained by the incorporation of 
a third assay (in addition to the folate whole blood and plasma measurements) using 
isolated RBCs from the patient. It is reasonable to assume that the clinical assay for the 
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determination of MTXPG status could be transferred (including sample preparation) into 
a method for the detection of the various folate polyglutamates. Since most of the 
polyglutamated folates are not available this assay would provide a more semi-
quantitative/or relative “snapshot” of folate distribution within the RBC. A schematic 
overview of the total analysis strategy is presented in figure 51. The following sections 
will deal with the development of the individual assays; whole blood folate analysis, 
plasma folate analysis, and RBC polyglutamation profiling respectively.  
 
 
Figure 51. Schematic overview of the proposed analytical method for comprehensive 
erythrocyte folate measurement. 
 
 
220 
 
7.3.2 Polyglutamation profiling 
7.3.2.1 Polyglutamation profiling on a relative basis using patient RBCs 
As stated in the method development rationale (section 7.3.1), the measurement of the 
folate polyglutamation distribution is challenged by the absence of standards, and 
therefore quantitation is virtually impossible since calibration cannot be accomplished. 
However to investigate the influence of MTX therapy on the folate distribution (using 
RBCs) in JIA patients an absolute quantitative measurement of this distribution is not a 
requirement, since one is interested in the MTX induced folate polyglutamation 
variability. Therefore the hall-mark of the polyglutamation profiling assay became; 
reproducible measurement of the relative polyglutamyl distribution of the various folate 
methylation/redox states. The term relative polyglutamyl distribution should be 
interpreted as measurement of the “observed” or relative distribution by mass 
spectrometry, rather than measurement of the true folate polyglutamation distribution on 
an absolute quantitative basis, that would require standards and calibration to correct for 
differences in recovery and instrument related sensitivity of the individual analytes.  
 
7.3.2.2 FolatePGs mass spectrometry settings. 
Based on the successful separation of FAPG1-7 in chapter 5 (internal standard 
selection for MTXPG analysis), it was hypothesized that the IP-LC/MS/MS method 
presented in chapter 4 and 5 could be applied in a slightly modified fashion for the 
measurement of the remaining folatepolyglutamates (THF, 5-MTHF, 5,10-MTHF and 5-
FMTHF). Since polyglutamation standards of THF and 5-MTHF and 5,10-MTHF were 
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unavailable mass spectrometer settings for MRM had to be estimated. It was observed 
that the sequential polyglutamates of MTX, FA and 5-FTHF under positive ESI 
conditions all produced predominantly the singly charged (M+H+) ion. Furthermore all of 
these molecules yielded a charged pteroate species upon collision induced dissociation. 
This pteroyl residue serves as the common reporter ion for all of the explored 
polyglutamated species. In order to maximize the signal for the charged pteroyl 
fragment, it was observed that a linear increase in collision energy was necessary 
(figure 52A for FAPGs, figure 52B for 5-FTHFPGs, and figure 52C for MTXPGs). 
Furthermore the fragmentation behavior of the pteroyl chain appeared to be 
independent of ring redox/methylation state. Based on these observations, MRM 
settings for the measurement of 5-MTHFPG1-12, THFPG1-12, FAPG8-12 and 5-FTHFPG7-
12 were extrapolated (table 27).  
 
Figure 52. Collision energy plots for optimal formation of the pteroyl residue by MS/MS.  
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7.3.2.3 Folatepolyglutamate extraction from RBCs 
 In order to measure RBC folate distribution, folate extraction has to occur, and 
thus a sample preparation procedure had to be developed. As mentioned earlier in the 
dissertation, (anti-)folates are highly protein/tissue bound in mammalian tissues and are 
not readily available for analysis/extraction. Therefore it is reasonable to assume that 
folate extraction suffers from the same problems that were reported for MTXPG 
extraction in chapter 4 and 5. Furthermore, extraction of the various folates is further 
complicated by unique (in)stabilities associated with each folate form. For example, acid 
extraction that was useful for the extraction of MTXPGs, as described in chapter 4, could 
not be applied for folate extraction as THF demonstrates poor acid stability. As MTXPGs 
could be released from the RBCs by heat extraction (chapter 5) a similar strategy was 
explored for the extraction of folates. To stabilize the folate pool, packed RBC samples 
were diluted in a 1 to 1 ratio with a pH 7.85 Wilson and Horne buffer, including ascorbic 
acid and mercaptoethanol. The interconversion stability of various deglutamated folate 
forms under these conditions within the RBC matrix has been demonstrated by 
Smulders et al[16]. The interconversion stability of the polyglutamates of interest (i.e. 5-
MTHF and THF) could not be tested but were assumed to be stable since the 
problematic molecular interconversions are associated with the pteroyl functionality of 
the polyglutamated folate molecules, as opposed to the poylglutamatyl chain length.  
Another concern is deglutamation stability during sample preparation. Since the 
packed RBCs immediately washed following isolation, the presence of the 
deglutamation enzyme (pteroylpoly-ɣ-glutamylcarboxypeptidase) is highly unlikely. 
Furthermore the pH of the RBC lysate of 7.85 is too alkaline for optimal human 
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pteroylpoly-ɣ-glutamylcarboxypeptidase activity, and thus deglutamation is not expected. 
In order to demonstrate the absence of folate deglutamation during the sample 
preparation procedure, a 1:1 diluted RBC sample with extraction buffer was enriched 
with 100 nM of hexa-glutamyl folic acid. The hemolysate was allowed to incubate for 15 
minutes, before folates were extracted by a 5 minute boiling extraction. Three replicate 
experiments demonstrated that deglutamation does not occur within this time frame. As 
the other polyglutamated folates were not available for testing, the glutamyl chain of the 
additional folates were assumed to be stable during sample extraction. 
 
7.3.2.4 Chromatography and RBC folate polyglutamation analysis 
 As standards were unavailable, the chromatography method initially developed 
for the analysis of MTXPGs (chapter 5) was adapted for RBC folate extracts. RBC 
samples, drawn from eight healthy volunteers on site, were used for folate method 
development as they were readily available. Each volunteer was genotyped for MTHR 
polymorphism, as this appears to be the main predictor of intracellular folate 
redox/methylation state distribution. It was found that all of the available donors fell 
either in the 677 CC or 677 CT category, meaning that their folate pool was largely (> 
90%) present in the methylated form (5-MTHF). These RBC samples therefore provided 
a solid basis for the development of the 5-MTHFPG assay. Using these RBCs, a fast 
separation of the 5-MTHFPG species was obtained using gradient elution, consisting of 
a 2 minute isocratic hold at 5% B (focusing the analytes), followed by a rapid gradient to 
35% B in 8 minutes (gradient profile is illustrated in figure 53A).   
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 The optimized chromatographic procedure was applied for polyglutamation 
profiling of a JIA patient on MTX therapy (figure 53B, demonstrating the total ion 
current). The various 5-MTHFPGs were separated within 10 minutes, and the 
polyglutamation length appears to be centered around 5-6 glutamyl residues (please 
note that this is an observed distribution). The same data is also presented in figure 54, 
where the individual channels are plotted as opposed to the total ion current (figure 53 
B). Using the individual SIR channels, it became appearant that 5-MTHF was distributed 
between 3 and 10 glutamyl residues.  
 As mentioned before 5-FTHF(PGs), 10-FTHF(PGs) and 5,10-MTHF(PGs) readily 
interconvert in an pH governed equilibrium process. At acidic pH values the dehydrated 
form 5,10-MTHF dominates, and at alkaline pH values the formylated (hydrated) forms 
are exclusively formed. The sample pH is often altered during sample preparation, 
disturbing the equilibrium between these folate forms. Therefore these different folates 
are often analyzed as a group, at acidic pH (measurement of 5,10-MTHF) or alkaline pH 
(measurement of 5-FTHF). The analysis of the formylated (monoglutamated) form is not 
commonly performed as it requires the use of basic mobile phases that are in general 
incompatible with silica-based chromatography columns. Furthermore peak shapes in 
general are poor for this particular analyte.  
Since the pH during RBC folatepolyglutamate extraction has to be close to 8, in 
order to accomplish precipitation of the proteins (chapter 5 figure 39), the equilibrium 
between 5-FTHF(PGs), 10-FTHF(PGs) and 5,10-MTHF(PGs) lies exclusively in favor of 
5-FTHF(PGs). Additionally, the pH of the mobile phase was also fixed at 8.0, and 
therefore 5-FTHF was identified as the analytical reporter for this folate pool. From the 
analysis of the polyglutamyl-5-MTHFs it became clear that long polyglutamate chains 
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could be expected, and since these standards are not available, the method was 
optimized using RBC samples.  
As the content of non-methyl folates is low in MTHFR 677 CC and 677 C>T 
phenotypes , which are also the phenotypes of the healthy voluntary RBC donors, these 
RBCs samples were found to be inadequate for 5-FTHFPG method development. 
Patient 46 of the folate group was identified as a 677 TT homozygote and therefore it is 
expected that the folate distribution in the RBC sample of this patient is shifted from the 
methylated- towards the non-methylated (i.e. formylated, THF, 5,10-MTHF) form, 
providing a basis for initial method development, as formylated species are typically the 
highest in this phenotype.  
A chromatogram of the RBC extract from patient 46, analyzing for 5-FTHFPG 
species is demonstrated  in figure 55. A similar polyglutamation distribution was 
observed for the 5-FTHFPGs when compared to the 5-MTHFPGs (figure 53B), 
demonstrating the ability of the chromatographic method to measure 5-FTHFPGs in 
addition to the 5-MTHFPGs. In general however, chromatograms for 5-FTHFPGs were 
much more complicated to analyze, due to the appearance of an additional peak (figure 
55). The peak was well separated for 5-FTHFPG4-5, but the resolution between the two 
compounds diminishes quickly when polylgutamation chain length was further 
increased. It was hypothesized that the additional peak indicated the presence of 10-
FTHF. As the difference between 5-FTHF and 10-FTHF is the position of the 
formylgroup, both compounds are isobaric. Furthermore, these compounds could not be 
separated by collision induced dissociation in the gas phase as the formylgroup remains 
on the measured pteroyl-fragment. For the dominant species 5-THFPG5-6 signal 
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integration was in particular compromised by the large elution volume of the 5-FTHF/10-
FTHF mixture, increasing the chance of co-integration of interferents.  
 THF could also be measured in its polyglutamated form, in the RBC sample of a 
JIA patient, classified as a 677 TT phenotype (figure 56). Despite the fact that 
polyglutamation profiling was technically possible, the patient group was not analyzed 
for THFPGs, because THF could not be accurately quantitated by the whole blood assay 
(section 7.3.3.3).  
 
7.3.2.5 Multiple injects for polyglutamation profiling of various folate 
redox/methylation states 
 As described in chapter 5 the scan rate of the Ultima mass spectrometer limits 
the amounts the amount of SIR channels that could be monitored simultaneously. 
Therefore, when analyzing patient samples, multiple chromatographic runs per sample 
were made, with each injection being specific for a class of folates (1st run detecting 5-
MTHF, 2nd sample introduction detecting 5-FTHF, etc). A faster scanning instrument 
would be desirable in these experiments as it would allow for simultaneous 
determination of the various analytes in a single run, reducing the required sample 
volume and increasing sample throughput 
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7.3.2.6 Robustness of the polyglutamation assay, response factors and data 
interpretation 
The previous section demonstrates the ability of the analysis method to measure 5-
MTHFPGs, 5-FTHFPGs and THFPGs, however reproducibility has to be addressed if 
one wishes to compare the polyglutamation distribution of the two large patients pools 
(JIA patients on MTX therapy (n=100), and JIA patients without MTX treatment (n=100)). 
As the goal of the polyglutamation analysis method was to measure the relative 
distribution of the various folate polyglutamates (i.e. a polyglutamate is expressed as a 
fraction (%) of the total folate distribution (100%) of a certain methylation/redox state), 
drifts in overall sensitivity of the detector, variations in volumes due to pipetting error etc, 
will not affect the observed polyglutamation pattern, and in that regard the method can 
be considered robust. However, during method development for MTXPG analysis, it was 
observed that a “dirty” ion-path in the mass spectrometer led to diminishing sensitivity of 
the instrument, with the high molecular weight compounds affected more severely. This 
type of drift was not much of a concern in MTXPG analysis as timely calibration corrects 
for such processes. However in relative quantitation experiments, with analytes 
displaying a wide mass range, such a drift in sensitivity should be accounted for as this 
sensitivity diminishment in high molecular weight detection would result in a change in 
relative appearance of the folate polyglutamates (i.e. the observed distribution would 
shift to shorter polyglutamyl length). In order to minimize the effects of mass related 
sensitivity drifts of the mass spectrometer on the folate polyglutamation data set, all 
patient samples were sequentially analyzed after a thorough instrument cleaning (i.e. 
front-end, hexapoles and transfer lenses). The drift in mass related instrument sensitivity 
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was probed by the analysis of an aqueous solution (50 nM) of MTXPGs1-7 after each 
batch of 25 injections. The use of MTXPG1-7 over FAPG1-7 was made on a stability 
basis, with MTXPG1-7 demonstrating excellent aqueous stability, allowing repetitive 
analysis of the same solution over the 4 days time course of folate polyglutamation 
analysis. From the relative response of the various MTXPGs one could estimate the 
mass related sensitivity drifts of the mass spectrometer and correct accordingly using 
the concept of response factors. Chromatograms of the MTXPG mixture after 0, 100, 
200 and 400 folatepolyglutamate injections are demonstrated in figure 57. It was 
observed that while overall sensitivity of the mass spectrometer changed a factor 1.5 
(note the y-axis scale), the observed relative distribution of the various MTXPG 
molecules was not affected. Therefore it was believed that correction, using response 
factors was unnecessary and for all of the analyzed samples, polyglutamation patterns 
are reflective of their true relative peak areas. 
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Figure 53. Method development for the detection of 5-MTHFPGs, (A) optimal gradient 
for rapid separation of the various 5-MTHFPGS. (B) Total ion current chromatogram 
demonstrating the separation of 5-MTHFPG3-10 in a RBC extract obtained from a donor 
that was a MTHFR 677 CC genotype. 
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Figure 54. Individual MRM channels for each 5-MTHFPG. 
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Figure 55. 5-FTHFPGs chromatogram of a RBC extract obtained from patient 46 in the 
folate control group that was identified as a MTHFR 677 TT homozygote. 
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Figure 56. Chromatogram analyzing the RBC extract from patient 46 for THFPGs. 
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Figure 57. Analysis of an aqueous 50 nM MTXPG1-7 mixture to monitor (mass related) 
sensitivity drifts of the mass spectrometer during the folate polyglutamation profiling of 
patient RBCs. The sensitivity was relatively constant over the entire sample set, and 
therefore correction using response factors was not necessary. 
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7.3.3 Whole blood folate analysis  
 The previous section described method development for the relative 
measurement of folate polyglutamation status. As presented in section 7.3.1, the 
quantification of RBC folate has to occur through an alternative indirect route, involving 
folate analysis in whole blood and plasma, due to absence of standards. The first step, 
in whole blood analysis is cell lysis and deglutamation of the various 
folatepolyglutamates to their mono-glutamyl-analogs. Since isotope labeled mono-
glutamyl-folate standards are commercially available, folates can be quantified 
accurately using stable isotope dilution mass spectrometery. The following sections deal 
with the individual analytical components required for successful whole blood folate 
analysis. 
 
7.3.3.1 Deglutamation 
Folate deglutamation is catalyzed by the pteroylpoly-ɣ-glutamylcarboxypeptidase 
enzyme. This enzyme has also been called pteroyl-y-glutamate hydrolase, or folate 
hydrolase, and even the misleading term folate conjugase has been used. For the folate 
analysis in various food products external sources of pteroylpoly-ɣ-
glutamylcarboxypeptidase are used. Commonly used sources of pteroylpoly-ɣ-
glutamylcarboxypeptidase are: hog kidney, chicken pancreas or rat plasma. The pH 
range where optimal enzyme activity is obtained varies with the enzyme source, from 
4.5 for hog kidney to 7.5 for chicken pancreas pteroylpoly-ɣ-glutamaylcarboxypeptidase.  
Pteroylpoly-ɣ-glutamylcarboxypeptidase is also present in the human plasma, 
where it plays an important role in the deglutamation of consumed folates, a process 
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which is essential for folate absoption and bioavalability. Researchers have taken 
advantage of the presence of pteroyl-ɣ-glutamylcarboxypeptidase in plasma, by using it 
as an “auto-deconjugase” in human whole blood folate assays, where red blood cell lysis 
is induced to expose their folate content to the plasma pteroyl-ɣ-
glutamylcarboxypeptidase enzyme, resulting in folate deglutamation. 
The optimal conditions for folate polylgutamate conversion have been the subject 
of a number of recent papers discussing methodology for the measurement of RBC 
folate concentent. As each of the presented analytical methods was geared to folate 
measurement in the monoglutamated or diglutamated form, reproducible analytical 
recovery of the deglutamation process was the hall-mark. In 2005 Fazili et al. published 
a report where the important reaction (i.e. deglutamation) variables, pH, temperature 
and time required to obtain quantitative deglutamation were investigated. It was 
concluded optimal deconjugation condition consisted of 3 a hour incubation of the 
hemolysate, at a pH of 4.7, with the temperature fixed at 37 ˚C. Furthermore it was 
demonstrated that by the use of ascorbic acid as anti-oxidant, folate interconversion was 
avoided through the entire procedure.  
Whilst this method of preparing deconjugated folate hemolysates has been 
generally accepted, the incubation period has often been shorter (in contrast to what 
Fazili had demonstrated). Smulders et al. used deconjugation times of 90 minutes, 
Zhang et al. used 4 hours at room temperature. As we have developed a strategy to 
measure the various individual folate polyglutamates, we studied the deglutamation 
behavior of 5-MTHPGs in whole blood at pH 4.7, incubated at 37˚C (figure 58 A). At 0 
minutes of incubation (the pH of the solution was adjusted to 4.7 and titrated back up to 
approximately pH 7.8 with HEPES/CHES buffer before placing it in boiling water) a 
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spectrum of 5-MTHF species were observed up to 5-MTHFPG9. After 10 minutes of 
incubation the observed polyglutamation picture had shifter significantly in towards the 
short chain mono- and di-glutametes (figure 58B), demonstrating the deglutamation 
capability of human plasma. After 60 minutes of incubation (figure 58C), the 
deglutamation was 97.4% complete (i.e. 97.4% was in the 5-MTHF monoglutamate form 
and 2.6% was in the diglutamate form). After 2 hours the deglutamation procedure was 
99.3% complete (figure 58D). 5-MTHF could not be detected after 3 hours of incubation 
(results not shown), consistent with the statements made by Fazili. Conveniently the 100 
µL pH whole blood lysate could be adjusted to 4.7 by the addition of 100 µL of a 10 g/L 
(1% W/W) solution of ascorbic acid solution, therefore redox stabilization and pH 
adjustment occurred in a single step. 
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Figure 58. Deglutamation of erythrocyte folates in a whole blood lysate. (A) 
Instantaneous analysis of the diluted whole blood sample. (B) analysis after 10 minutes 
of incubation. (C) analysis after 1 hour of incubation. (D) analysis after 2 hours of 
incubration, revealing almost complete deglutamation 
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7.3.3.2 Whole blood mono-glutamyl-folate analysis 
The previous section demonstrates that folates in their polyglutmated form can be 
quantitatively converted to their mono-glutamyl analogs, using a tightly controlled 
deglutamation process. The quantitation of the various mono-glutamyl-folates using 
stable isotope dilution LC-MS/MS has been described by a select number of recent 
publications. Analysis parameters described by these publications formed the basis for 
method development of our clinical whole blood polyglutamation assay, where analysis 
of a large samples sets is a expected.  
7.3.3.3 LC/MS/MS method development 
Separation of the various folate forms is commonly performed by reversed phase 
chromatography. As a consequence, the pH of the mobile phase is kept low (i.e. acidic) 
to enhance chromatographic retention by avoiding charge formation on the glutamyl 
residue. J.D.M. Patring et al., investigated ionization efficiency of the various mono-
glutamyl folates under different acidic mobile phase conditions[39]. It was demonstrated 
that the optimal resolution and sensitivity was obtained by using a mobile phase that 
consisted of an aqueous blend of acetonitrile with an aliquot of methanol, acidified by 
acetic acid. The consequence of the use of low pH mobile phases is that 5-formyl- and 
10-formylTHF dehydrate to 5,10-MTHF, and thus sample preparation and analytical 
targets have been defined accordingly. Based on previously reported RBC folate 
compositions, analytes were identified as FA, THF, 5-MTHF, 5,10-MTHF (representative 
for the 5,10-MTHF, 5-FTHF and 10-FTHF group). Furthermore as these JIA patients are 
on MTX therapy, MTX quantification was desirable as well. The structures of the target 
analytes together with their internal standard are presented in figure 59. 
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Figure 59. (mono-glutamyl) Analytes of interest with their corresponding isotope labeled 
internal standard. All analytes are [13C5]-labeled in the glutamic acid residue, with the 
exception of MTX that has a D3 methyl group.  
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Prior to LC method development, mass spectrometer settings such as 
electrospray ionization mode (positive or negative), cone voltage and collision energy 
required for SIR of the folates of interest were optimized. It was found that the ionization 
mode had little effect on the absolute ionization efficiency (i.e. MS1 signal) of the folates 
in their monoglutamate form, with the exception of 5,10 methenylTHF that was only 
detectable in positive ion-mode due to the fixed positive charge. A comparison between 
positive and negative electrospray ionization for representative folate is demonstrated in 
figure 60A and 60C, where a 1 µM solution of 5-methylTHF is infused in the MS (note 
the signal intensity in the right top of each quadrant).   
In contrast to the absolute ionization efficiency, the fragmentation behavior of the 
various folates was found to be much more favorable in positive ion mode (figure 60B 
and 60D). The buildup of a positive charge in the molecule together with relatively low 
collision energies (25 eV) leads to a clean intra molecular fragmentation of the amide 
bond, linking the glutamic acid to the pteroyl moiety (m/z 313). The efficiency of this gas 
phase reaction appears to be close to 100% (note signal intensity) in positive mode. 
Fragmentation in negative ion-mode required elevated collision energies (35 eV) and led 
to the formation of a wide spectrum of fragment ions. Furthermore, as a result of the 
various competing fragmentation pathways, signal generated by the most abundant ion 
was an order of magnitude lower (m/z 329.1), compared to the intensity of the pteroyl 
fragment obtained in positive ion-mode. Whilst this example discusses the optimal 
settings for 5-methyltetrahydrofolate, it was found to be representative for all of the 
folates of interest. 
Fragmentation spectra of MTX, 5-MTHF, THF and 5,10-MTHF are presented in 
figures 61-64, along with the fragmentation spectra of their stable isotope labeled 
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versions. The spectra of FA, 13C5-FA and 3C5-5,10-MTHF are not presented in this 
dissertaion, however MS parameters were optimized in a similar manner as the other 
folates. 
 
7.3.3.4 A sample preparation and chromatographic method for the detection of the 
target folates 
The analysis of THF in addition to FA, 5-MTHF, 5,10-MTHF and MTX is 
complicated by the fact that THF is not stable in acidic samples. Huang and colleagues  
developed an analysis strategy to address this issue by analyzing an extracted (C18 
SPE) whole blood patient sample twice[19]. First the whole blood folate extract was 
analyzed for FA, 5-MTHF and THF and the remainder of the extract was acidified by the 
addition of an aliquot of 1M HCl. Three hours after acidification, 5-FTHF and 10-FTHF 
were quantitatively converted to 5,10-MTHF and the sample was re-analyzed for 5,10-
MTHF content. Analysis occurred by chromatographic methodology involving gradient 
elution and had a cycle time of 25 minutes. Since each whole blood sample has to be 
analyzed twice, quantitation of whole blood folate would require approximately one hour 
of instrument time per sample.  
Since our study consisted of whole blood samples obtained from 200 participants, 
the re-analysis of the samples would result in an excess of 400 analysis using LC-
MS/MS, requiring over 400 hours of instrument time for whole blood analysis. This 
excluding the plasma and RBC analysis time that would be required for the 
determination of erythrocyte folatepolyglutamation. In attempt to reduce analysis time, a 
faster chromatographic method was developed using a phenomenex kinetex C18 
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column. The stationary phase for this type of columns consists of fused core C18 silica 
particles, resulting in short analyte diffusion distances. The chromatographic properties 
of a fused core particle (3 µM) therefore mimic that of much smaller particle (1.7 µM). 
Since the column is effectively packed with larger particles, these columns typically do 
not demonstrate the high back-pressures associated with actual small particle columns, 
and therefore linear velocities can be increased without reaching excessive back-
pressures. 
The mobile phase conditions described by J.D.M. Patring and colleagues[39] were 
used in combination with the Phenomenex Kinetex chromatographic column. A gradient 
elution program was developed consisting of a 1 minute isocratic hold at 1% B, allowing 
focusing of the analytes on the head of the chromatographic column (especially 
necessary since large volume of sample is introduced).  After the focusing phase, a 
gradient was initiated with a steepness of 6% increase in B per minute to 6 minutes 
(reaching 30% B). The gradient was followed by a step-gradient and re-equilibration for 
2 minutes, resulting in a total runtime of 8 minutes. A representative chromatogram is 
presented in figure 65. Calibrations reports for the various [13C5]-folates are 
demonstrated in figure 66. Calibrations were linear in the 10 to 1000 range for each 
folate form, except THF, and correlation coefficients were adequate, except for THF. 
Using this analysis procedure, analytical throughput was effectively enhanced by a 
factor of 3. 
When the presented whole blood analysis strategy was applied towards whole 
blood sample analysis of our large patient set, it was discovered that the sample 
preparation strategy did not yield adequately clean extracts. Repetitive injection of whole 
blood samples extracts lead to clogging of the chromatographic material in typically 10-
 
 
243 
 
30 injections. Furthermore chromatographic peak shape changed and peak splitting 
started to occur, indicating an alternative retention mechanism, possibly induced by 
coating of the chromatographic media by residual proteins in the sample extract. Various 
guard columns in a number of sizes were explored in an attempt to increase the number 
of samples that could be analyzed sequentially, but none of these attempts were 
successful. Next an additional boiling step was incorporated prior to folate extraction by 
SPE. It was hypothesized that this boiling step would denature the majority of the 
proteins, allowing removal by centrifugation and avoiding breakthrough of these entities 
during SPE. Again, analysis of 10 to 30 sample extracts would lead to a clogged guard 
column in the chromatographic system and prevented further analysis. It was therefore 
concluded that whilst the presented sample preparation method involving SPE extraction 
was useful for the analysis of a limited amount of samples, it was not suitable for routine 
clinical analysis or analysis of larger sample sets. 
In an attempt to develop a more robust folate extraction procedure, acid and 
organic mediated protein precipitations were explored. Organic mediated protein 
precipitations resulted in low but reproducible recoveries. The recovery for THF and FA 
was about 10-15% and resulted in detection limits in the order of 50-100 nM for THF and 
FA. These folates are typically present in lower concentrations in whole blood, and 
therefore this sample preparation strategy was abandoned. This sample preparation 
strategy could however be revisited when a more sensitive mass spectrometer is used.  
Perchloric acid mediated protein precipitation such as presented in chapter 4 lead 
to clean whole blood extracts that did not lead to increases in backpressure as observed 
when using SPE. Perchloric acid protein precipitation is typically performed by two 
uncomplicated steps. First, an aliquot of 70% perchloric acid was added to the whole 
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blood lysate to induce protein precipitation. In a second step the precipitated proteins 
are removed by centrifugation, yielding a chromatographic compatible extract. As a 
result perchloric acid protein precipitation was found to be a convenient sample 
preparation technique suitable for the analysis of a large number of sample. The 
disadvantage of acid mediated protein precipitation is that THF is degraded during the 
procedure. Attempts were made to stabilize THF, such as direct neutralization following 
protein precipitation, but none of these attempts resulted in reproducible THF analysis.   
THF is the most unstable of the folate forms identified as analytical targets. As 
mentioned before, THF is so unstable that 20% degradation occurs instantaneously 
upon dissolving the standard[16]. This instability raises the question as to if THF values 
could be reproducibly obtained, in order to provide a basis for inter patient pool 
comparisons. Furthermore, this instability required a complicated sample preparation 
process (i.e. SPE extraction) and analysis schemes (re-analysis after acidification) that 
were not suitable for analysis of larger sample sets. Perchloric acid protein precipitation 
was identified as a simple robust sample preparation procedure that was suitable for the 
analysis of large sample sets for FA, 5-MTHF and 5,10-MTHF. Based on the arguments 
presented above, the analysis of THF in whole blood extracts was abandoned. All 
patients were analyzed by the perchloric acid protein precipitation method. Example 
chromatograms of perchloric acid precipitated whole blood extracts from a MTHFR 677 
CC healthy volunteer, and a JIA patient on MTX therapy identified as a MTHFR 677 TT 
homozygote, are demonstrated in figure 67 and 68. A typical calibration report for the 
folates of interest (i.e. 5-MTHF, 5,10-MTHF, MTX and FA) is given in figure 69. Whole 
blood folate values for all the patients in the study are presented in table 30.  
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Figure 60. Ionization and fragmentation behavior of 5-MTHF under positive ionization 
conditions (A) and (B) and negative ionization conditions (C) and (D). (A) MS1 scan from 
400-500 m/z showing the parent at 460m/z. (B) fragmentation for the parent (m/z 460) to 
form the charged pteroyl residue with a mass of 313. (C) in negative ion-mode the 
deprotonated form of 5-MTHF was detected by the MS1 scan (m/z 458), sensitivity was 
about 20% higher when compared to detection in positive mode. (D) fragmentation of 
the negatively charged parent yielded a wide spectrum of fragment ions. 
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Figure 61. Fragmentation spectrum of 5-FTHF and its internal standard ([13C5])-5-FTHF 
in positive ion-mode. 
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Figure 62. Fragmentation spectrum of 5-MTHF and its internal standard ([13C5])-5-
MTHF in positive ion-mode. 
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Figure 63. Fragmentation spectrum of THF and its internal standard ([13C5])THF in 
positive ion-mode. 
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Figure 64. Fragmentation spectrum of MTX and its internal standard D3-MTX in positive 
ion-mode. 
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Figure 65. Whole blood folate chromatogram, folate exctration occurred according to 
Huang and colleagues. 
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Figure 66. Calibration plots for [13C5]-5-MTHF, [13C5]-FA, [13C5]-THF and [13C5]-5,10-
MTHF out of whole blood. Sample extraction occurred according to Huang and 
colleagues using SPE extraction 
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Figure 67. Whole blood extract chromatogram of MTHFR CC genotype healthy 
volunteer 
 
 
253 
 
 
 
 
Figure 68. Whole blood extract chromatogram of JIA patient 22 on MTX therapy 
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Figure 69. Calibration plots for [13C5]-5-MTHF, [13C5]-FA, [13C5]-5,10-MTHF, and D3-
MTX extracted from whole blood. Sample extraction occurred by perchloric acid protein 
protein precipitation. 
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7.3.4 Plasma folate analysis 
For the calculation of RBC folate content, whole blood folate concentrations need to be 
corrected for the plasma folate content. In contrast to the earlier reported whole blood 
and RBC analysis, plasma folate analysis is relatively straight forward as folates reside 
in the monoglutamyl form within plasma and are not protein or tissue bound. Therefore 
deglutamation can be circumvented, extraction is uncomplicated, and the appropriate 
isotopically labeled standards are available through commercial sources, allowing for 
accurate quantitation using stable isotope dilution LC-MS/MS. Plasma folate analysis 
occurred by sample preparation according to Huang et al., followed by LC-MS/MS using 
the chromatographic method presented for whole blood analysis. The analysis of SPE 
extracted plasma samples did not lead to the increasing backpressures and clogging of 
analytical guard columns after a limited amount of injections, that occured during whole 
blood analysis as previously noted. Therefore the folate extraction procedure was not 
altered and sample extracts were analyzed twice. In the primary injection of the extract 
FA, 5-MTHF and THF were quantititated. Following the first analysis, samples were 
acidified and re-analyzed for 5,10-MTHF and MTX. Representative patient plasma 
chromatograms are presented in figure 70. Typical calibration curves for FA, 5-MTHF, 
THF, 5,10-MTHF and MTX in plasma are presented in figure 71. Correlation coefficients 
0.998 or better, and the intercept of the calibration curves was equal to 0 at the 95% 
confidence interval. The results of the JIA patients plasma analysis are presented in 
table 30 folate control group, and for the group on MTX therapy. Typically folate 
plasma folate values were relatively low (30 nM) and predominantly in the 5-MTHF form, 
conform earlier reports using LC-MS/MS for plasma analysis. 
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Figure 70. Plasma folate chromatogram for JIA patient 91 on MTX therapy. MRM 
channels for THF, [13C5]-THF, 5-MTHF, [13C5]-5-MTHF, FA, [13C5]-FA, 5,10-MTHF, 
[13C5]- 5,10-MTHF, MTX, and D3-MTX are displayed individually. 
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Figure 71. Calibration reports using for the various folate forms and MTX, measured in 
plasma extracts. Calibrations were linear and correlation coefficients were acceptable. 
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7.3.5 Patient Results 
 
 
RBC samples from JIA patients for the folate control group (n=100) and for the MTX 
group were analyzed by the presented comprehensive folate measurement strategy 
(table 30 attached at the end of the chapter). Analysis of the obtained results is being 
conducted in conjunction with our collaborators at Children’s Mercy Hospitals, and was 
beyond the scope of this dissertation. At the time of dissertation preparation, analysis of 
the patients data was still in progress, however a brief summary of the obtained 
preliminary clinical relevant results is provided below. 
  Subjects on MTX had expectedly lower folate isoform concentrations than those 
not on MTX including 5-MTHF (678.6 ± 281.2 nmol/L vs. 1022.2 ± 489.3 nmol/L, 
p<0.0001) and 5,10-MTHF (68.4 ± 77.0 nmol/L vs. 91.7 ± 106.3 nmol/L, p=0.04). 5-
MTHFPG relative distribution analysis revealed higher proportions of long chain 
polyglutamates in patients receiving MTX over the control group, suggesting an up- 
regulation of folate polyglutamation status when a cell reaches a folate depleted state 
(table 29). Increasing folate polyglutamation status upon folate depletion has been 
observed in various rat tissues before[40].  
Of all clinical variables tested (including the use of folate supplementation) only 
MTX dose (in mg/kg) was inversely related to 5-MTHF concentrations (p=0.0009). More 
importantly, it was also observed that study participants with active arthritis had higher 
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concentrations of summed RBC folates than those without active arthritis (p=0.01), 
suggesting a correlation between folate status and disease activity.  
 
7.4 Conclusion 
 The quantitative measurement of erythrocyte folate isoform in combination with 
polyglutamation status is an analytical challenge at various levels. The complex nature 
arises from the fact that standards are largely unavailable, extraction is complicated, 
folates are unstable, interconversion is dependant of analytical conditions, analytes are 
present at low levels, and changes in polyglutamation status alters physical chemical 
properties. This chapter of the dissertation was centered around dealing with each of 
these variables and the presented analytical method was ultimately a compromise 
between all of these factors. Erythrocyte polyglutamayl folate isoforms were measured 
semi-quantitatively using whole blood and its individual components. Pools of folate 
isoforms were quantitatively measured in whole blood after deglutamation by stable 
isotope dilution LC-MS/MS strategies. Erythrocyte folate isoforms were quantitatively 
established after plasma folate determination. Finally, polyglutamation distribution was 
measured on a relative basis using erythrocyte extracts in combination with IP-LC-
MS/MS. The combined method was applied towards the analysis of two JIA patients 
groups, with and without MTX therapy. A total of over 200 patients were analyzed and 
data analysis revealed a correlation between a patients folate status and disease 
activity. Since a patients folate status seems to play a major role in disease activity the 
comprehensive measurement of folates might provide a quantitative basis for 
individualization of patient therapy in the future.  
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8.1 General conclusions 
This dissertation focused on development of analytical detection strategies for 
pharmaceutically relevant compounds including: the antifolate MTX, its (in)active 
metabolites, its conjugates, and endogenous folates in biological systems. All of the 
target analytes share a common structural feature, the pteroyl ring system, analyte 
identity is resulting from limited variations in ring redox state, minor structural 
substitutions of the pteridine ring, and changes in conjugation status (i.e. polyglutamated 
or nanoparticle conjugated). Specific and sensitive detection of the individual species is 
of high interest as they may constitute biomarkers for individualizing low dose MTX 
therapy in autoimmune diseases such as JIA, but is also required for the (pre)clinical 
studies of novel MTX drug delivery entities. In this dissertation various assays are 
presented for the specific determination of these analytes in the presence of each other. 
Each of these strategies has their own strengths and weaknesses, and the appropriate 
analysis strategy is dependent on the nature of the analyte, its biological environment, 
stability and the clinical question to be answered.    
 Chapter 2 and 3 of this dissertation focused on bioanalytical method development 
for a G5-MTX-FA nanoparticle. The effectiveness of this experimental therapeutic for the 
treatment of neoplastic diseases has been demonstrated in various in vitro [1] and in 
vivo [2] studies. Continued development requires the establishment of bioanalytical 
methodology in order to appropriately study the in vivo behavior (i.e. MTX release profile 
etc), pharmacokinetics and dosing regimen of the entity. Since the nanoparticle was 
designed as a delivery system for MTX, analytical targets were identified as nanoparticle 
conjugated MTX, nanoparticle released (free) MTX and (free) 7OH-MTX, a product 
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resulting from MTX metabolism. The specific measurement of these diverse entities was 
accomplished by an innovative cascade of complementary assays. First total MTX 
content (i.e. the sum of free and G5-MTX-FA related MTX) was determined in the 
sample by initiating a non-selective reductive cleavage of the C(9)-N(10) bridge in MTX. 
The resulting fluorescent pteridine derivative could subsequently be determined by 
reversed phase separation and fluorescence detection. A second assay involving HPLC 
separation followed by online postcolumn photochemical degradation of the same C(9)-
N(10) bond was then used to reveal the MTX origin (i.e. free or dendrimer conjugated).  
 The newly developed methodology was validated in plasma and urine obtained 
from rats and dogs. The validated method was applied to determine the in vivo 
pharmacokinetics of G5-MTX-FA in animals, dosed at various different concentrations 
by either a bolus IV injection or through the subcutaneous tissue. The nanoparticle did 
not demonstrate significant release of MTX in the systemic circulation, indicating that the 
conjugate linkage is esterase stable and observed therapeutic effects cannot be 
attributed to free MTX generated by rapid release from the MTX-nanoparticle conjugate.     
 Chapter 4 and 5 address bioanalytical method development for MTX polyglutamyl 
conjugates, which are bioactive metabolites of MTX, and present in human erythrocytes 
of JIA patients on MTX therapy. Erythrocyte MTXPGs content is currently of high interest 
, as it may provide a biomarker for therapeutical guidance of MTX treatment in RA[3]. 
However such strategy was conceived to the present investigation and had not 
previously been applied to JIA patients. The present work was conducted in 
collaboration with Childrens Mercy Hospital (KC, MO). The Initial plan were to implement 
a previously described HPLC postcolumn reactor method for the measurement of 
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MTXPG in a cohort involving JIA patients (n=99). Trial experiments revealed the 
approach to be inadequate, thus necessitating the development of methodology of 
improved sensitivity and selectivity.  The approach ultimately employed was a ion-pair 
based HPLC separation, coupled with tandem mass spectrometric detection for 
MTXPGs present in human erythrocytes.  
This methodology was applied towards the analysis of erythrocyte samples 
obtained from 99 JIA patients on MTX therapy. Analysis of the intracellular MTXPG 
distribution revealed the route of administration (oral vs subcutaneous) as a primary 
determinant of intracellular MTX glutamate chain elongation (appendix 1)[4]. Furthermore 
JIA patients that were encountering liver toxicity (defined as an elevated liver function 
test) had a tendency to form longer intracellular MTXPGs (appendix 2)[5]. Attempts to 
correlate intracellular MTXPG levels to MTXs efficacy in JIA were unsuccessful, and 
recently similar observations are being reported in adulthood arthritis[6].  
Due to the discrepancies in findings between different research groups, the utility 
of erythrocyte MTXPG determination is still an unresolved clinical issue[3]. Larger 
standardized studies are required in order to fully understand the clinical impact of these 
measurements, supported by more specific and sensitive bioanalytical assays, as 
presented in chapter 4 and 5.  The observation that MTXPG population distribution is 
related to drug induced toxicity and is dependent of route of administration, advocates 
for the routine measurement of erythrocyte MTXPGs in JIA, especially in an attempt to 
reduced drug induced toxicity, which is the primary cause of MTX discontinuation.  
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 Chapter 7 of the dissertation focuses on the comprehensive measurement of 
folate isoform and polyglutamation distribution in human erythrocytes. The assay was 
developed with the intent to measure the influence of low-dose MTX therapy upon folate 
homeostasis, as it was hypothesized that the antagonist (MTX)/agonist (folate) ratio 
within the cell is important for MTX efficacy and toxicity. Semi-quantitative 
comprehensive folate measurement was accomplished by the development of a 
cascade of highly specific and sensitive LC tandem mass spectrometric assays. First, 
the various folate isoforms were quantitated individually utilizing a deglutamated whole 
blood sample and stable isotope dilution techniques. A second assay determined the 
plasma folate contribution in a similar manner. Erythrocyte folate content was calculated 
by the method of Lamers[7] utilizing plasma and whole blood folate concentrations. As 
folates were quantitated in the monoglutamyl form, the folate polyglutamation fingerprint 
was lost. The folate polyglutamation fingerprint was determined by performing a third 
assay where intact folates were extracted from erythrocytes, with relative quantitation 
accomplished by ion-pair LC separation followed by tandem mass spectrometry, in the 
absence of an isotopic standard.  
 The method was utilized to determine the impact of MTX therapy on the folate 
status of a JIA pediatric population by analyzing blood samples obtained from 
approximately 100 JIA patients not on MTX, and 100 JIA patients on MTX therapy (in a 
collaborative effort with Childrens Mercy Hospitals KC, MO). It was found that patients 
on MTX had on average a statistically significant lower folate status. Furthermore patient 
folate status correlated with the effectiveness of MTX therapy, indicated by the fact that 
individuals with low(er) erythrocyte folate status were more likely to be responders to 
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MTX therapy and disease more adequately controlled. Although not yet confirmed this 
might be indicative of an important balance between agonist and antagonist within the 
biological system.  
It is acknowledged that this study has limitations. It is a cross-sectional analysis of 
patients suffering from JIA supplied by a single center, which is a design that does not 
allow us to dynamically follow up trends over time or related to disease activity. 
However, this is the largest cohort of JIA patients reported to date, and data has been 
obtained by the most advanced bioanalytical methods in the field to date, providing a 
detailed description of intracellular red blood cell folate isoform, polyglutamation and 
antifolate (MTX) polyglutamation status. At the time of dissertation preparation, it is 
unclear and impossible to predict what the exact impact will be of the presented bio-
analytical methodology in the field of JIA. Larger more controlled patient studies are 
necessary to prove its usefulness in guiding JIA therapy in the future. However the 
potential of simultaneous MTXPG and comprehensive folate measurement to 
differentiate various patient phenotypes has been demonstrated in this dissertation by a 
single center study. With the bioanalytical methods in place, the next step is up to 
collaborative research between the bioanalyst and physician to gain an understanding in 
how to utilize the presented methodology, and translate raw bioanalytical measurements 
ultimately in the optimization of MTX treatment in the pediatric population. 
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8.2 Future directions of pteroyl analysis 
Overall, the presented bioanalytical methods are validated and their robustness 
has been demonstrated extensively. An exception is the folate methodology, where the 
limited availability of (isotope) labeled standards complicated method development, 
validation and quantitation. As suggested in the previous section, larger patient studies 
are required to validate our initial observations and further investigate the importance of 
folate measurement during MTX therapy. However such studies do need to be backed 
up by stable and standardized bioanalytical methods to avoid assay induced bias. 
Ideally the quantitation of folatePG species in human erythrocytes requires the synthesis 
of stable isotope labeled standards of each folate polyglutamyl form of interest. This 
dissertation suggests that these biological relevant folate species include the isoforms of 
5-MTHF, 5-FTHF, 10-FTHF, 5,10-MTHF and THF. Furthermore the ɣ-glutamyl chain 
length of these standards needs to span from 3-10 residues minimally. Although the 
synthesis of many of these entities has not been reported to date, it appears that 
synthesis could be accomplished by the use of biological  or chemical (solid phase or 
solution) procedures, utilizing specialized building blocks. 
  The presented bioanalytical methodology may also have potential application in 
other clinical areas where MTX is commonly used, or where folate metabolism is critical 
such as oncology[8], dermatology[9], gastroenterology[10-12], neurology[13], genetics[14], and 
maternal fetal medicine[15]. Gastrointestinal toxicity and hepatotoxicity from the drug limit 
its use in all conditions and there are no predictors to help clinicians identify patients at 
risk for these effects, nor the full understanding of how to optimize therapy to a specific 
patient.  Additionally, alterations in maternal folate have been linked to congenital heart 
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disease[16], neural tube defects[16], and Down syndrome[14], therefore the bioanalytical 
measurement of folates, and if relevant antifolates, has the potential to impact diverse 
patient populations in several fields in medicine 
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Appendix 1: Analysis of Intracellular Methotrexate Polyglutamates in 
Patients with Juvenile Idiopathic Arthritis. 
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Abstract 
 
Objective. Intracellular methotrexate (MTX) polyglutamates (MTXGlu) have been shown 
to be potentially useful biomarkers of clinical response in adult patients with rheumatoid 
arthritis. The present study was undertaken to measure intracellular MTXGlu 
concentrations in a cohort of patients with juvenile idiopathic arthritis (JIA) to determine 
the predictors of MTXGlu variability in these patients.  
Methods. Blood samples were obtained from patients with JIA who were being treated 
with a stable dose of MTX for >3 months. Clinical data were collected by chart review. 
Concentrations of MTXGlu1–7 in red blood cell lysates were quantitated using an 
innovative ionpairing chromatography procedure, with detection by mass spectrometry. 
Results. Patients with JIA from a single center (n = 99; mean ± SD age 117.8 ± 56.5 
months, 69 female) were included in the analysis. The mean ± SD dose of MTX was 
0.51 ± 0.25 mg/kg per week, with a median treatment duration of 18 months 
(interquartile range 3–156 months). MTX was administered subcutaneously in 66 
patients (67%). Fifty-six patients (57%) had active arthritis at the time of the clinic visit. 
Totalintracellular MTXGlu (MTXGluTOT) concentrations varied 40-fold, with a mean ± SD 
total concentration of 85.8 ± 48.4 nmoles/liter. Concentrations of each MTXGlusubtype 
(MTXGlu1–7) were measured individually and as a percentage of MTXGluTOT in each 
patient. 
MTXGlu3 was the most prominent subtype identified, comprising 42% of MTXGluTOT, 
and the interindividual variability in the concentration of MTXGlu3 was the most highly 
correlated with that of MTXGluTOT (r = 0.96). The route of MTX administration was 
significantly associated with MTXGlu1–5 subtypes; higher concentrations of MTXGlu1-2 
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were observed in patients receiving oral doses of MTX, whereas higher concentrations 
of MTXGlu3–5 were observed in patients receiving subcutaneous doses of MTX (P < 
0.0001).  
Conclusion. In this cohort of patients with JIA, the MTXGluTOT concentration varied 
40-fold. Individual MTXGlu metabolites (MTXGlu1–7), which have, until now, not been 
previously reported in patients with JIA, were detected. The route of MTX administration 
contributed to the variability in concentrations of MTXGlu1–5. 
 
For complete publication see: 
M. L. Becker, L. van Haandel, R. Gaedigk, A. Lasky, M. Hoeltzel, J. Stobaugh, J. S. 
Leeder, Analysis of intracellular methotrexate polyglutamates in patients with juvenile 
idiopathic arthritis: Effect of route of administration on variability in intracellular 
methotrexate polyglutamate concentrations. Arthritis & Rheumatism. 2010, 62, 1803. 
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Appendix 2: The Effect of Genotype on Methotrexate Polyglutamate 
Variability in Juvenile Idiopathic Arthritis and Association with Drug 
Response 
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Abstract 
Objective: Response and toxicity to methotrexate (MTX) are unpredictable in Juvenile 
Idiopathic Arthritis (JIA). Intracellular MTX polyglutamates (MTXGlu) have shown 
promise as a predictor of drug response. We investigated genetic predictors of MTXGlu 
variability and associations between MTXGlu and drug response in JIA. 
Methods: This is a single center cross-sectional study evaluating JIA patients on 
stabledoses of MTX at a tertiary care children’s hospital. After obtaining informed 
consent, blood was drawn from 104 JIA patients during routine MTX screening labs. 
Clinical data was collected by chart review. Genotyping for 34 SNPs in 18 genes within 
the MTX metabolic pathway was performed. An ion-pairing chromatographic procedure 
with mass spectrometric detection measured MTXGlu1-7.  
Results: MTXGlu analysis and genotyping was completed in 104 patients. K-means 
clustering resulted in 3 distinct patterns of MTX polyglutamation. Cluster 1 had low RBC 
MTXGlu concentrations, cluster 2 had moderately high RBC MTXGlu1+2 concentrations, 
and cluster 3 had high concentrations of MTXGlu, specifically MTXglu3-5. SNPs in the 
purine and pyrimidine synthesis pathway, as well as the adenosine pathway were 
significantly associated with cluster subtype. The cluster with high concentrations of 
MTXGlu3-5 was associated with elevated liver function studies (LFTs), and there were 
higher concentrations of MTXGlu3-5 in children who reported GI side effects and LFT 
elevation. No association was noted between MTXGlu and active arthritis. 
Conclusions: MTXGlu remains a potentially useful tool for determining outcomes of JIA 
patients on MTX. The genetic predictors of MTXGlu variability may also contribute to the 
better understanding of MTX intracellular biotransformation. 
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For complete publication see: 
M. L. Becker, R. Gaedigk, L. van Haandel, B. Thomas, A. Lasky, M. Hoeltzel, H. Dai, J. 
Stobaugh, J. S. Leeder, The effect of genotype on methotrexate polyglutamate variability 
in juvenile idiopathic arthritis and association with drug response. Arthritis & 
Rheumatism. 2010, online first. 
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Appendix 3: LC-MS/MS Method for the Determination of 
Carbamathione in Human Plasma 
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Abstract 
Liquid chromatography-tandem mass spectrometry methodology is described for the 
determination of S-(N,N-diethylcarbamoyl)glutathione (carbamathione) in human plasma 
samples. Sample preparation consisted of a straightforward perchloric acid medicated 
protein precipitation, with the resulting supernatant containing the carbamathione 
(recovery ~98%).  For optimized chromatography/mass spec detection a carbamathione 
analog, S-(N,N-di-i-propylcarbamoyl)glutathione, was synthesized and used as the 
internal standard. Carbamathione was found to be stable over the pH 1-8 region over 
the timeframe necessary for the various operations of the analytical method. Separation 
was accomplished via reversed-phase gradient elution chromatography with analyte 
elution and re-equilibration accomplished within 8 minutes.  Calibration was established 
and validated over the concentration range of 0.5-50 nM, which is adequate to support 
clinical investigations.  Intra- and inter-day accuracy and precision determined and found 
to be < 4% and < 10%, respectively.  The methodology was utilized to demonstrate the 
carbamathione plasma-time profile of a human volunteer dosed with disulfiram (250 
mg/d).  Interestingly, an unknown but apparently related metabolite was observed with 
each human plasma sample analyzed.   
 
For complete publication see: 
A.A.M. Heemskerk, L. van Haandel, J.M. Woods, E. F. McCance-Katz, T. D. Williams, J. 
F. Stobaugh, M. D. Faiman, LC-MS/MS Method for the Determination of Carbamathione 
in Human Plasma. JPBA. 2010, online first. 
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Appendix 4: Phenylisothiocyanate as a Multiple Chemical 
Dimension Reagent for the Relative Quantitation of Protein 
Nitrotyrosine 
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Abstract 
A highly selective sequential derivatization sequence has been developed for the 
transformation of 3-nitrotyrosine to a 2-anilino-benzoxazole derivative. This sequence 
can be applied to any ortho-nitrophenol, such as 3-nitrotyrosine or 3-nitrotyrosine 
residues present in proteins and/or peptides as a result of oxidative stress. The 
sequence involves a standard 
reduction of the nitro functional group to the corresponding amine using aqueous 
dithionite, followed by aqueous solution coupling with phenylisothiocyanate (PITC) and 
then eventual product formation by a photochemical mediated intramolecular cyclization 
of the intermediate thiourea. While this cyclization step has been effected numerous 
times by various reagents commonly used in synthetic organic chemistry, many 
requiring non-aqueous reaction media, the present transformation appears to the be first 
description this reaction using 350 nm light in aqueous media. The resulting overall 
transformation provides a specific mass shift signature of 116 amu when conducted with 
1H5-PITC and 121 amu with 2H5-PITC, thus forming the basis of relative quantitation by 
MS detection. In preliminary experiments, relative quantitation was accomplished for the 
decapeptide angiotensin I that had been subjected to nitration. 
 
For complete publication see:  
L. van Haandel, J. Killmer, X. Li, C. Schöneich, J. F. Stobaugh. Phenylisothiocyanate as 
a Multiple Chemical Dimension Reagent for the Relative Quantitation of Protein 
Nitrotyrosine. Chromatographia, 2008, 7-8, 507 
 
